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SUMMARY 
Diabetes is a major global public health challenge, afflicting 380 million people 
worldwide. The onset is insidious and progression is associated with irreversible medical 
complications, including oral diseases. Little is known about the oral health of patients 
with diabetes in developing countries such as The Sudan, which is currently experiencing 
an alarming increase in diabetes cases. 
The overall aim of this thesis was to evaluate oral health indicators in Sudanese adults 
with type 2 diabetes (T2D) and to investigate the impact of T2D and chronic periodontitis 
on biomarkers of inflammation and glucose regulation in gingival crevicular fluid (GCF) 
and saliva. 
The subjects comprised 157 T2D cases and 304 controls without diabetes, 461 in all. 
Participants were interviewed using a structured questionnaire on socio-demographics, 
lifestyle and oral health related quality of life (OHRQoL). The clinical examination 
comprised full mouth probing depths, bleeding on probing, dental plaque index, tooth 
mobility index, furcation involvement and coronal and root caries. In GCF samples, the 
levels of 10 glucoregulatory molecules and 27 inflammatory molecules were measured by 
bead-based multiplex assays. MMP-8, MMP-9, OPG and RANKL in whole saliva 
samples were quantified by ELISA. Subgingival plaque samples were analysed by 
conventional polymerase chain reaction (PCR), to assess the prevalence of six periodontal 
pathogens. 
T2D patients had poorer periodontal parameters, more missing teeth and poorer 
OHRQoL than individuals without diabetes. Chronic periodontitis was associated with 
disturbed GCF levels of biomarkers related to the onset and medical complications of 
T2D. On the other hand, T2D was associated with a high Th-2/Th-1 cytokines ratio and 
disturbed levels of molecules involved in the anti-inflammatory and healing processes. 
T2D had no significant effect on either the prevalence of the investigated periodontal 
pathogens or the levels of salivary MMP-8, MMP-9 and OPG. Further research is 
warranted to identify disease markers which could form the basis of a test to alert the 
dentist to patients with undiagnosed T2D, or those at risk of developing the disease. 
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1. INTRODUCTION 
1.1 Diabetes  
Diabetes mellitus is a metabolic disorder characterised by chronic hyperglycaemia and 
disturbed carbohydrate, fat and protein metabolism caused by defective insulin secretion, 
action, or both (1). Insulin is a hormone secreted by the β-cells of the pancreas. It allows 
the cells to utilise glucose and prevents conversion of glycogen (the stored form of 
glucose) to glucose in the liver. Thus the net effect of insulin is to reduce the level of 
circulating glucose. Disturbance to insulin function may occur either because β-cells are 
unable to produce sufficient insulin, or because tissue response to the secreted insulin is 
impaired. The end result is elevated blood glucose level (hyperglycaemia) (2). The 
classical symptoms of the disease are polyuria, polydipsia, polyphagia and blurred vision 
(3). If hyperglycaemia is not controlled, serious acute life-threatening complications, such 
as diabetic ketoacidosis and non-ketotic hyperosmolar syndrome, may ensue (3). 
Hyperglycaemia might also lead to chronic, irreversible tissue damage. Long-term 
complications include nephropathy, retinopathy, neuropathy, cardiovascular diseases, 
peripheral vascular diseases, delayed healing and periodontal diseases. The severity of the 
disease lies in the fact that it might remain undiagnosed for a long time, allowing 
hyperglycaemia to cause long-term tissue damage (3, 4).   
Diabetes is a major public health concern, with 380 million people afflicted 
worldwide. It is reported that about 50% may be undiagnosed (5). Moreover, about 80% 
of patients with diabetes are from low- and middle-income countries (5). The African 
region is doubly burdened by disease: as well as the existing challenges such as malaria 
and HIV, the prevalence of non-communicable diseases is increasing  (6). By 2030, it is 
expected that Africa will experience the largest proportional increase in adults with 
diabetes (7). In 2014, The Middle East and North Africa had the highest age-adjusted 
global prevalence of diabetes (about 11%) (5). In North African countries with limited 
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resources, such as The Sudan, diabetes and its medical complications impose a heavy 
economic burden and there is an urgent need for interventions to address this issue (8).  
There is little research into diabetes in The Sudan. A search of PubMed using MeSH 
terms “diabetes” and “Sudan” revealed only 17 studies during the last 10 years. None 
included oral health aspects of diabetes (updated 28th July, 2015).  
To date, the true prevalence of diabetes in The Sudan is unknown. In 1996, a study 
conducted among adults (≥ 25 years) in the northern part of the country reported a 
prevalence of 3.4% (9). In 1998, another study among the same age group and from the 
same geographical area reported a prevalence of 10% (10). According to a 2014 report by 
the International Diabetes Federation (IDF), the age-adjusted prevalence of diabetes in 
The Sudan is about 18% (5). This figure ranks The Sudan among countries with a high 
prevalence of the disease, not only in Africa, but also worldwide. Limited resources and 
challenging economic status in The Sudan have led to lack of satisfactory diabetic care 
and education, low rates of clinical attendance, a high prevalence of diabetes-related 
medical complications and poor quality of life (11, 12). 
1.1.1 Diagnosis of diabetes 
According to the American Diabetes Association (13), diagnosis is based on the following 
criteria: 
x Fasting plasma glucose (no caloric intake for at least 8 h) of ≥ 126 mg/dL (7.0 
mmol/L), OR 
x Random plasma glucose (anytime of the day) of ≥ 200 mg/dL (11.1 mmol/L) AND 
the classical symptoms mentioned earlier, OR 
x Plasma glucose of ≥ 200 mg/dL (11.1 mmol/L) after 2 h oral administration of 75 g 
anhydrous glucose dissolved in water. 
According to a World Health Organisation (WHO) report from 2011 (14), glycated 
haemoglobin (HbA1c) of 6.5% (48 mmol/mol) can be used as a cut-off point to diagnose 
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diabetes, although HbA1c levels below this do not exclude the disease. HbA1c results 
may vary according to age, ethnicity and haemoglobin level. Therefore, these factors 
should be taken into consideration when using HbA1c as a diagnostic measure (13). 
HbA1c is also considered to be a good indicator of glycaemic control in patients with 
diabetes. It reflects the average blood glucose level within a range of 8 to 12 weeks, 
corresponding to the life span of circulating red blood cells (15). 
There is a transient stage between normal glucose homeostasis and diabetes, in which 
individuals are at increased risk of developing the disease. This stage is referred to as pre-
diabetes or impaired glucose tolerance. At this stage, fasting plasma glucose ranges 
between 100 mg/dL (5.6 mmol/L) and 125 mg/dL (6.9 mmol/L), the 2 h glucose tolerance 
test ranges between 140 mg/dL (7.8 mmol/L) and 199 mg/dL (11.0 mmol/L), and HbA1c 
from 5.7% (39 mmol/mol) to 6.4% (46 mmol/mol) (13). The pre-diabetic state is highly 
relevant in clinical dental practice. Oral manifestations may present as one of the early 
signs of the disease, hence the dental practitioner might recognise undiagnosed cases (16, 
17). 
1.1.2 Classification of diabetes 
Categorisation of patients with diabetes into a specific type is sometimes challenging. 
Nevertheless, diabetes mellitus can be broadly classified as follows (13): 
Type 1 diabetes 
This type of diabetes affects 5-10% of patients with the disease; mostly children and 
young adults. It is characterised by absolute insulin deficiency due to cell-mediated 
autoimmune destruction of the β-cells of the pancreas (3). As the rate of destruction varies 
among patients, the age at which the disease becomes symptomatic also varies. Less 
commonly, the aetiology of type 1 diabetes might not be related to auto-immunity 
(idiopathic diabetes). This sub-class is characterised by strong genetic susceptibility. Most 
of the patients are either of African or Asian origin (3). Patients with type 1 diabetes may 
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also suffer from other auto-immune diseases and most require insulin therapy to survive 
(3). 
Type 2 diabetes 
Type 2 diabetes (T2D) is the most common type, affecting about 90% of patients with the 
disease. It usually affects adults and may remain undiagnosed for a long time. During the 
early stages of the disease, tissues become resistant to the secreted insulin. As a result, 
cells starve for glucose and produce signals that force the liver to release more glucose by 
hydrolysing the stored glycogen, and β-cells of the pancreas to secrete more insulin. 
Subsequently, hyperglycaemia occurs and the β-cells become less efficient over time, 
leading to relative insulin deficiency. Although the specific aetiology of T2D is unknown, 
obesity, high fat and sugar intake, physical inactivity and genetic predisposition have been 
implicated. T2D can be controlled by changing life style (dietary restriction of sugar and 
fat, weight loss and physical exercise). In addition, oral hypoglycaemic drugs might be 
used to enhance insulin secretion by β-cells and/or to reduce insulin resistance. Insulin 
therapy might be indicated for poorly controlled cases (3). 
Gestational diabetes 
This form of diabetes occurs during pregnancy. It is characterised by any degree of 
glucose intolerance that is recognised for the first time during the pregnancy period. In 
2009, the International Association of the Diabetes and Pregnancy Study Groups modified 
the case definition by excluding high-risk women diagnosed with diabetes at their initial 
prenatal visit. This type of diabetes accounts for 7% of all pregnancies with about 200,000 
cases per year (3). In some cases, the condition may persist after pregnancy. Associated 
risk factors for this type of diabetes include age, previous history of glucose intolerance, 
high blood glucose level and neonates who are large for gestational age (1, 3). 
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Other specified types of diabetes 
These include less common forms of the disease such as monogenic diabetes syndromes, 
diseases of the exocrine pancreas and drug - or chemical - induced diabetes (13). 
1.1.3 Oral manifestations of diabetes 
There is abundant evidence that diabetes is associated with pathological changes in the 
oral cavity. These changes include mucosal ulceration, fungal infection, burning mouth 
syndrome, tooth loss, xerostomia, dental caries and periodontal disease (18). These 
manifestations are more pronounced among patients with uncontrolled blood glucose 
levels (19). It is important to note that these oral changes are not pathognomonic for 
diabetes (20, p187). Another important point is that pathological changes in the oral 
cavity are one of the early signs of diabetes (16). As diabetes may remain undiagnosed for 
a long time, dentists could be instrumental in facilitating early detection of diabetes. Early 
detection is the key factor for prevention of medical complications, as well as the 
economic burden related to management of the disease (21). 
 
 
Figure 1. Clinical case of T2D patient with extensive periodontal tissue destruction and tooth 
loss. 
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1.2 Periodontal diseases 
The periodontium is the apparatus that keeps the teeth in place. It consists of the gingiva, 
periodontal ligaments, cementum and alveolar bone. Together, the four components 
function as a one unit to support the teeth and maintain their function and stability (20, 
p9). Periodontal disease is an inflammatory condition that affects the above mentioned 
tissues that surround the teeth (22). It starts with the reversible form “gingivitis”. Page 
and Schroeder (23) classified the histological changes that occur during the course of 
periodontal disease. According to their classification, the disease starts as sub-clinical 
mild inflammation (initial lesion). Thereafter, the classical signs of gingivitis become 
noticeable and the gingiva becomes red, swollen and bleeds readily (early lesion). If the 
condition is not treated, it goes into a chronic stage (established lesion). As the disease 
progresses, bone tissue and periodontal ligaments become involved (advanced lesion) and 
the transition to periodontitis starts. Socransky et al., (24) described the progression of the 
disease as intermittent i.e. periods of exacerbation followed by periods of remission, 
while Kinane (25) suggested that the process is continuous, with occasional episodes of 
exacerbation and remission.  
1.2.1 Classification of periodontitis 
Destructive periodontal diseases can be classified as follows (26): 
x Chronic periodontitis 
x Aggressive periodontitis  
x Periodontitis as a manifestation of systemic diseases 
x Necrotising ulcerative periodontitis 
x Abscesses of the periodontium 
x Combined periodontic-endodontic lesions 
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1.2.2 Chronic periodontitis 
Unlike gingivitis, periodontitis is an irreversible condition, characterised by apical 
migration of epithelial attachment, accompanied by loss of supporting bone (27). This 
chronic inflammatory condition leads to pathological deepening of the gingival sulcus to 
form a periodontal pocket (28). If left untreated, tissue destruction may eventually lead to 
tooth loss (25). During the early stages of the disease, there is an increase in the vascular 
permeability and migration of the immune cells (mainly neutrophils) to the site of 
infection. As the disease progresses, lymphocytes and macrophages migrate to the 
affected site. If the condition remains untreated, destruction of the connective tissues and 
bone occurs and the junctional epithelium migrates apically along the root surface to form 
the periodontal pocket: at this point, plasma cells and lymphocytes become predominant 
(29). 
Clinical presentation of the disease is determined by two major components: the 
periodontal pathogens and the host immune-inflammatory response (30, 31). Other factors 
implicated as potential mediators of these two determinants of the disease are age, gender, 
education, genetic background, smoking, life style and systemic conditions (32). 
1.3 How diabetes affects chronic periodontitis 
Diabetes and chronic periodontitis are both chronic inflammatory conditions. There are 
some commonalities of immune-inflammatory response throughout the course of both 
diseases. While this can partially explain the bi-directional relationship of the two 
diseases, it also reflects the complexity of the mechanisms by which one disease affects 
the other (33). The temporality of this bi-directional relationship was demonstrated in a 
study by Chiu et al., (34) claiming that both diseases may share common latent traits and 
pathways. 
The effect of diabetes on periodontal tissues has been thoroughly investigated in 
observational studies, demonstrating that diabetes is associated with exaggerated 
periodontal tissue destruction (35-39). Moreover, a 20-year follow-up study reported a 
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29% increased risk of periodontitis and a 22% increased risk of bone loss in patients with 
T2D (40). Another 5-year follow-up study demonstrated that periodontal tissue 
destruction is associated with poor glycaemic control (HbA1c ≥ 6.5%) (48 mmol/mol) 
with an OR of 2.9 (19). 
 
Figure 2. Clinical case of T2D patient with chronic periodontitis. 
1.3.1 Putative periodontal pathogens, “starting the battle” 
Dental plaque is a structured, yellowish-greyish biofilm that accumulates on the hard 
surfaces of the oral cavity including teeth (41). With the gingival margin serving as an 
anatomical reference, dental plaque is located supra- or subgingivally. Subgingival plaque 
is a complex ecosystem containing vast numbers of micro-organisms (42). Some of those 
micro-organisms have been found to be associated with chronic periodontitis, such as 
Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, Tannerella forsythia, 
Treponema denticola, and Prevotella intermedia (43, 44). The periodontal pathogens are 
considered to be the initiating factors in the disease (45), challenging the periodontal 
tissues with metabolic waste products such as ammonia and hydrogen sulfide (20, p81). 
Understanding the role of periodontal pathogens in the pathogenesis of chronic 
periodontitis has evolved over time, from the regarding dental plaque bacteria as the main 
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cause of the disease (46), to the theory of dysbiosis, whereby tissue destruction is caused 
by the host immune response, due to disturbance in the balance of relative quantities of 
existing bacteria in the dental biofilm. This implies that periodontal pathogens have an 
indirect role, changing the existing bacterial environment in the dental plaque from 
symbiotic to dysbiotic (47, 48). The pathogens able to play this role are called  “keystone 
pathogens” (49). These keystone pathogens are essential, but cannot, on their own, cause 
a periodontal lesion (45). 
1.3.2 Diabetes influences oral microbiota, “myth or truth?” 
The impact of hyperglycaemia on the composition of dental plaque microbiota has been 
questioned for many years. Some studies report no significant differences in the bacterial 
composition of dental plaque between individuals with and without diabetes (39, 50). 
Moreover, the level of glycaemic control among patients with diabetes seems to have no 
significant effect on the microbial composition of dental plaque (51). In contrast, other 
studies have indicated significant differences in dental plaque bacteria between 
individuals with and without diabetes (52, 53). One of the suggested mechanisms that 
might lead to dissimilarities in microbial composition is the high glucose levels in saliva 
and gingival crevicular fluid (GCF) caused by hyperglycaemia, which in turn affects the 
level of carbohydrates in dental plaque. As a consequence, the biofilm environment will 
favour for the growth of the pathogens (53). 
1.3.3 Host immune-inflammatory response, “losing the balance” 
The response of the immune system to various stimuli is a fundamental process for 
maintenance of periodontal health. It involves a highly sophisticated and integrated series 
of events, starting with pathogen recognition, followed by activation of innate and 
adaptive immunity and concluding with healing and resolution (54). It is widely accepted 
that plaque-induced periodontal tissue destruction is the consequence of the host immune-
inflammatory response to micro-organisms (31).  
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Inflammation is a process by which tissues react to stressful situations such as injury 
or infection. It is a protective mechanism intended to eliminate harmful stimuli and return 
the tissue to its homeostatic condition (55). The process involves recruitment of 
neutrophils, macrophages, activation of T- and B-lymphocytes, as well as activation of 
the complement system (29). The cross-talk between these cells is the responsibility of 
small soluble molecules called cytokines (56). Cytokines are secreted by immune cells 
such as neutrophils, macrophages, lymphocytes and mast cells, as well as non-immune 
cells such as fibroblasts and epithelial cells (57, 58). They can act in an autocrine, 
paracrine, endocrine or juxtacrine manner, and their action can be pleotropic (59). When 
binding to their receptors, they initiate an intra-cellular signalling cascade that eventually 
leads to up-regulation or down-regulation of specific genes. They thus function as a 
complex network, guiding the immune system towards an appropriate immune response, 
such as pro- or anti-inflammatory response, T-cell maturation and differentiation, B-cell 
class switching, etc (56). 
The cells of the immune system respond to bacterial invasion through specific 
receptors called pattern recognition receptors (PRRs). The latter can recognise bacterial 
lipopolysaccharide, peptidoglycan, bacterial DNA, and double stranded RNA. These 
stimulators are collectively called microbe - or pathogen - associated molecular patterns 
(MAMPs or PAMPs). In periodontal tissues, toll-like receptors (TLRs) (one of the PRRs) 
on the surface of resident cells (such as epithelial cells, fibroblasts and neutrophils) 
recognise the PAMPs and initiate an innate immune response through activation of 
transcription factors such as nuclear factor-ߢB (NF-ߢB). Subsequently, the resident cells 
produce cytokines such as IL-1β, IL-6 and TNF-α, and chemokines such as IL-8. As a 
result, the tissue undergoes vascular changes accompanied by recruitment of more 
inflammatory cells (neutrophils, macrophages and natural killer cells) to the affected site 
(29, 60). 
If the innate immune response fails to eliminate the stimulus, bacterial antigen will be 
taken, processed and presented to the cells of the adaptive immune system by antigen-
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presenting cells such as macrophages and dendritic cells, leading to activation of adaptive 
immunity (29). IL-12 and IL-4 enhance the development of Th-1 and Th-2 from naive 
Th-cells, respectively (61). The bridging between the innate and adaptive immune 
response is orchestrated by cytokines such as IL-12, IL-18 and INF-γ (62). 
As the disease progresses, the tissue experiences continuous stress from the pro-
inflammatory molecules produced by the immune cells, causing what is called para-
inflammation. Although the condition might not be clinically detectable, dramatic 
changes might occur if the condition persists, leading to chronic inflammatory status (55). 
At this point, more neutrophils and macrophages will be attracted to the inflamed site by 
IL-8 and MCP-1, respectively (63). Like the other immune cells, neutrophils secrete 
inflammatory mediators such as IL-1β, TNF-α, prostaglandins and matrix 
metalloproteinases (MMPs). Concurrently, Th-1 secretes IL-2 and INF-γ, Th-2 mediates 
humoral immunity and Th-17 secretes IL-17 (61, 64). 
Following the establishment of the chronic inflammatory process, some of the 
inflammatory molecules such as MMPs and receptor activator of nuclear factor-κB ligand 
(RANKL) will be up-regulated. These two molecules participate in the destruction of the 
non-mineralised and mineralised tissues of the periodontium, respectively (65, 66). 
MMPs are structurally related but genetically distinct zinc-dependent proteolytic enzymes 
produced by neutrophils, macrophages, fibroblasts and other resident cells (65). Apart 
from their role in normal physiological processes such as cell migration and tissue 
remodelling, they play a major role in extracellular matrix degradation (65, 67). Elevated 
MMPs have been associated with chronic periodontitis, particularly MMP-8 (collagenase-
2), MMP-9 (gelatinase-B) and MMP-13 (collagenase-3) (68). The action of MMPs is 
modulated by serum inhibitors such as glycoprotein α1-antitrypsin and α2-macroglobulin, 
as well as tissue inhibitors of metalloproteinases (TIMPs) (20, p84). As a result of the 
non-mineralised tissue destruction, the inflammatory activity migrates apically towards 
the alveolar bone. 
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Bone remodelling is a dynamic process, involving a balanced system of bone 
turnover, whereby osteoclasts are responsible for bone resorption, and osteoblasts are 
responsible for bone deposition (69). Thus, if the balance shifts towards increased 
osteoclast activity, bone resorption occurs. Bone remodelling is highly regulated by the 
RANKL-RANK-osteoprotegerin (OPG) axis (70). RANKL is one of the TNF 
superfamily. When binding to its receptor (RANK), RANKL stimulates the maturation 
and activation of osteoclasts (66, 71). Pro-inflammatory cytokines such as TNF-α and IL-
1β enhance RANKL secretion by T- and B-cells (54, 72). On the other hand, OPG - a 
soluble decoy receptor - inhibits the differentiation of osteoclasts by competing with 
RANKL on its receptor (73). Therefore, the RANKL/OPG ratio is a good indicator of 
bone tissue destruction in periodontitis (70). Inflammatory mediators such as cytokines, 
chemokines and prostaglandins can enhance bone tissue destruction by increasing the 
RANKL/OPG ratio. They can also enhance bone destruction directly through a non-
RANKL pathway, by activating osteoclasts through specific receptors (74). Given the fact 
that the immune system works in balance (i.e. pro-/anti-inflammatory cytokines, 
RANKL/OPG, MMPs/TIMP), an imbalance among the different elements of the immune 
system may determine the clinical presentation of periodontitis. 
1.3.4 Effect of diabetes on host immune-inflammatory response 
The exact mechanism(s) by which diabetes affects the host immune response is not fully 
elucidated (51). However, there is a general agreement that hyperglycaemia is the main 
cause of diabetic complications (3). The mechanisms proposed to explain the link 
between chronic hyperglycaemia and disturbed host immune-inflammatory response are 
discussed below. 
1.3.4.1 Induction of inflammation 
One of the proposed mechanisms by which hyperglycaemia could cause periodontal 
tissue damage is by oxidative stress. Hyperglycaemia affects the mitochondrial oxidation 
process which leads to accumulation of reactive oxygen species (ROS) such as oxygen 
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superoxide and hydrogen peroxide (75). When the anti-oxidant defence mechanisms fail 
to remove the ROS, oxidative stress occurs. ROS are considered as signalling molecules 
that can influence cellular proteins, lipids and DNA in high concentrations. In addition, 
these harmful substances can enhance the release of inflammatory mediators by activation 
of the intra-cellular signalling pathway NF-κB (75, 76). Oxidative stress can also 
influence bone remodelling by enhancing osteoclast activity and inhibiting 
osteoblastogenesis (77). 
Another mechanism by which hyperglycaemia can affect the host immune response is 
by accumulation of advanced glycation end products (AGEs). The process involves non-
enzymatic irreversible glycation and oxidation of proteins and lipids (78). AGEs affect 
the tissue directly by provoking phenotypic and functional changes in collagen and other 
matrix molecules. They can also act through the receptor for advanced glycation end 
products (RAGE) (78). Moreover, hyperglycaemia can increase RAGE expression by 
epithelial cells (79). The binding of AGEs to their receptors triggers intra-cellular events 
that lead to up-regulation of pro-inflammatory cytokines, chemokines and cell adhesion 
molecules. Moreover, it is claimed that AGEs (as one of the TLR ligands) are associated 
with increased TLRs expression and impaired tissue repair in periodontal tissues (51, 80). 
Another indirect effect of AGEs is the enhancement of oxidative stress by increasing the 
production of ROS (81). It is also reported that blocking of the AGE-RAGE axis 
improves periodontal tissue integrity (82). 
Neutrophils play a pivotal role in plaque-induced periodontal tissue destruction (83). 
Hyperglycaemia is reported to interfere with neutrophil rolling, chemotaxis and 
phagocytosis (4). It also increases the expression of leukocyte adhesion molecules (84). 
Moreover, neutrophil priming might be a consequence of increased levels of protein 
kinase-C as a result of hyperglycaemia (85). Under normal conditions, neutrophil 
apoptosis (programmed cell death) is delayed when interacting with bacteria. In a 
hyperglycaemic environment, however, neutrophil apoptosis is defective and this 
delaying effect is disrupted (86).  
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It is well documented in the scientific literature that apoptosis plays a critical role in 
diabetic complications, including periodontitis (87). Apoptosis is essential for maintaining 
tissue integrity by selective elimination of “bad” cells i.e. abnormal or aged cells. When 
the rate of apoptosis exceeds normal limits, there will be a lack of the matrix-producing 
cells essential for tissue healing and repair (88). Apoptosis can be provoked by 
accumulation of AGEs, oxidative stress and inflammatory mediators such as TNF-α (89). 
It is reported that hyperglycaemia enhances human periodontal ligament fibroblast 
apoptosis (90). Moreover, in animal models, diabetes is associated with fibroblast, 
osteoblast and osteocyte apoptosis in periodontal tissues (89, 91). These cells are the key 
players in bone coupling (69). In this context, there is ample clinical evidence that 
hyperglycaemia exacerbates periodontal bone tissue destruction by influencing the 
RANKL/OPG ratio (92, 93). It is also reported that in a rat model, hyperglycaemia 
negatively influences bone tissue turnover (94). 
1.3.4.2 Resolution of inflammation 
Resolution of inflammation is an active process involving the production of specific 
molecules through different pathways (95). The underlying mechanisms have been 
investigated in order to develop new therapeutic approaches to inflammatory diseases 
(96). Under normal conditions, the process involves termination of neutrophil 
recruitment, enhancement of neutrophil apoptosis and generation of functional decoys for 
chemokine receptors (95, 97). In addition, macrophage activity changes from production 
of pro-inflammatory cytokines to production of IL-10 and TGF-β instead (98). The 
macrophages also help with engulfing dead cells and tuning the sensitivity to TLRs (99). 
The above mechanisms are orchestrated by lipid molecules such as lipoxins and resolvins 
(100). Moreover, Th-2 produces IL-4, an anti-inflammatory cytokine that down-regulates 
MMPs and RANKL and promotes the secretion of their antagonists: TIMP and OPG, 
respectively (57). In addition, myeloid-derived suppressor cells and T-reg cells also have 
a role in counteracting the pro-inflammatory process and maintaining tissue homeostasis 
(95, 101). 
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The above-mentioned process is essential to resolve acute inflammation and prevent 
the condition from progressing to the chronic stage where tissue injury occurs. In mild 
cases, the condition is resolved by “regeneration”, whereby necrotic cells are replaced 
with new ones. If the tissue damage is extensive, the extracellular matrix will be 
damaged, limiting tissue regeneration. As a result, there will be deposition of fibroblast-
mediated collagen and formation of granulation tissue. This process is called “tissue 
repair” or “scarring”(102).   
In patients with diabetes, defective resolution of inflammation might be one of the 
mechanisms underlying the extensive periodontal tissue destruction these patients 
experience in comparison with systemically healthy individuals. The findings of an 
experimental study by Herrera et al., (103) suggested impaired resolution pathways in 
T2D. A flawed reparative process was also reported in an animal study of T2D rats with 
periodontitis (104). Another study in diabetic mice reported failure of macrophages to 
clean dead cells from the diabetic wound site (efferocytosis) (105). 
1.4 Periodontitis goes beyond the oral cavity  
It is widely appreciated that the effect of chronic periodontitis extends beyond the 
periodontal tissues to have a systemic impact. Several studies have reported an 
association between periodontal disease and systemic conditions such as cardiovascular 
diseases, respiratory diseases, low birth-weight infants, rheumatoid arthritis and diabetes 
(83, 106).  
The effect of periodontal disease on diabetes has been highlighted in several studies. 
The study of the First National Health and Nutrition Examination Survey (NHANES I) 
reported a two-fold increase in the odds of developing diabetes among individuals with 
periodontitis, compared to those without the disease (107). Moreover, the risk of 
developing diabetes was about 3.5 times higher for those with severe periodontitis (108). 
In a five-year follow-up study, periodontal disease was associated with deteriorating 
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glycaemic control (109). In contrast, a seven-year follow-up study from Japan indicated 
no significant association between periodontitis and the incidence of diabetes (110).   
In the advanced stages of chronic periodontitis, oral bacteria, bacterial products and 
inflammatory mediators might escape the local environment into the systemic circulation 
through the ulcerated periodontal tissues, creating a chronic low-grade systemic 
inflammatory state (111). Almaghlouth et al., (112) indicated an increase in systemic 
inflammatory molecules among individuals with periodontitis. Moreover, it was reported 
that non-surgical periodontal therapy significantly decreases the serum level of 
inflammatory molecules such as IL-6, TNF-α and C-reactive protein (112, 113).  
Systemic up-regulation of certain pro-inflammatory molecules such as TNF-α, IL-1β 
and IL-6 has been linked to insulin resistance and the aetiology of T2D (114). Under 
normal conditions, binding of insulin to its membrane receptor leads to phosphorylation 
and activation of the insulin receptor substrate. These changes facilitate the cellular 
import of glucose (115). The high levels of pro-inflammatory molecules activate the intra-
cellular signalling pathway (NF-κB) which eventually leads to structural changes in the 
insulin receptors (116). Moreover, up-regulated inflammatory molecules might also affect 
the activity of pancreatic β-cells through accumulation of ROS (117). Interestingly, one of 
the proposed mechanisms of the systemic impact of periodontitis on diabetes is by 
altering the composition of gut microbiota. Systemic inflammatory changes were 
observed after oral administration of P.gingivalis in mice, suggesting that oral bacteria 
can disturb the balanced microbial environment of the gut, which in turn induces systemic 
inflammation (118). 
Among patients with diabetes, periodontitis is regarded as a predictor of non-oral 
complications (119). In longitudinal studies among Pima Indians - a population with a 
high prevalence of diabetes - periodontitis was associated with nephropathy, end-stage 
renal disease and cardio-renal mortality (120, 121).  
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Figure 3. Schematic illustration of the proposed mechanisms explaining the bi-directional 
relationship between diabetes and chronic periodontitis. Hyperglycaemia increases reactive 
oxygen species (ROS), advanced glycation end products (AGEs) and protein kinase-C, which in 
turn causes intra-cellular events through activation of NF-ߢB leading to up-regulation of pro-
inflammatory molecules and/or down-regulation of anti-inflammatory, healing and 
regeneration molecules. Pro-inflammatory molecules on the other hand, escape to the systemic 
circulation through the inflamed periodontium, which might eventually lead to structural 
changes in the insulin receptors. The Figure is produced using Servier Medical Art. 
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1.5 Effect of periodontal therapy on diabetic status, “is it worth it?” 
Management of periodontitis includes non-surgical mechanical removal of debris and 
calculus as a standard procedure, i.e. scaling and root planing. Adjuvant local or systemic 
antibiotic therapy might be indicated in some cases, and surgical intervention is 
sometimes indicated. With all these therapies, behavioural modification, oral hygiene 
instructions and follow-up are crucial to prevent recurrence (20, p409).  
As in systemically healthy individuals, periodontal therapy in patients with T2D is 
associated with reduced systemic inflammation, reflected in the reduction of the systemic 
levels of TNF-α, C-reactive protein and other inflammatory mediators (122, 123). 
Nevertheless, the findings of studies of the effect of periodontal therapy on metabolic 
control among patients with diabetes are inconsistent. Two meta-analysis studies 
conducted in 2010 reported a significant HbA1c reduction of 0.40% (124, 125). 
Engebretson et al., (126) in 2013 concluded with similar findings. Moreover, Nesse et al., 
(127) reported a dose-response relationship between the inflamed surface area and HbA1c 
level among patients with T2D. On the other hand, some reports failed to confirm the 
association (128, 129). This inconsistency might be attributable to differences in the 
treatment protocol, i.e. surgical vs non-surgical periodontal therapy, and the use of 
antibiotics. 
Whether periodontal therapy is effective in controlling glycaemic levels or not, a key 
factor in reducing the risk of medical complications related to diabetes is maintenance of 
blood glucose levels within the normal range. Improved glycaemic control over 10 years 
was shown to be associated with decreased risk of diabetes-related microvascular 
complications (130). It was also reported that each 1% (3 mmol/mol) reduction in HbA1c 
is associated with reduced diabetes-related microvascular complications by 37% (131).  
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1.6 Diabetes and dental caries 
Dental caries is a major public health problem characterised by destruction 
(demineralisation) of the dental hard tissues by acidic by-products produced by bacterial 
biofilm as a result of fermentation of dietary carbohydrates (132). The suspected microbes 
responsible for dental caries are Streptococcus mutans, Streptococcus sobrinus and 
Lactobacillus (133). 
Anatomically, dental caries can be classified into coronal and root caries. The lesion 
starts when demineralisation by microbial acids exceeds remineralisation (uptake of 
calcium, phosphate, and fluoride from food and saliva). During the early stages, the 
condition is reversible, but as the lesion progresses, the destruction of dental hard tissue 
becomes permanent and needs to be restored by dental material (132).  
Data from epidemiological studies of the relationship between diabetes and dental 
caries are inconsistent. Higher caries experience in patients with diabetes is reported in 
some studies (134, 135), and not in others (136, 137). On the other hand, there is stronger 
evidence supporting higher prevalence of root caries in patients with diabetes (138). 
 
Figure 4. Clinical case of T2D patient represents the exposed and decayed roots  
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1.7 Diabetes and oral health related quality of life 
Inspired by the WHO definition of health “a complete state of physical, mental, and social 
well-being and not merely the absence of disease” (139), quality of life assessment covers 
crucial aspects of health, such as physical, mental and oral health (140). In addition to the 
generic measurements of quality of life, disease-specific measurements have been 
developed to improve patients’ responsiveness (141).  
OHRQoL associates oral health with the other aspects of quality of life by linking the 
patient’s health experience to the clinical variables, and addressing the psycho-social 
consequences of oral diseases (142). Hence, both the psycho-social and clinical indicators 
are important for health promotion, disease prevention and allocation of resources (141). 
Moreover, it is important to consider both clinical and non-clinical variables, in order to 
gain a more comprehensive understanding of the processes that determine the influence of 
chronic disease on individuals’ daily life (143). 
The OHRQoL of patients with diabetes is poorly documented. Improving quality of 
life of T2D patients is regarded as an important target for diabetes management (144). It 
adds another dimension to the “traditional” medical care of the disease. Moreover, 
improvement in oral health is reflected in general health, especially in patients with 
diabetes (145). Diabetes has an adverse effect on an individual’s quality of life (146). 
Patients with diabetes have a limited understanding of the detrimental effect of poor oral 
health on their general health (147). They also lack knowledge and awareness about the 
oral complications of diabetes (147, 148). Furthermore, it has been reported that the 
general oral health practices of patients with diabetes are poor (149). Neglect of oral 
health of patients with diabetes, at a professional as well as at patient level, seems to be a 
global issue, and is not limited to a specific geographical area (150). An important factor 
which might influence how patients with diabetes perceive oral health is that they are 
already burdened by other non-oral medical complications of the disease and are 
therefore, less likely to seek oral health care (147). 
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2. AIMS 
The overall aim of this project was to study oral health indicators in Sudanese subjects 
with T2D and to investigate the impact of T2D and chronic periodontitis on biomarkers of 
inflammation and glucose regulation in gingival crevicular fluid (GCF) and saliva. It was 
hypothesised that T2D adversely influences oral health parameters, the expression of the 
related inflammatory molecules and the prevalence of periodontal pathogens. A further 
hypothesis to be tested was that chronic periodontitis exerts a systemic effect on glucose 
metabolism and this is reflected in the local expression, in GCF, of molecules that 
regulate glucose metabolism. 
The specific objectives were: 
I. To compare clinical and subjective oral health indicators (periodontal parameters, 
dental caries and OHRQoL) in T2D subjects and in age- and gender-matched controls 
without the disease (Study I).  
 
II. To investigate the influence of chronic periodontitis on the levels of glucoregulatory 
biomarkers in GCF (Study II). 
 
III. To investigate the effect of T2D on the local expression of molecules involved in 
periodontal inflammation and healing in GCF (Study III). 
 
IV. To investigate the impact of T2D on the prevalence of putative periodontal pathogens 
in dental plaque, and on levels of salivary MMP-8, MMP-9, RANKL and OPG (Study 
IV). 
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3. MATERIALS AND METHODS 
3.1 Study area and participants 
3.1.1 Enrolment of patients with type 2 diabetes 
The T2D patients were recruited from the dental clinic at Jaber Abol’ez Diabetes Centre 
in Khartoum city. It is one of the main public specialised referral hospitals for patients 
with diabetes in Khartoum state and the country, with a daily average of 250 patients 
visiting the centre (151). The study participants were enrolled between July and 
December 2012. One hundred and fifty seven T2D patients were invited to participate in 
the study (63 men and 94 women). Three patients resigned from participation due to time 
constraints. The mean age for T2D patients was 52.59 ± 10.50 years (range 24 to 70 
years). Diabetes was diagnosed by specialist physicians at the centre according to the 
criteria of the American Diabetes Association (152). The eligibility criteria for enrolment 
were: 
x Diagnosed with T2D more than one year ago. 
x At least 10 remaining natural teeth. 
x No medication with antibiotics or steroidal and/or non-steroidal anti-inflammatory 
agents over the past 3 weeks. 
x No immunosuppressive chemotherapy, no current acute illness, no professional 
periodontal treatment during the last 6 months and no pregnancy or lactation. 
To determine the level of glycaemic control, the T2D patients underwent an HbA1c 
test by boronate affinity chromatography (153) (well-controlled: HbA1c ≤ 8% and poorly 
controlled: HbA1c > 8%, 8% = 64 mmol/mol). 
3.1.2 Enrolment of subjects without diabetes 
Three hundred and four subjects without diabetes were recruited from the outpatient 
dental clinic at the Khartoum Dental Teaching Hospital in Khartoum city (119 men and 
185 women). One participant was diagnosed with diabetes and excluded after recruitment. 
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Khartoum Dental Teaching Hospital is the main public referral hospital in Khartoum 
state, providing dental services for the entire country. The mean age of participants 
without diabetes was 52.36 ± 10.50 years (range 24 to 70 years). With the exception of a 
diagnosis of diabetes, the same selection criteria as above were applied to recruitment of 
participants without diabetes. Subjects without diabetes were asked about signs and 
symptoms of diabetes and if suspected, they were referred for confirmation. 
3.1.3 Allocation of participants in studies I-IV 
x Study I: All the enrolled participants were included in this study (457 in total). 
Participants were grouped according to diabetic status: 154 patients with T2D and 303 
without the disease. The two groups were individually matched according to age and 
gender, with a ratio of 2 controls for each case.  
x Study II: A total of 152 participants were included in this study. Subjects were 
allocated into 4 groups according to diabetic and periodontal status; 54 with both T2D 
and chronic periodontitis, 24 with T2D, 30 with chronic periodontitis and 44 with 
neither T2D nor periodontitis.  
x Study III: In this study, 108 individuals were included, representing three groups: 54 
with both T2D and chronic periodontitis, 30 with chronic periodontitis and 24 with 
T2D.  
x Study IV: There were 80 participants, stratified as follows: 31 with both T2D and 
chronic periodontitis, 29 with chronic periodontitis and 20 with T2D. 
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Figure 5. Flowchart of the studies comprising the thesis. 
3.2 Questionnaire-guided interview 
All participants were interviewed by trained research assistants (three in total) using a 
structured questionnaire. The questionnaire was designed to gather data about socio-
demographic characteristics (age, gender, employment status and educational level), life 
style factors (alcohol consumption, tobacco use and consumption of sugary drinks), 
medical history, regularity of dental attendance and self-assessed oral health evaluation. 
In addition, the OHRQoL was assessed using the eight-item Oral Impact on Daily 
Performance inventory (OIDP) (154). 
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3.3 Clinical examination 
After completion of the interview, the participants underwent clinical examination of all 
teeth (except 3rd molars) and soft tissues of the oral cavity. One examiner, the author, 
conducted all examinations. The examination comprised assessment of dental plaque 
[Silness and Loe Index (155)], tooth mobility index (156), bleeding on probing (yes/no), 
probing depth [measured from the gingival margin to the base of the periodontal pocket 
(mm) at four sites of each tooth (mesial, distal, buccal and lingual)], furcation 
involvement (157), root caries (yes/no) and DMFT Index (158). 
3.4 Collection and laboratory analysis of biological samples 
GCF, dental plaque and saliva samples were obtained from 309 participants (154 T2D 
patients and 155 controls).  
3.4.1 Gingival crevicular fluid  
Method of collection 
GCF samples were collected using paper strips (PERIOPAPER® Gingival Fluid 
Collection Strips, Oraflow Inc., New York, USA). Four samples, representing the four 
quadrants, were obtained from each participant. The samples were immediately pooled, 
labelled and stored in liquid nitrogen. 
Protein extraction and quantification 
Protein was extracted from the GCF samples by Tween buffer, and quantified using a 
commercially available kit (PierceTM BCA Protein Assay Kit, ThermoScientific, 
Rockford, USA). Absorbance was measured at 560 nm on a plate reader (FLUOstar 
OPTIMA- BMG Labtech, Germany). Total protein per sample (4 strips) was calculated in 
micrograms (μg). 
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Multiplex assays 
Bead-based multiplex assays were used to detect 10 glucoregulatory molecules (Study II) 
(Appendix A) and 27 inflammatory molecules (Study III) (Appendix B) in the GCF 
samples (Bio-Plex Human Cytokine Assay, Bio-Rad Inc., Hercules, CA, USA) (159).   
3.4.2 Subgingival plaque 
Method of collection 
Subgingival plaque samples were collected on sterile endodontic paper points ISO 
(International Organisation for Standardisation) size 40. The samples were taken from the 
same sites as the GCF samples. The samples were immediately pooled, labelled and 
stored in liquid nitrogen. 
DNA purification 
DNA was purified using a commercially available kit, according to the manufacturer's 
instructions (MasterPure DNA purification kit, Epicentre Biotechnologies, Madison, 
Wisconsin). The amount of DNA was quantified for each sample by NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
Polymerase chain reaction 
After DNA purification, conventional polymerase chain reaction (PCR) was performed 
under standard conditions, to investigate the prevalence of P.gingivalis, T.forsythia, 
P.intermedia, T.denticola, C.rectus, and A.actinomycetemcomitans. The PCR products 
were loaded and separated by agarose gel electrophoresis (2.2% FlashGel DNA system, 
Lonza, Walkersville, MD). The stained DNA bands were visualised by ultraviolet light. 
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3.4.3 Whole saliva 
Method of collection 
Unstimulated whole saliva was collected by instructing the participants to rinse their 
mouths with water, tilt their heads downwards and expectorate into a sterile container for 
5 minutes. The samples were then aliquoted and immediately stored in liquid nitrogen 
(160). 
Enzyme linked immunosorbent assay 
The concentrations of MMP-8, MMP-9, OPG (Sigma-Aldrich, St. Louis, MO, USA) and 
RANKL (MyBiosource, CA, USA., and PeproTech EC, London, UK) were determined 
using enzyme linked immunosorbent assays (ELISA) according to the manufacturers’ 
instructions. Optical densities were determined using a microplate reader (FLUOstar 
OPTIMA- BMG Labtech, Germany). 
3.5 Ethical considerations 
Ethical clearance was obtained from The Ministry of Health in The Sudan and The 
Norwegian Research Ethics Committee at The University of Bergen (2012/1470/REK 
Vest). Participation was confirmed by written informed consent (Appendix C), and the 
steps involved in the clinical examination and sampling procedures were explained to 
each participant. Participants were also informed that their participation was voluntary 
and that they had the right to withdraw at any time. All participants were provided with 
verbal and written oral hygiene instructions, informed of their dental diagnosis and 
referred for appropriate dental treatment if needed. 
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Figure 6. Methods used for biological samples collection and laboratory analysis 
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4. METHODOLOGICAL CONSIDERATIONS 
4.1 Study design and participants 
This series of studies is the first time to present the oral health status of Sudanese adults 
with T2D. The project was therefore designed to record as much information as possible 
about this section of the Sudanese population, to serve as a firm foundation for further 
research and interventions. The recruitment of both T2D patients and controls was 
hospital-based. Both hospitals are part of the public healthcare system, providing services 
covered by government health insurance. Thus, these two hospitals provide healthcare to 
a wide sector of the residents of Khartoum state. As both cases and controls were 
hospital-based, there might be some selection bias, because the participants were seeking 
healthcare at the time of recruitment, implying that they probably have more severe oral 
diseases and higher treatment needs than subjects of population-based studies, recruited 
from the general population (161).   
The sample size calculation was performed according to the first objective of this 
project (Study I). It was not feasible to process all the biological samples obtained from 
the participants. Therefore, the sample size was reduced for Studies II-IV in order to be 
comparable with other scientific studies on the same topic. Moreover, participants without 
T2D and chronic periodontitis were excluded from Studies III and IV because all the study 
participants were dental attendees. Therefore, other dental problems might influence the 
results of these two studies (local expressions of different inflammatory molecules) (162); 
while in Study II, most of the investigated molecules are systemically produced, thus the 
influence of the local oral environment on their level of expression is minimal. For each 
study, the allocation of participants and the statistical analyses were planned in 
accordance with the specific objective.  
OIDP is one of the inventories for assessing OHRQoL. It quantifies the potential 
impact of oral problems on 8 daily tasks (141, 154). The Arabic version of the OIDP 
inventory has been validated and applied in The Sudan to a sample of 12 year-old school-
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children and to adults with mucocutaneous diseases (163, 164). The OIDP has also been 
applied in other low-income countries such as Tanzania and Uganda (165, 166). 
Both pocket depth and bleeding on probing were used to define cases of chronic 
periodontitis. These clinical parameters reflect the current activity of the disease, which 
was the focus of this project (167, 168). Bleeding on probing is regarded as a sign of 
active host inflammatory response. Its absence indicates periodontal stability (169). Both 
pocket depth and bleeding on probing are highly correlated with dental plaque microbiota 
and inflammatory status (170). 
The intra-examiner reliability of the solo examiner HGM was assessed by Cohen's 
kappa (κ) to estimate coefficients of agreement of dichotomous judgments in two 
different sessions (171). For this purpose, within 2 weeks, the oral examination was 
repeated for 20 randomly selected participants (172), and (κ) was calculated for tooth 
mobility (0.74), root caries (0.80), periodontal diagnosis (0.88) and dental caries (1.00). 
 The formula used for calculating (κ) is:  
κ =  
௉ᩞି௉ǝ
ଵି௉ǝ   
Where P˳ is the proportion of agreement of the units, and P˛ is the proportion of units for 
which agreement is expected by chance. The κ value ranges from 0 to 1 (1 = perfect 
agreement). 
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4.2 Biological sampling techniques and laboratory analysis  
4.2.1 Gingival crevicular fluid 
GCF is a complex fluid containing molecules derived from serum, cells of the periodontal 
tissue, immune cells and micro-organisms. Some of these molecules can be used as 
indicators of periodontal disease progression and the healing process (173). GCF can be 
collected by gingival washing, capillary tubes or absorbent paper strips (174). In Studies 
II and III, GCF was collected by paper strips. This method is non-invasive, but time 
consuming and technique sensitive (175). Guentsch et al., (176) compared the three main 
GCF sampling techniques: paper strips, paper points and washing method. They 
concluded that collecting GCF with paper strips is the method of choice for detection of 
most biomarkers in immunologic studies. As the availability of GCF for sampling varies 
from tooth site to site, hence the collected GCF samples should be standardised. One 
means of standardisation is measuring the GCF volume. Weighting of strips before and 
after the GCF sampling is also suggested, though this requires very sensitive scales, able 
to detect such a minor change in strip weight (174). An alternative approach is to 
standardise the time of collection (175). In Studies II and III, GCF collection time was 
standardised (30s) and the results were reported as the total amount in the timed sample.  
Although ELISA is considered as the gold standard for measuring inflammatory 
molecules, the multiplex assay is a powerful tool that offers some advantages over ELISA 
(177). It is a high throughput technology, able to detect up to 100 different analytes in a 
relatively small sample volume (159, 178). Moreover, both antigens and capture 
antibodies are freely suspended inside the reaction wells of the multiplex plate, while in 
ELISA, the capture antibodies are attached to the bottom of the well. Multiplex assays are 
therefore claimed to be at least as sensitive as ELISA (178). By assaying a relatively wide 
range of both glucoregulatory and inflammatory molecules, application of the multiplex 
technique in Studies II and III revealed a global picture of the inflammatory process 
involved in both diabetes and periodontal disease.  
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4.2.2 Subgingival plaque 
Several techniques are available for sampling dental plaque. Paper points and curettes are 
widely used in practice (179). It is claimed that a curette samples the entire pocket, while 
a paper point collects the outer layer, which contains more pathogens (180). In contrast, a 
recent study reported higher bacterial DNA in curette samples (181). Jervoe-Storm et al., 
(182) in a comparative study of samples collected by paper points and curettes, reported 
quite similar compositions of plaque microbiota. In the present study, subgingival plaque 
samples were collected on sterile paper points, ISO size 40. The use of paper points was 
more convenient in the field. It was less invasive for the patient and it was possible to 
transfer the samples immediately to transport vials. One disadvantage is that paper points 
might absorb moisture from GCF (183). To ensure a dry field, the subgingival plaque was 
sampled after collecting GCF from the sampling sites. In Study IV, plaque samples were 
obtained from 4 sites, one in each quadrant. This sampling strategy provides a 
representative, whole-mouth sample of subgingival microbiota. Moreover, sampling 4 
sites minimises false negative results associated with sampling only one or two sites 
(184). As the focus of interest was at the individual level rather than site-specific, the 
pooled design was adopted for both GCF and dental plaque samples (60, 185). 
In general, microbial analysis of dental plaque falls into one of the following 
methods: (i) polymerase chain reaction (PCR) i.e. conventional  and quantitative PCR, (ii) 
DNA-DNA hybridisation methods, which include in situ hybridisation, checkerboard 
hybridisation and oligonucleotide microarrays, and (iii) sequencing techniques (186). 
PCR is a powerful tool for gene amplification in simplified and automated fashion 
developed in 1985 by Kary Mullis and associates (187). In Study IV, conventional PCR 
was used to determine the prevalence (presence or absence) of the bacteria under 
investigation.  
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4.2.3 Whole saliva 
Saliva is produced mainly by the three major salivary glands; the parotid, submandibular 
and sublingual. Saliva can be sampled in the resting or stimulated state and may comprise 
whole or gland-specific saliva. Saliva also contains secretions from the minor salivary 
glands, GCF, desquamated epithelial cells, micro-organisms, immune cells, food 
remnants and circulating blood (188). Several biomarkers related to the pathogenic 
process of periodontal disease can be identified by saliva proteomic analysis (189). In 
Study IV, unstimulated (resting) saliva samples were collected. For detection of disease 
markers, resting whole saliva is preferred to stimulated saliva. It is also reported that 
substances used to stimulate salivary flow influence the pH and make saliva more watery, 
which might result in dilution of the protein content (190). 
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5. SUMMARY OF RESULTS AND GENERAL DISCUSSION 
5.1 Type 2 diabetes patients have poorer oral health indicators than controls 
The results of Study I reveal that T2D patients have a higher prevalence of tooth mobility 
(OR: 5.90, 95% CI: 2.26-15.39), furcation involvement (OR: 2.96, 95% CI: 1.36-6.45) 
and periodontal pocket ≥ 4 mm (OR: 4.07, 95% CI: 1.74-9.49). These findings are in 
accordance with those of several earlier studies reporting compromised periodontal 
parameters among patients with T2D (36, 38, 39). Moreover, a four-year follow-up study 
by Timonen et al., (191) indicated an association between impaired glucose metabolism 
(insulin resistance and β-cell function) and periodontal pocket formation among subjects 
without diabetes. They reported that impaired glucose metabolism weakly predicted 
periodontal pocket formation over the study period. 
Tooth loss is a serious dental problem which can have a negative impact on a 
person’s quality of life (192). Study I demonstrated that T2D patients suffered from more 
tooth loss (≤ 21 remaining teeth) than their controls (OR: 4.31, 95% CI: 1.57-11.76). This 
is in agreement with other reports (35, 40). Moreover, Costa et al., (19) have found an 
association between the level of glycaemic control and the number of standing teeth. Kaur 
et al., (193) reported an adjusted OR of 1.93 (95% CI: 1.37-2.71) that those with type 1 
diabetes have more missing teeth, while their results for those with T2D were not 
statistically significant. The non-significant results were attributed to the effect of age as a 
confounding factor. However, in Study I, after controlling for potential confounders 
including age, the results remained statistically significant. 
The adjusted analysis of Study I revealed no significant difference between T2D cases 
and controls for DMFT or root caries (OR: 0.38, 95% CI: 0.09-1.66) and (OR: 1.65, 95% 
CI: 0.84-3.26), respectively. A search of the scientific literature revealed conflicting 
findings about an association between T2D and dental caries. The lack of consensus can 
be attributed to the fact that many factors confound the association. For example, T2D 
patients are usually under strict dietary control, with low sugar intake. In addition, 
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xerostomia  is an acknowledged complication of diabetes, and this increases susceptibility 
to caries (135). One of the suggested explanations for high prevalence of caries in T2D 
patients is the high glucose level in saliva and GCF, which increases the activity of 
saccharolytic bacteria. These bacteria produce organic acids that cause demineralisation 
of enamel (194). The association between T2D and root caries is reported more frequently 
(138). Hintao et al., (195) reported a significant association between root caries and T2D, 
while the association with coronal caries was not significant. In Study I, the sub-group 
analysis among T2D patients indicated an association between duration of the disease and 
DMFT, with higher DMFT in those diagnosed with T2D more than 10 years ago (OR: 
2.94, 95% CI: 1.24-6.94). Similar findings were reported elsewhere (196). It has also been 
reported that duration of diabetes adversely influences the periodontal parameters (197), 
however, the results of  Study I disclosed no significant association between duration of 
diabetes and periodontal parameters. 
In general, utilisation of dental services by T2D patients was low in Study I, as only 
7.8% of the T2D patients reported that they were regular dental attenders. A low rate of 
dental attendance (10.8%) was also reported among Indian patients with T2D (198). Poor 
dental attendance might be attributable to financial restraints, dental anxiety or ignorance 
(199). It might also be due to the fact that oral diseases are not a priority for T2D patients, 
especially those who have serious non-oral medical complications (147). 
Studying OHRQoL adds another dimension to the objective measurements of dental 
problems such as periodontitis and dental caries, by taking into account the patients’ 
perceptions of their oral health status. Inclusion of OHRQoL assessment contributes to 
our understanding of the impact of the disease on the patient’s functional and psycho-
social well-being (141). The results of Study I indicated that T2D impacts OIDP - as a 
measure of OHRQoL - with an OR of 3.46 (95% CI: 1.61-7.42). Another study among 
adults with diabetes in the USA reported that poor health-related quality of life was 
associated with deterioration of oral health and lack of dental care (200). In contrast, Irani 
et al., (201) investigated OHRQoL in patients with and without T2D using the oral health 
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impact profile (OHIP-49) and concluded that periodontal diseases (gingivitis and 
periodontitis), but not T2D, were associated with poorer OHRQoL. Moreover, two 
qualitative studies, one in Ghana (202) and the other in the USA (203) investigated 
contextual factors related to diabetes and oral health care and concluded that patients with 
T2D did not perceive a correlation between diabetes and oral diseases to be a 
complication of diabetes.  
Study I is the first to report OHRQoL among adults with T2D in The Sudan. 
OHRQoL has been investigated in Sudanese 12 year-old school attendees  (163) and in 
Sudanese adults with mucocutaneous diseases (164). A study by Abdelgadir et al., (11) 
investigated health-related quality of life in Sudanese patients with diabetes who had 
undergone lower limb amputation, concluding that lower limb amputation negatively 
affected the quality of life of patients bearing the disease. 
The results of Study I prompted more questions about why patients with T2D have 
poorer periodontal parameters and whether chronic periodontitis has any impact on 
glucose metabolism. Within the limits of the study design and logistics, these questions 
were addressed in Studies II-IV. 
5.2 Chronic periodontitis influences gingival crevicular fluid levels of 
glucoregulatory biomarkers 
C-peptide, insulin and insulin-stimulating hormones 
Study II revealed that the levels of insulin-stimulating hormones (GIP and GLP-1) were 
higher in T2D patients with chronic periodontitis than in those without periodontitis.  In 
subjects without diabetes, the differences between those with periodontitis and those 
without were not statistically significant. Both GIP and GLP-1 are incretin hormones 
which reduce blood glucose levels by stimulating insulin secretion in response to food 
intake (204). Recently, these hormones have been intensively investigated for their 
therapeutic potential in treatment of high blood glucose (205). Although there was no 
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statistically significant difference in GCF levels of insulin between the two groups of 
patients with T2D (with and without chronic periodontitis), the high levels of GIP and 
GLP-1 in T2D patients with chronic periodontitis might be due to negative feedback from 
exogenous insulin, as the percentage of subjects on insulin therapy was low (29.6%) in 
patients with chronic periodontitis compared to those without periodontitis (50.0%). In 
this context, C-peptide is considered to be a better indicator of β-cell activity than insulin, 
because its level is not affected by exogenous insulin (206). The results for C-peptide 
were not statistically significant among patients with T2D. On the other hand, in 
participants without T2D, those with chronic periodontitis had lower levels of C-peptide 
than those without periodontitis. This might reflect lower β-cell activity in patients with 
chronic periodontitis than in their control group. Animal studies also indicate that 
periodontal disease adversely influences insulin metabolism and provokes insulin 
resistance (207, 208)  
Glucagon 
In Study II, GCF levels of glucagon were higher in T2D patients with chronic 
periodontitis than in their controls (T2D patients without periodontitis). Glucagon is an 
important hormone secreted by the pancreatic α-cell. It increases the blood glucose level 
by enhancing glycogenolysis (glycogen breakdown) and gluconeogenesis (synthesis of 
glucose from non-carbohydrate molecules) in the liver (209). Therefore, the high level of 
glucagon in T2D patients with chronic periodontitis might reflect the adverse systemic 
effect of chronic periodontitis on metabolic control in those patients. 
Anti-diabetic hormones (ghrelin and leptin) 
Ghrelin and leptin are both anti-diabetic hormones. Leptin improves peripheral insulin 
resistance (210), while ghrelin enhances insulin secretion, although recent evidence 
questions the role of ghrelin in insulin secretion (211). In Study II, the results for leptin 
were not statistically significant. In individuals without T2D, expression of ghrelin was 
lower in periodontitis patients than in their controls. In general, low systemic levels of 
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both hormones are reported in patients with T2D (212, 213). Moreover, Yilmaz et al., 
(214) reported elevated plasma ghrelin levels in individuals with chronic periodontitis 
compared to those without periodontitis. Ohta et al., (215) were the first to detect ghrelin 
in the GCF of 12 healthy volunteers. To the best of our knowledge, there are no data 
about GCF ghrelin levels in patients with T2D and periodontitis. 
An experimental study indicated that leptin negatively influences the regenerative 
capacity of human periodontal ligament cells (216). Another study reported that serum 
leptin levels are higher in patients with chronic periodontitis than in those without the 
disease (217), while Ay et al., (218) reported no variations in serum leptin levels 
associated with periodontal status. Furthermore, it was reported that leptin is expressed in 
lower amounts in gingival tissues of chronic periodontitis patients with T2D than in those 
without diabetes (219). 
Plasminogen activator inhibitor-1  
In Study II, there was a tendency towards increased plasminogen activator inhibitor-1 
(PAI-1) levels in T2D patients with chronic periodontitis compared to those without 
periodontitis. The opposite trend was observed in individuals without T2D. Neither of 
these results reached the level of significance. PAI-1 is a known marker for 
cardiovascular complications, especially among patients with diabetes (220, 221). 
Bizzarro et al., (222) reported higher levels of plasma PAI-1 in subjects with chronic 
periodontitis than in healthy controls. Moreover, a recent in vitro study found that 
P.gingivalis induces the expression of PAI-1 by human gingival fibroblasts (223). 
Resistin and visfatin 
The name resistin is derived from its action “insulin resistance”. It is claimed that the 
main source of resistin in humans is macrophages rather than adipocytes (224). The levels 
of resistin were above the detection limit in Study II. Some studies have reported up-
regulated GCF levels of resistin in patients with T2D and chronic periodontitis compared 
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to healthy controls (225, 226). Moreover, a review article by Devanoorkar et al., (227) 
indicated that chronic periodontitis is associated with increased resistin levels. In contrast, 
another study found that periodontal status does not influence serum resistin levels (228). 
Visfatin is known to mimic insulin. Its expression is induced by hyperglycaemia 
(229). Visfatin is also considered as a pro-inflammatory molecule which enhances the 
expression of IL-1β, TNF-α and IL-6 (230). In addition, it up-regulates the expression of 
MMP-1 and MCP-1 genes (231). It might also influence periodontal healing and 
regeneration (232). The results of Study II show a weakly positive correlation between 
visfatin levels and periodontal pocket depth. Elevated levels of visfatin have been 
reported in the serum, saliva and GCF of patients with chronic periodontitis (233, 234). It 
was found to be expressed in higher amounts in the gingival tissues of chronic 
periodontitis patients with T2D than in those without diabetes (219). 
5.3 Type 2 diabetes enhances Th-2 response and adversely influences local 
expression of anti-inflammatory and healing molecules 
Pro-inflammatory cytokines and chemokines 
Among the pro-inflammatory cytokines investigated in Study III, IL-1β levels were higher 
in T2D patients with chronic periodontitis than in those with T2D alone and chronic 
periodontitis alone, but the differences were not statistically significant. The levels of 
TNF-α were significantly higher in individuals with chronic periodontitis than in T2D 
patients with chronic periodontitis. It is claimed that there is insufficient evidence to 
support the effect of diabetes on TNF-α expression (51). There is, however, stronger 
evidence to support an association between diabetes-mediated periodontal tissue 
destruction and IL-1β (235). 
IL-6 is a pleotropic cytokine with both pro- and anti-inflammatory effects. It is 
involved in the activation of osteoclasts and Th-17 cells (236, 237). In contrast, IL-6 also 
induces the production of IL-1ra, thus contributing to the anti-inflammatory process 
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(238). In Study III, IL-6 levels were lower in T2D patients with chronic periodontitis than 
in those with T2D without periodontitis. A meta-analysis study reported no significant 
difference in IL-6 levels between periodontally diseased patients with and without T2D 
(235). 
Our data showed significantly lower levels of IL-7 in T2D patients with chronic 
periodontitis than in the other groups. In contrast, Duarte et al., (239) observed higher 
GCF levels of IL-7 in patients with uncontrolled T2D than in healthy controls. IL-7 is a 
key cytokine in naive T-cell homeostasis and also enhances Th-1 response (240, 241). 
Therefore, the present results suggest a disturbance of IL-7 mediated Th-1 response in 
T2D patients with chronic periodontitis. 
In Study III, some of the investigated chemokines such as IL-8 and MIP-1β were up-
regulated in T2D patients with chronic periodontitis, while others such as MIP-1α and 
RANTES were down-regulated. Longo et al., (242) studied serum IL-8 in T2D patients 
with chronic periodontitis and reported no significant difference in relation to diabetic or 
periodontal conditions. Moreover, it was reported that the levels of IP-10, RANTES and 
MCP-1 correlate negatively with increased periodontal tissue inflammation (243). IP-10 
works specifically as Th-1 activator, thus enhancing the production of INF-γ (244). The 
adjusted analysis of Study III indicated a non-significant trend towards decreased IP-10 
levels in T2D patients with chronic periodontitis compared to the other groups, which 
might explain the low INF-γ level (Th-1 cytokine) in this group. 
T-helper cells 
Cells of the adaptive immunity play a pivotal role in inflammatory-mediated periodontal 
tissue destruction (57). Th-1 secretes IL-2 and INF-γ, while Th-2 secretes IL-4, IL-5, IL-
6, IL-10 and IL-13 (64). In Study III, chronic periodontitis patients with T2D had 
significantly lower levels of INF-γ than those without diabetes. INF-γ is associated with 
up-regulation of other pro-inflammatory cytokines and chemokines (57). On the other 
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hand, INF-γ was found to have a protective role in bone tissue destruction, exerting an 
anti-osteoclastogenic effect (245). 
It is suggested that the Th-2/Th-1 cytokines ratio could determine the progression of 
chronic periodontitis (244). In Study III, T2D patients had a higher Th-2/Th-1 ratio than 
those without T2D (regardless of periodontal status). Shifting the activity of Th-cells from 
Th-1 to Th-2 reflects an enhanced humoral immune response and progression of 
periodontal tissue destruction in T2D patients via Th-2/B-cell axis (61, 246). However, 
others have identified Th-1 as the predominant response in periodontal tissue destruction 
(247). 
In Study III, levels of Th-17 cytokine (IL-17) were found to be low in T2D patients 
(with and without chronic periodontitis) compared to chronic periodontitis subjects 
without diabetes. However, the results did not reach significance. Low IL-17 level is 
associated with reduced neutrophil activity and increased bacterial dissemination (248). 
Duarte et al., (249) reported high IL-17 gene expression in gingival biopsies obtained 
from chronic periodontitis patients regardless of their diabetic status. In contrast, Zhao et 
al., (250) indicated that T2D patients had higher plasma IL-17 levels than their healthy 
counterparts. 
Anti-inflammatory and healing molecules 
T2D is reported to down-regulate IL-4, a cytokine involved in modulation of 
inflammation as well as in the healing process (57, 251). The present results demonstrated 
that chronic periodontitis patients with T2D had lower levels of IL-4 compared to those 
without diabetes. Ribeiro et al., (92) reported similar findings in T2D patients compared 
with systemically healthy subjects with comparable periodontal conditions. In Study III, 
subjects with chronic periodontitis had significantly lower levels of IL-10 than T2D 
patients without periodontitis. The interpretation of IL-10 results is complicated by the 
fact that it has both pro- and anti-inflammatory effects. A part from its immune-regulatory 
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effect [inhibition of osteoclastogenesis (252)], IL-10 is involved in stimulation of adaptive 
immunity (253). 
In Study III, the GCF levels of VEGF were higher in patients with T2D than in 
chronic periodontitis subjects without diabetes. Similar trends are reported elsewhere 
(254). This observation might be attributable to the fact that oxidative stress induces the 
VEGF signalling in patients with T2D (255). In addition, the data demonstrated that T2D 
is associated with down-regulation of FGF and PDGF. These molecules are involved in 
periodontal tissue regeneration, angiogenesis and the healing process (256). Therefore, 
disturbance to the levels of molecules involved in the anti-inflammatory and healing 
processes might be one of the mechanisms by which T2D adversely influences 
periodontal health in our patients. 
After investigating the local expression of molecules involved in the host 
inflammatory response, the next step was to explore whether T2D has any influence on 
the prevalence of putative periodontal pathogens in dental plaque, or markers of 
periodontal tissue destruction in saliva. 
5.4 Type 2 diabetes has no significant effect on either prevalence of periodontal 
pathogens or salivary MMP-8, MMP-9 and OPG 
The results of Study IV demonstrated that the investigated bacteria were more prevalent in 
individuals with chronic periodontitis (regardless of diabetic status) than in T2D patients 
without periodontitis, suggesting that T2D does not have a significant influence on the 
prevalence of the microbes under investigation.  
The prevalence of P.gingivalis was highest in the subjects with chronic periodontitis 
(81.5%), followed by T2D patients with chronic periodontitis (59.3%) and T2D patients 
without periodontitis (55.0%) (P > 0.05). The results for both P.intermedia and 
T.denticola showed similar tendencies. All plaque samples obtained from chronic 
periodontitis patients were positive for T.forsthysia, compared to 90% in samples of T2D 
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patients without periodontitis. C.rectus scored positive in plaque samples of all the study 
participants. In contrast, the prevalence of A.actinomycetemcomitans was generally low: 
7.4% in T2D patients with chronic periodontitis, 11.1% in subjects with chronic 
periodontitis; in the T2D patients without periodontitis, all the samples were negative to 
A.actinomycetemcomitans. Using quantitative PCR, Field et al., (50) reported similar 
findings, that the quantities of A.actinomycetemcomitans, F.nucleatum and P.gingivalis 
vary according to periodontal disease status and that T2D does not influence sub-gingival 
microbiota. Moreover, Li et al., (257) reported no significant differences in P.gingivalis 
between chronic periodontitis patients with T2D and those without diabetes. They also 
reported lower levels of P.intermedia in T2D patients with chronic periodontitis. Their 
results are in agreement with the present findings for P.gingivalis and P.intermedia. In 
contrast, other studies report significant variations in microbial composition of 
subgingival plaque between individuals with and without T2D (52, 53). Furthermore, a 
recent study by Demmer et al., (258) reported that increased levels of periodontal 
pathogens (A.actinomycetemcomitans, P.gingivalis, T.denticola and T.forsythia) were 
associated with two- to three-fold higher prevalences of prediabetes. 
The present data did not show any significant association between the prevalence of 
the periodontal pathogens investigated and the level of glycaemic control. As part of the 
Third National Health and Nutrition Examination Survey (NHANES III), Merchant et al., 
(259) investigated the levels of serum antibodies of putative periodontal pathogens in 
adults. They concluded that hyperglycaemia is associated with high antibody titres against 
periodontal micro-organisms. Moreover, an interventional study from Japan reported that 
the response of T2D patients with decreased HbA1c was better than that of T2D patients 
with increased HbA1c in terms of the prevalence of P.gingivalis after periodontal 
treatment (260). In contrast, another study reported no significant difference in 
periodontal pathogens between patients with and without T2D after periodontal treatment 
(261). It was suggested that the virulence of P.gingivalis varies according to its fimbriae, 
the hair-like extensions from the bacterial wall, and it was claimed that type II fimbriae 
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are associated with diabetes-mediated chronic periodontitis (262). This observation was 
confirmed by others (260). 
In Study IV, comparisons among the study groups failed to disclose any statistically 
significant differences in the concentrations of salivary MMP-8, MMP-9 or OPG. 
Nonetheless, there was a tendency towards increased salivary MMP-8 in subjects with 
chronic periodontitis (regardless of diabetic status) compared to T2D patients without 
periodontitis (P > 0.05). These results are in accordance with those of Costa et al., (263). 
They reported no significant differences in salivary MMP-8 between patients with T2D 
alone, subjects with chronic periodontitis alone, and patients with both diseases. Another 
study reported comparable levels of salivary MMP-8 and MMP-9 in subjects with and 
without T2D (264). In contrast, Rathnayake et at., (265) observed higher levels of 
salivary MMP-8 in T2D patients than in systemically healthy controls. Moreover, it is 
reported that MMP-8 and MMP-9 protein expression in the periodontal tissues of patients 
with T2D and chronic periodontitis is higher than in those with chronic periodontitis 
alone (266). 
The present results showed a non-significant trend towards increased OPG 
concentrations in patients with chronic periodontitis (regardless of diabetic status) 
compared to T2D patients without periodontitis. This can be explained by the fact that 
OPG concentration tends to be up-regulated in response to high osteoclastogenic activity 
(267). Conversely, a previous study observed significantly higher concentrations of 
salivary OPG in patients with T2D than in systemically healthy individuals with chronic 
periodontitis (263). Santos et al., (93) conducted a longitudinal study investigating 
RANKL and OPG in the GCF of well- and poorly controlled T2D patients before and 
after periodontal treatment. Throughout the study, the concentrations of RANKL and 
RANKL/OPG ratios were significantly higher in poorly controlled than in well-controlled 
T2D patients. In contrast, OPG concentrations did not differ significantly between the two 
groups at any time point. In Study IV, the concentrations of RANKL were below the 
detection limit, although two different commercial kits were used for detection. Frodge et 
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al., (268) also reported difficulty detecting RANKL in whole saliva. The reason might be 
that RANKL can be found as membrane-bound or soluble forms (71). 
One of the limitations of this project is the case definition of chronic periodontitis. 
Periodontal pocket depth and bleeding on probing were both used to define cases of 
chronic periodontitis, as clinical attachment loss data were not available. As a result, the 
effect of T2D on the study outcomes might be underestimated (269). Nevertheless, it was 
reported that both periodontal pocket depth and bleeding on probing reflect current 
disease status and are strongly related to local inflammatory activity, whereas clinical 
attachment loss reflects past disease experience (167, 270, 271). In order to exclude 
undiagnosed cases with diabetes, participants in the control group were asked about the 
classical symptoms of diabetes to exclude the disease. Confirmation by laboratory tests 
for this group was not achievable in the field. Therefore, there might be some cases of 
undiagnosed or pre-diabetes in the control group and this would underestimate the 
differences in the outcome variables between those with T2D and those without the 
disease. Another point to be considered is the sampling of GCF. Measuring GCF volume 
was not possible during the data collection in Khartoum. In the multivariate analysis to 
control for the potential effect of variability of GCF volume on the results, total GCF 
protein was used as a surrogate measure of GCF volume (272). 
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6. CONCLUSIONS 
The results confirm that patients with T2D have poorer OHRQoL and less favourable 
periodontal parameters than individuals without the disease. This seems to be related 
more to disturbed host immune-inflammatory response than to dissimilarities in the 
periodontal pathogens in dental plaque. Moreover, the deterioration in periodontal 
parameters influences local expression of molecules involved in glucose metabolism in 
the GCF of patients with and without T2D.  
The following conclusions can be drawn from the studies on which this thesis is based: 
x Patients with T2D present with more periodontal pockets (≥ 4 mm), tooth mobility, 
missing teeth, furcation involvement and OIDP than individuals without the disease. 
x Long-term T2D patients (> 10 years) have a higher DMFT than those who have had the 
disease for less than 10 years. 
x Poorly controlled T2D patients have a higher tooth mobility index than those with good 
glycaemic control. 
x Chronic periodontitis is associated with disturbed GCF levels of biomarkers related to 
the onset as well as to medical complications of T2D. 
x T2D and chronic periodontitis may adversely influence the GCF levels of 
inflammatory molecules, not only independently, but also synergistically. 
x T2D is associated with a high Th-2/Th-1 cytokines ratio, reflected in the GCF levels of 
the cytokines that they produce. 
x T2D adversely influences the local expression of molecules involved in the anti-
inflammatory and healing processes. 
x T2D has no significant effect on either the prevalence of the investigated periodontal 
pathogens, or the levels of salivary MMP-8, MMP-9 and OPG. 
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7. FUTURE PERSPECTIVES 
There is ample evidence to support the bi-directional relationship between diabetes and 
chronic periodontitis. Several mechanisms that might explain this complex relationship   
are highlighted, but the puzzle of the role of the immune system and the factors which 
modulate its action have yet to be solved. 
To date, there is no ideal biomarker which can be applied as a point-of-care test to 
assess risk, to diagnose, monitor progression, or predict the prognosis of either diabetes or 
chronic periodontitis. Research over the last decade, has focused on the interaction 
between different inflammatory molecules within different pathways, for better 
understanding of the complex inflammatory process that governs the pathophysiology of 
both diseases. Further research is warranted to identify disease markers which could be 
used by dentists to predict risk, diagnose and monitor T2D. 
There is emerging evidence of the importance of the anti-inflammatory response as 
an active process in controlling the progression of chronic inflammatory diseases. Anti-
inflammatory molecules, such as lipoxins and resolvins, which modulate the host defence 
mechanisms, are showing good potential as therapeutic agents (95, 102). To date, 
subantimicrobial dose doxycycline (SDD) is the only drug to have been approved by the 
United States Food and Drug Administration for modulating the host response by 
antagonising the action of MMPs (273). Yet, the therapeutic challenges require a 
sophisticated biological approach to develop an efficient therapy for chronic 
inflammatory conditions including chronic periodontitis and diabetes. 
The development of a multidisciplinary approach by the medical and dental 
professions for the management of chronic diseases, including diabetes, warrants further 
attention. In this context, in countries such as The Sudan, where diabetes is a rapidly 
escalating burden on the healthcare system, there is an urgent need to bridge the current 
gap between physicians and dentists. 
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9. APPENDICES 
Appendix A. The source and action of the glucoregulatory molecules investigated in 
Study II 
Inflammatory molecule 
(alternative names) 
Production cells Action References 
C-peptide (Connecting 
peptide) 
β-cells Links the A and B chains of insulin Hoekstra et al., 
1982 (274) 
Insulin β-cells Anti-inflammatory effect,  
stimulates glucose uptake and lipid 
synthesis, inhibits lipolysis, 
proteolysis, glycogenolysis and 
gluconeogenesis 
Mao et al., 2009 
(275) 
Sonksen and 
Sonksen, 2000 (2) 
GIP (Gastric inhibitory 
polypeptide, Glucose-
dependent insulinotropic 
peptide)   
Gastrointestinal track in 
response to food intake 
Glucose dependent potentiation of 
insulin secretion 
Fujita et al., 2010 
(204) 
GLP-1 (Glucagon-like 
peptide-1) 
Gastrointestinal track in 
response to food intake 
Stimulates insulin secretion and 
inhibits glucagon secretion 
Larsson et al., 
1997 (276) 
Glucagon 
 
α-cells Gluconeogenesis , increases hepatic 
glucose production 
D'Alessio, 2011 
(277) 
Lin and Accili, 
2011 (278) 
Ghrelin (Hunger hormone) Oxyntic mucosa of the 
stomach 
Stimulates food intake, energy 
homeostasis and anti-inflammatory 
activity 
Ohta et al., 2011 
(215) 
Leptin (Satiety hormone) Adipocytes Control of appetite, pro-
inflammatory  actions 
Fantuzzi, 2005 
(224) 
PAI-1 (Plasminogen 
activator inhibitor-1, 
Endothelial plasminogen 
activator inhibitor, Serpin 
E1) 
Hepatocytes, vascular 
smooth muscle cells, 
endothelial cells, 
fibroblasts and 
adipocytes 
Promotes thrombosis and fibrosis Lyon and Hsueh, 
2003 (220) 
Visfatin (Pre-B-cell colony-
enhancing factor-1, 
Nicotinamide 
phosphoribosyltransferase) 
Adipocytes Pro-inflammatory role, activates 
insulin receptor, insulin-mimetic 
actions 
Fantuzzi, 2005 
(224)  
Adeghate, 2008 
(229) 
Resistin (Tissue-specific 
secretory factor, C/EBP-
epsilon-regulated myeloid-
specific secreted cysteine-
rich protein) 
Macrophages, 
adipocytes 
Induces insulin resistance Fantuzzi, 2005 
(224) 
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Appendix B. The source and action of the inflammatory molecules investigated in Study 
III  
Inflammatory molecule 
(alternative names) 
Production cells Action References 
IL-1β (IL-1F2, Catabolin) Monocytes, macrophages, 
neutrophils, fibroblasts, 
epithelial cells  
Activation of innate immunity, 
regulation of adaptive immunity (T-
cells and myeloid cells), stimulation 
of connective tissue turnover  
Preshaw and 
Taylor, 2011 (31) 
Janeway et al., 
2001 (279) 
IL-1ra (Interleukin-1 
receptor antagonist) 
Monocytes, macrophages, 
neutrophils, fibroblasts, 
epithelial cells 
Antagonises IL-1β and IL-1α Preshaw and 
Taylor, 2011 (31) 
 
IL-2 (T-cell growth 
factor, Lymphokine) 
T-cells T-cells and natural killer cells 
proliferation, maintaining T-
cytotoxic, directing the 
development and function of T-reg 
cells 
Gaffen and Liu, 
2004 (280) 
IL-4 (BCGF-1, BSF-1) T-cells, mast cells Activation of B-cells, suppression of 
Th-1 cells 
Janeway et al., 
2001  (279) 
IL-5 (EDF, TRF) T-cells, mast cells Differentiation of eosinophil and B-
cells  
Janeway et al., 
2001  (279) 
IL-6 (HGF, HSF, BSF-2) T-cells, macrophages, 
endothelial cells 
T- and B-cells growth and 
differentiation, increases MCP-1, 
adhesion molecules and IL-1ra 
Kishimoto, 2006 
(281) 
Preshaw et al., 
2007 (62) 
Janeway et al., 
2001 (279) 
IL-7 (Lymphopoietin-1, 
Pre B-cells factor) 
Non-morrow derived 
stromal and epithelial cells 
T- and B-cells development Fry and Mackall, 
2002 (241) 
IL-8 (CXCL-8) Endothelial cells, 
neutrophils 
Attracts neutrophils, basophil and 
T-cells 
Janeway et al., 
2001 (279) 
IL-9 (T-cell growth 
factor p40) 
T-cells Enhances mast cells and Th-2 
activity 
Goswami and 
Kaplan, 2011 (282) 
IL-10 (B-TCGF, CSIF, 
TGIF) 
T-cells (mainly T-reg), 
macrophages,  
Suppresses innate immunity and 
cytokines, activates B-cells,  
counteracts macrophages function 
Garlet, 2010 (57) 
IL-12 (TcMF-1, CLMF, 
TSF) 
B-cells, macrophages  Activates natural killer cells, 
enhances Th-1 and INF-γ 
Preshaw and 
Taylor, 2011 (31) 
IL-13 (P600) T-cells Inhibits macrophages and Th-1, 
enhances B-cells proliferation 
Janeway et al., 
2001 (279) 
IL-15 Monocytes, macrophages, 
dendritic cells 
T-cells and natural killer cells 
activation and proliferation 
Fehniger and 
Caligiuri, 2001 (283) 
IL-17 (CTLA-8) Th-17 Induces the production of pro-
inflammatory cytokines and 
chemokines 
Gaffen and 
Hajishengallis, 2008 
(61) 
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Inflammatory molecule 
(alternative names) 
Production cells Action References 
Eotaxin (CCL-11, 
Eosinophil chemotactic 
protein) 
INF-γ stimulated 
endothelial cells, TNF-α 
stimulated monocytes  
Attracts eosinophils Janeway et al., 2001 
(279) 
Basic FGF (Basic 
fibroblast growth factor, 
HBGF-2) 
Neutrophils, macrophages, 
fibroblasts, mast cells, 
epithelial cells 
Wound healing and 
angiogenesis 
Sonmez and 
Castelnuovo, 2014 
(284) 
G-CSF (Granulocyte-
colony stimulating factor, 
CSF-3) 
Fibroblasts, monocytes, 
endothelial cells  
Neutrophil proliferation and 
maturation 
Root and Dale, 1999 
(285) 
GM-CSF (Granulocyte 
monocyte-colony 
stimulating factor, CSF-2) 
Fibroblasts, monocytes, 
endothelial cells, T-cells 
Neutrophil, macrophages and 
eosinophils proliferation and 
maturation 
Root and Dale, 1999 
(285) 
INF-γ  (Interferon- γ) T-cells, natural killer cells Activates macrophages, 
suppresses Th-2 
Janeway et al., 2001  
(279) 
IP-10 (Interferon 
inducible protein-10, 
CXCL-10, crg-2) 
Monocytes, lymphocytes, 
keratinocytes and 
endothelial cells in 
response to IFN- γ 
Activates Th-1 Gemmell and 
Seymour, 2004 (244)  
Cassatella et al., 1997 
(286) 
MCP-1 (Monocyte 
chemo-attractive 
protein-1, CCL-2) 
Macrophages, 
fibroblasts, epithelial cells, 
endothelial cells 
Attracts T-cells, monocytes 
basophils, natural killer and 
dendritic cells 
Takahashi et al., 2009 
(287) 
MIP-1α (Macrophage 
inflammatory protein-1 
α, CCL-3) 
Macrophages, dendritic 
cells, lymphocytes 
Attracts macrophages, T-
cytotoxic and natural killer cells  
Maurer and von 
Stebut, 2004 (288) 
MIP-1β (Macrophage 
inflammatory protein-1β,  
CCL-4) 
Macrophages, dendritic 
cells, lymphocytes 
Attracts macrophages, T-
cytotoxic and natural killer cells 
Maurer and von 
Stebut, 2004 (288) 
PDGF-BB (Platelet-
derived growth factor 
subunit B) 
Activated platelets, 
macrophages, endothelial 
cells 
Attracts neutrophils, 
macrophages and fibroblast, 
wound healing and 
angiogenesis 
Barrientos et al., 
2014 (256) 
RANTES (Regulated upon 
activation, normally T-
expressed, and 
presumably secreted, 
CCL-5) 
Neutrophils, macrophages, 
fibroblasts, mast cells, 
epithelial cells 
Attracts memory T-cells, 
monocytes, basophils and 
eosinophils  
Preshaw and Taylor, 
2011 (31) 
 
TNF-α (Tumor necrosis 
factor- α, Cachectin) 
Macrophages, natural killer 
cells, T-cells, neutrophils, 
fibroblasts, B-cells 
Vasodilatation, increases 
vascular permeability, enhances 
intra-cellular adhesion 
molecules 
Preshaw and Taylor, 
2011 (31) 
VEGF (Vascular 
endothelial growth 
factor, Vascular 
permeability factor) 
Macrophages, platelets Increases vascular permeability 
and angiogenesis  
Yanagita et al., 2014 
(289) 
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Appendix C: Consent forms 
Informed Consent 
Permission Code:   KS/MH/AA/AB                  
We are inviting you to participate in this application. Participation is entirely voluntary. Please 
read each sentence below and think about your choice. After reading each sentence, select 
‘Agree’ or ‘Disagree’ and sign your name on the consent. If you have any questions, please talk 
to our medical service staff or research assistants, or call our research review board at the 
Federal Ministry of Health phone number (+24983769928). 
Title of this Application: Association between oral health status and diabetes mellitus (D.M.) 
among Sudanese patients with type 2 diabetes. 
 
Principle Investigator: Hasaan Mohamed              Telephone No.: (+249912225656) 
Sponsors: University of Bergen- Norway           (+249123025656) 
Purpose: 
Aim of this large-scale study is to investigate the effect of type 2 diabetes mellitus on oral health 
among individuals with type 2 D.M.  
The purpose and procedures have been explained to the participants.  
Do you agree to participate in this study?!
ɍAgree 
ɍDisagree 
 
I agree to participate in this research entitled “: Association between oral health status and 
diabetes mellitus (D.M.) among Sudanese patients with type 2 diabetes”, which is being 
conducted by principle investigator: Hasaan Mohamed and phone number: (+249912225656) 
(+249123025656) where he can be contacted. I understand that this participation is entirely 
voluntary; I can withdraw my consent at any time and have the results of the participation 
returned to me, removed from the experimental records, or destroyed. I have read and 
understand the potential risks and side-effects of the sampling.   
Signature of participant:                                    Date:                                   
If you are an agent of the participant,  
Please sign your name:                                       Date:              
Interviewer’s name:                                            Date:      
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  tnesnoc demrofni eht fo noitalsnart cibarA *
 
 ﺇﻗﺭﺍﺭ ﻣﻁﻠﻊ ﻋﻠﻳﻪ
 
  ﺭﻣﺯ ﺍﻟﺑﺣﺙ: ﻭﺥ/ﻭﺹ/ﺍﻉ/ﺍﺏ          
ﺍﻟﺑﺣﺙ. ﺍﻟﻣﺷﺎﺭﻛﺔ ﺗﻁﻭﻋﻳﺔ ﺗﻣﺎﻣﺎ.ً ﺍﻟﺭﺟﺎء ﻗﺭﺍءﺓ ﻛﻝ ﺟﻣﻠﺔ ﻭ ﺍﻟﺗﻔﻛﻳﺭ ﻓﻲ ﺍﻟﺧﻳﺎﺭﺍﺕ. ﺑﻌﺩ ﻗﺭﺍءﺓ ﻛﻝ ﺟﻣﻠﺔ ﺍﺧﺗﺎﺭ )ﺃﻭﺍﻓﻕ( ﻧﺩﻋﻭﻛﻡ ﻟﻠﻣﺷﺎﺭﻛﺔ ﺑﻬﺫﺍ 
ﺃﻭ  ﺃﻭ )ﻻ ﺃﻭﺍﻓﻕ( ﺛﻡ ﻗﻡ ﺑﺎﻟﺗﻭﻗﻳﻊ ﻓﻲ ﻧﻬﺎﻳﺔ ﺍﻹﻗﺭﺍﺭ. ﺇﺫﺍ ﻛﺎﻥ ﻟﺩﻳﻙ ﺃﻱ ﺍﺳﺗﻔﺳﺎﺭ ﺍﻟﺭﺟﺎء ﺍﻟﺗﺣﺩﺙ ﺇﻟﻰ ﻛﻭﺍﺩﺭﻧﺎ ﺍﻟﻁﺑﻳﺔ ﺃﻭ ﺍﻟﺑﺎﺣﺛﻳﻥ ﺍﻟﻣﺳﺎﻋﺩﻳﻥ
  +(.٨٢٩٩٦٧٣٨٩٤٢ﺍﻟﺑﺣﻭﺙ ﺑﻭﺯﺍﺭﺓ ﺍﻟﺻﺣﺔ ﺍﻟﻭﻻﺋﻳﺔ ﺗﻠﻔﻭﻥ: ) ﺍﻻﺗﺻﺎﻝ ﺑﻬﻳﺋﺔ ﻣﺭﺍﺟﻌﺔ
  .٢ﻣﻥ ﺍﻟﻧﻭﻉ  ﺍﻟﻣﺻﺎﺑﻳﻥ ﺑﺩﺍء ﺍﻟﺳﻛﺭﻱ ﺍﻟﻣﺭﺿﻰ ﺍﻟﺳﻭﺩﺍﻧﻳﻳﻥ ﺑﻳﻥﻣﺭﺽ ﺍﻟﺳﻛﺭﻱ ﻭ ﺻﺣﺔ ﺍﻟﻔﻡ ﺍﻟﻌﻼﻗﺔ ﺑﻳﻥﻋﻧﻭﺍﻥ ﺍﻟﺑﺣﺙ : 
   +( ٦٥٦٥٢٠٣٢١٩٤٢+( )٦٥٦٥٢٢٢١٩٩٤٢ﺍﻟﺑﺎﺣﺙ ﺍﻟﺭﺋﻳﺳﻲ : ﺣﺳﺎﻥ ﻗﺎﺳﻡ ﺳﻌﺩ ﻣﺣﻣﺩ                     ﺗﻠﻔﻭﻥ)
  ﺍﻟﻧﺭﻭﻳﺞ.                              -ﺍﻟﻣﺗﻛﻔﻝ ﺑﺎﻟﺑﺣﺙ :ﺟﺎﻣﻌﺔ ﺑﻳﺭﻗﻥ
 ﺍﻟﻬﺩﻑ: 
  .٢ﻓﻲ ﺻﺣﺔ ﺍﻟﻔﻡ ﻟﺩﺍ ﺍﻷﻓﺭﺍﺩ ﺍﻟﻣﺻﺎﺑﻳﻥ ﺑﻣﺭﺽ ﺍﻟﺳﻛﺭﻱ ﻣﻥ ﺍﻟﻧﻭﻉ   ٢ﺩﺍء ﺍﻟﺳﻛﺭﻱ ﻣﻥ ﺍﻟﻧﻭﻉ  ﺩﺭﺍﺳﺔ ﺗﺄﺛﻳﺭ ﻫﻭﺍﻟﻐﺭﺽ ﻣﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺳﺔ 
 ﺍﻟﻬﺩﻑ ﻭ ﺍﻟﻁﺭﻳﻘﻪ ﺗﻡ ﺷﺭﺣﻬﺎ ﻟﻠﻣﺷﺎﺭﻛﻳﻥ ﺑﺎﻟﺑﺣﺙ.
  ﺑﻬﺫﻩ ﺍﻟﺩﺭﺍﺳﺔ ؟ ﻫﻝ ﺗﻭﺍﻓﻕ ﻋﻠﻰ ﺍﻟﻣﺷﺎﺭﻛﺔ
  . ﺃﻭﺍﻓﻕ    ١
  . ﻻ ﺃﻭﺍﻓﻕ٢
ﻭ ﻣﺭﺽ ﺍﻟﺳﻛﺭﻱ ﺑﻳﻥ ﺍﻟﻣﺭﺿﻰ ﺍﻟﺳﻭﺩﺍﻧﻳﻳﻥ ﺍﻟﻣﺻﺎﺑﻳﻥ ﺑﺩﺍء ﺍﻟﺳﻛﺭﻱ ﻣﻥ ﺍﻟﻧﻭﻉ  ﺻﺣﺔ ﺍﻟﻔﻡ ﺃﻭﺍﻓﻕ ﻋﻠﻰ ﺍﻟﻣﺷﺎﺭﻛﺔ ﺑﻬﺫﺍ ﺍﻟﺑﺣﺙ )ﺍﻟﻌﻼﻗﺔ ﺑﻳﻥ
+(, ﺃﺗﻔﻬﻡ ﺃﻥ ٦٥٦٥٢٠٣٢١٩٤٢+( )٦٥٦٥٢٢٢١٩٩٤٢ﺍﻟﺛﺎﻧﻲ(, ﺍﻟﺑﺎﺣﺙ ﺍﻟﺭﺋﻳﺳﻲ: ﺣﺳﺎﻥ ﻗﺎﺳﻡ ﺳﻌﺩ ﻣﺣﻣﺩ, ﺭﻗﻡ ﺗﻠﻔﻭﻧﻪ ﻟﻼﺗﺻﺎﻝ ﺑﻪ : )
ﻫﺫﻩ ﺍﻟﻣﺷﺎﺭﻛﺔ ﻫﻲ ﺍﺧﺗﻳﺎﺭﻳﺔ ﺗﻣﺎﻣﺎ,ً ﺃﺳﺗﻁﻳﻊ ﺍﻟﺗﺧﻠﺹ ﻣﻥ ﺇﻗﺭﺍﺭﻱ ﻭﻗﺗﻣﺎ ﺃﺷﺎء ﻛﻣﺎ ﺃﺳﺗﻁﻳﻊ ﺍﻻﻁﻼﻉ ﻋﻠﻰ ﻧﺗﺎﺋﺞ ﺍﻟﻣﺷﺎﺭﻛﺔ ﻭ ﺗﻣﺣﻰ ﻣﻥ 
 ﺍﻟﺳﺟﻼﺕ ﻭ ﺗﺩﻣﺭ ﻭﻗﺗﻣﺎ ﺃﺷﺎء .ﻟﻘﺩ ﻗﺭﺃﺕ ﻭ ﻓﻬﻣﺕ ﺍﻟﻣﺧﺎﻁﺭ ﻣﻥ ﺃﺧﺫ ﺍﻟﻌﻳﻧﺔ  
 
 
 
  ﺍﻟﺗﺎﺭﻳﺦ:                              ﺗﻭﻗﻳﻊ ﺍﻟﻣﺷﺗﺭﻙ:                                          
 ﺍﺫﺍ ﻛﻧﺕ ﻭﻛﻳﻝ ﺍﻟﻣﺷﺗﺭﻙ,
 ﺍﻟﺭﺟﺎء ﺍﻟﺗﻭﻗﻳﻊ:                                                                        ﺍﻟﺗﺎﺭﻳﺦ:
 ﺍﺳﻡ ﺍﻟﺑﺎﺣﺙ :                                                                          ﺍﻟﺗﺎﺭﻳﺦ:
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Appendix D. Questionnaire  
 
 
 
 
 
 
 
 
 
 
Serial No./ID.         □□□  
Interview date /          /               
Interviewer _________           
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1-Personal information 
Interviewee:   _________________________ 
Hospital:          _________________________ 
Tel. number:   _________________________ 
Address:       _______________________ 
 
2-Dietary Habits and physical activity: 
1-What is the frequency of your consumption of the following food per week?  
a- Milk               □□□       b- Red Meat          □□□             c- Chicken                   □□□ 
d- Fish                □□□      e- Eggs                    □□□             f- Fresh Green Salad □□□ 
g- Fresh Fruits   □□□      h- Fresh Fruit Juice□□□             i- Cakes & Deserts     □□□ 
j- Natural honey □□□    K- bread                 □□□ 
2- What is the type of food you eat the most (or your most frequent main dish) in the week? 
□ 1. Kisra, Gurrasa or Bourages (Sorghum , Wheat , Maze, ...)       □ 2. Meat. 
□ 3. Beans with bread.         □ 4. Cooked vegetables.                □ 5. Others. ____________ 
3- What is the frequency of your consumption of sugary drinks per day? 
*Example: soft drinks, beverages with added sugar, sweet soup. 1 cup؆ 250 ml.  
□0.  None             □1.   ≤1 Cup                       □2.   2-3 Cups                    □3.   ≥4 Cups 
 
1.Gender: □ 1. Male □ 2. Female  
2.Age: _________  
3.Marital status: □ 1. Married □ 2. Not married 
4.Education: □ 1. Illiterate □ 5. High secondary school 
 □ 2. Literate  □ 6. College, university 
 □ 3. Primary school □ 7. Graduate institute  
 □ 4. Middle secondary school  
5.Employment: □ 1. Unemployed  
 Unemployed, but is  □ 2. Student 
  □ 3. Housewife 
  □ 4. Retired 
 □ 5. Employed Your occupation type:__________________                
  
Title:__________________ 
 
6. Where were you born? _______  
7. Tribe: _______  
8. Current weight:      ____  kg 
9. Current Height:      ____  cm   
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4- Do you eat regular meals every day? (Breakfast, lunch and dinner). 
□0.  No                     □1. Yes 
5- Frequency of physical activity? 
□0.  Never         □1.  Once / week        □2.    2-3 times/week      □3.    > 3 times/week 
6- For how long do you exercise? 
□0.  Never     □1.   < 15 min.     □2.    15 - 29 min.      □3.   30 min to 1 hr.        □4.    > 1 hr. 
3-Medical History: 
No. Disease 0= No, 1= Yes,  2= Unknown 
Comments (site or more 
specification, etc. …)  
(1) Diabetes  Duration: ______ 
(2) Hypertension   
(3) Cancers  Type: ______ 
(4) Hyperlipidaemia   
(5) Asthma        
(6) Heart disease   
(7) Liver disease   
(8) Kidney disease   
(9) Gout   
(10) Skin warts? If yes, where?   
(11)* Sexually transmitted disease?  Which: ______ 
(12) Others      
 *(11) Syphilis; Gonorrhea; Condyloma/Warts; HIV/AIDS? 
2- Family history of diabetes: 
□ 0.   No                     □ 1.   yes,   If yes which side?   ______ 
3- Type of diabetes medication used:   
□  1.  Dietary control only              □  2.    Oral hypoglycaemic                 □  3.   Insulin     
□  4.  Both (Oral hypoglycaemic and insulin) 
4-Part A. Alcohol use: 
1. Do you ever habitually drink alcohol (Defined as at least 1 time per week)?ġ
□  0.No 
□  1. Yes, only less than twice in life time. 
□  2. Past drinker; when did you start to drink? ______ years old; when did you stop to 
drink?____ years old  
□  3. Current drinker; when did you start to drink? ______ years old 
 
 
 
 1- Whether you have the following diseases diagnosed by clinical doctors? 
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2. When you drink, what types of alcoholic beverages you drink?  
Illustration:  
Large bottle (1 L)           Medium bottle (500 ml.)                 Small bottle (250 ml)          Cup (150ml)       Shot (25 ml)            
                                                                                         
 
 
 
 
□ a. Marissa (Sorghum):  <6%   
 Days / week Average daily consumption  
 □1 □2 □3 □4 □ 1.Large bottle (1 L)         Units    
 □5 □6 □7  □ 2.Medium bottle (500 ml)         Units    
    ! □ 3.Small bottle (250 ml)         Units    
    ! □ 4.Cup (150ml)         Units    
     □ 5.Shot (25 ml)         Units    
□ b. Aragi: (dates, Sorghum , etc) <40% 
 Days / week Average daily consumption  
 □1 □2 □3 □4 □ 1.Large bottle (1 L)         Units    
 □5 □6 □7  □ 2.Medium bottle (500 ml)         Units    
    ! □ 3.Small bottle (250 ml)         Units    
    ! □ 4.Cup (150ml)         Units    
     □ 5.Shot (25 ml)         Units    
□ c. Imported alcohol: ≥40% ( Whisky, Vodka, Gin, Others) 
 Days / week Average daily consumption  
 □1 □ □3 □4 □ 1.Large bottle (1 L)         Units    
 □5 □6 □7  □ 2.Medium bottle (500 ml)         Units    
    ! □ 3.Small bottle (250 ml)         Units    
    ! □ 4.Cup (150ml)         Units    
     □ 5.Shot (25 ml)         Units    
□ d. Others: ____________             
 Days / week Average daily consumption  
 □1 □2 □3 □4 □ 1.Large bottle (1 L)         Units    
 □5 □6 □7  □ 2.Medium bottle (500 ml)         Units    
    ! □ 3.Small bottle (250 ml)         Units    
    ! □ 4.Cup (150ml)         Units    
     □ 5.Shot (25 ml)         Units    
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4-Part B. Toombak (smokeless tobacco) use: 
1. Do you ever habitually use Toombak (Defined as at least 1 Saffa per week)?ġ
□  0. No 
□  1. Yes, only less than twice in life time. 
□  2. Past user; when did you start dipping? ______ years old; when did you stop dipping?____ years old  
□  3. Current dipper; when did you start dipping? ______ years old 
2. What is the frequency of your usage? 
Days / week ______                How many times per day ______          How long (min/saffa) ______ 
4-Part C. Smoking: 
1. Do you ever habitually smoke cigarettes? (Defined as at least 1 cigarette per week)ġ
□ 0.  No 
□ 1. Yes, only less than twice in a life time. 
□  2. Past smoker; when did you start to smoke? ______ years old; when did you stop to smoke?____ years old  
□  3. Current smoker; when did you start to smoke? ______ years old 
2. When you smoke, what types of tobacco you smoke? (More than one answer is available): 
□Heavy cigarettes 
 □Light cigarettes 
 □Pipes: 
 
  
 
Days / week Average daily consumption (cigarettes/day) 
□1 □2 □3  
□4 □5 □6             Cigarettes 
□7    
 
Days / week Average daily consumption (cigarettes/day) 
□1 □2 □3  
□4 □5 □6             Cigarettes 
□7    
 
Days / week Average daily consumption (/day) 
□1 □2 □3  
□4 □5 □6                                             Times 
□7    
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□Shisha: 
 
□Others:              
 
5.  Self-assessed oral health evaluation: 
 
  
 
Days / week Average daily consumption (/day) 
□1 □2 □3  
□4 □5 □6                                            Times 
□7    
 Days / week Average daily consumption (/day) 
□1 □2 □3  
□4 □5 □6                                           Times 
□7    
   
 1. Tooth brushing (times/day)? ˎ 0.  Never               ˎ 1.   1                ˎ2įġġġ2            ˎ3.    t2 
 2. Which instrument you use for brushing? ˎ 0.  Tooth brush.     ˎ 1.  Muswaak.   ˎ 2.  Others ______ 
 3. Which material you use for brushing? ˎ 1.  Tooth paste.      ˎ 2.  Others ______  
 4. Do you have gum bleeding when washing/brushing teeth? ˎ 0.  No.                    ˎ 2.  Yes. 
 5. Do you use mouth wash?  ˎ 0.  No.                    ˎ 1.  Yes  
 6. Have you noticed any visible lesion in your mouth recently?  ˎ 0.  No.                    ˎ 1.  Yes  
 7. Do you Wear a denture? If yes, since when? ġ ˎ 0.  No                     ˎ1.  Yes: Since ______ ______ġġġġ 
 8. If last answer is yes, what is your denture type? ˎ 1.  Partial.              ˎ 2.   Complete. 
 9. Dental check-ups?ġ ˎ 0.  Never                ˎ1.   >5 years      ˎ2.  2-5 years     
ˎ 3.  Every year or less   
 10.Do you feel a change in the smell of your mouth ˎ 0.  No                    ˎġ1.  Yesġġġġġ
 11. Change in taste? ˎ 0.  No                    ˎ 1.  Yesġġġġ
 12. History of dry mouth?  ˎ 0.  No                    ˎ 1.  Yesġġġġ  ġ
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 PDIO
 
  -ﺳﺒﺒﺖ ﻟﻚ ﺑﻌﺾ ﺍﻟﺼﻌﻮﺑﺎﺕ  ﻓﻲ ﺍﻻﺗﻲ : ﺧﻼﻝ ﺍﻟﺴﺘﺔ ﺷﻬﻮﺭ ﺍﻻﺧﻴﺮﺓ , ﻫﻞ ﻋﺎﻧﻴﺖ ﻣﻦ ﻣﺸﻜﻠﺔ ﻓﻲ ﻓﻤﻚ ﻭﺃﺳﻨﺎﻧﻚ ﺃﻭ ﺃﺳﻨﺎﻧﻚ
 
  :ﺍﻛﻞ ﻭﻣﻀﻎ ﺍﻟﻄﻌﺎﻡ  -ﺃ 
 
  / ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ 2/ ﺍﻁﻼﻗﺎ                                    1
  /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒﺎ ﻳﻮﻣﻴﺎ 5/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                4/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ              3
 
  ﻧﻔﺴﻚ ﺑﻮﺿﻮﺡ :ﺍﻟﺘﺤﺪﺙ ﻭﺍﻟﺘﻌﺒﻴﺮ ﻋﻦ  -ﺏ
 
  / ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ 2/ ﺍﻁﻼﻗﺎ                                    1
  /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒﺎ ﻳﻮﻣﻴﺎ 5/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                4/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ              3
 
  ﻧﻈﺎﻓﺔ ﺃﺳﻨﺎﻧﻚ:  -ﺕ 
 
  ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ / 2/ ﺍﻁﻼﻗﺎ                                    1
  /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒﺎ ﻳﻮﻣﻴﺎ 5/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                4/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ              3
 
  ﺍﻟﻨﻮﻡ ﻭﺍﻻﺳﺘﺮﺧﺎء:   -ﺙ  
 
  / ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ 2/ ﺍﻁﻼﻗﺎ                                    1
  /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒﺎ ﻳﻮﻣﻴﺎ 5/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                4   / ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ           3
 
  ﺍﻟﺤﻔﺎﻅ ﻋﻠﻲ ﺍﻟﺤﺎﻟﺔ ﺍﻟﻨﻔﺴﻴﺔ:   -ﺝ
 
  / ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ 2/ ﺍﻁﻼﻗﺎ                                    1
  /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒﺎ ﻳﻮﻣﻴﺎ 5/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                4/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ              3
 
  ﺍﻟﻘﻴﺎﻡ ﺑﻤﻌﻈﻢ ﺍﻟﻮﺍﺟﺒﺎﺕ ﻭﺍﻻﻋﻤﺎﻝ:  -ﺡ
 
  / ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ 2/ ﺍﻁﻼﻗﺎ                                    1
  /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒﺎ ﻳﻮﻣﻴﺎ 5ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                / ﻣﺮﺓ 4/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ              3
 
  ﺍﻟﺘﻌﺎﻣﻞ ﻣﻊ ﺍﻟﻨﺎﺱ  ﺑﺎﺭﺗﻴﺎﺡ:  -ﺥ
 
  / ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ 2/ ﺍﻁﻼﻗﺎ                                    1
  ﺎ ﻳﻮﻣﻴﺎ /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒ5/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                4/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ              3
 
  ﺍﻻﺑﺘﺴﺎﻡ ﻭﺍﻅﻬﺎﺭ ﺍﻻﺳﻨﺎﻥ:  -ﺩ
 
  / ﺍﻗﻞ ﻣﻦ ﻣﺮﺓ ﻓﻲ ﺍﻟﺸﻬﺮ                                                    2/ ﺍﻁﻼﻗﺎ                                    1
  /  ﺩﺍﺋﻤﺎ ﺗﻘﺮﻳﺒﺎ ﻳﻮﻣﻴﺎ5/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻻﺳﺒﻮﻉ                4/ ﻣﺮﺓ ﺍﻭ ﻣﺮﺗﻴﻦ ﻓﻲ ﺍﻟﺸﻬﺮ              3 
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Appendix E. Examination sheet 
Index                                                                                          Date__/__/__ 
Name:      Age:    Sex: 
General examination: 
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
Mucogingival problems                             
Plaque index                             
Calculus                             
Recession                             
Mobility                             
Root caries                             
  47 46 45 44 43 42 41 31 32 33 34 35 36 37 
Mucogingival problems                             
Plaque index                             
Calculus                             
Recession                             
Mobility                             
Root caries                             
 
Specific examination: 
 
  
 
Periodontal pocket: blue (mm)                               Bleeding on probing: (red dot) 
Furcation involvement:  
                                                                                               
Furcation involvement:      I =          II =     III=    (red) 
Dental caries (DMFT): 
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
                            
                            
47 46 45 44 43 42 41 31 32 33 34 35 36 37 
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Appendix F. Oral hygiene instructions card 
 
 
Adapted from: Washington State Department of Social & Health Services, Division of 
Developmental Disabilities. Oral hygiene guidelines: Preventing dental disease in people 
with special health care needs. Olympia, WA: The Department; 2000. 
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Abstract
Aim: The purpose of this study was to compare the clinical and subjective oral health indicators of type 2 diabetic patients
(T2DM) with age and gender matched non-diabetic controls. A second aim was to identify clinical and subjective oral health
indicators that discriminate between well-controlled and poorly controlled T2DM patients as well as between patients with
long and short duration of the disease.
Methods: A total of 457 individuals participated in the study (154 T2DM cases and 303 non-diabetic controls). The T2DM
controlled: glycosylated haemoglobin test . 8%)] and according to duration of T2DM [(long duration: .10 years), (short
duration: #10 years)]. Participants were interviewed using a structured questionnaire including socio-demographics,
lifestyle and oral health related quality of life factors. The clinical examination comprised full mouth probing depths, plaque
index, tooth mobility index, furcation involvement and coronal and root surface caries.
Results: The T2DM patients presented with more probing depths $4mm, furcation involvement, tooth mobility, missing
teeth, and oral impacts on daily performance (OIDP). The corresponding adjusted odds ratios and their 95% confidence
intervals were 4.07 (1.74–9.49), 2.96 (1.36–6.45), 5.90 (2.26–15.39), 0.23 (0.08–0.63) and 3.46 (1.61–7.42), respectively.
Moreover, the odds ratio was 2.60 (1.21–5.55) for the poorly controlled T2DM patients to have high levels of mobility index
and 2.94 (1.24–6.94) for those with long duration of T2DM to have high decayed, missed and filled teeth (DMFT) values.
Conclusion: This study revealed that chronic periodontitis, tooth mobility, furcation involvement and OIDP were more
prevalent among T2DM patients compared to their non-diabetic controls.
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Introduction
Diabetes Mellitus (DM) is a metabolic disorder characterized by
chronic hyperglycaemia and disturbances of carbohydrate, fat and
protein metabolism [1]. Type 1 DM is most common in children
and adolescents, whereas type 2 DM (T2DM) affects adults.
T2DM constitutes about 90–95% of all patients having the disease
[2]. Patients with T2DM usually have insulin resistance which
alters the utilization of endogenously produced insulin at the target
cells. During the early stage of the disease, insulin production is
increased resulting in hyperinsulinemia. However, as the condition
progresses, the production of insulin decreases leading to insulin
deficiency [2]. Whereas both type 1 DM and T2DM have a
genetic predisposition, the aetiology of T2DM is also related to life
style factors such as high fat and sugar intake, physical inactivity
and obesity [2]. Worldwide; 346 million people suffer from DM
[3] and this disease is ranked as the ninth most common disorder
amassing a 68% increase from 1990 to 2010 [4]. Between the
years 2010 and 2030, the number of adults with DM in developing
countries is expected to increase by 70%, most extensively in
Africa [5]. In the Sudan, the prevalence of DM is increasing to
epidemic proportions, affecting about 14% of a total population of
31 million [6].
Poorly controlled DM has been associated with increased
susceptibility to oral infections including periodontal disease [7–
10]. Periodontal disease is characterized by loss of connective
tissue and bone support, which eventually might lead to tooth loss.
Previous studies have suggested that periodontal infection and DM
have a two-way relationship [10,11]. Lo¨e, [12] stated that
periodontal disease is the sixth most common complication of
DM, whereas Lalla et al., [10] reported that DM is the strongest
risk factor for periodontal infection compared to the other systemic
conditions such as hypertension. Moreover, it has been demon-
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group was sub-divided according to metabolic control [(well-controlled: glycosylated haemoglobin test #8%), (poorly
strated that individuals with periodontal pocket $6mm are 3.5
times more likely to develop T2DM than those having periodontal
pocket ,6mm [13]. By now there is strong evidence suggesting
that the prevalence and severity of periodontal disease are higher
among T2DM patients when compared with non-diabetic
individuals [8,9,14–18]. Few studies have reported on no
difference in periodontal disease between individuals with and
without T2DM [19,20]. Whereas some studies have reported
worse periodontal condition among poorly controlled T2DM
patients [8,9], others have disconfirmed an association between
periodontal disease and metabolic control [21,22].
Few studies have examined the situation of dental caries among
T2DM patients. It has been demonstrated that the number of
decayed, missed and filled teeth (DMFT) is higher among
individuals with than without T2DM [18,23,24]. Moreover,
Leung et al., [25] have found the risk of dental caries to be twice
as high in T2DM patients compared to healthy controls. Other
studies have disconfirmed such an association [26–28]. Compared
to coronal caries; a relationship between DM and root surface
caries has been more obvious [10]. Thus, individuals with T2DM
have higher prevalence of root surface caries compared to non-
diabetic individuals [26,29]. This evidence is equivocal as some
studies have found no difference in root surface caries between
individuals with and without T2DM [28,30].
The overall contribution of oral diseases to quality of life
among T2DM patients has not been frequently investigated.
According to the literature, oral health-related quality of life
(OHRQoL) did not discriminate between individuals with and
without DM [31,32]. It has also been reported that patients with
both types of DM have limited awareness of the possible health
consequences of poor oral health [32]. OHRQoL measures have
been tested in various populations to supplement clinical
indicators of oral diseases [33]. One promising measure is the
oral impact of daily performance inventory (OIDP) [34]. This
measure is based on the WHO classification of impairments,
disabilities and handicaps [35] and Locker’s theoretical frame-
work [36]. Since its development, the OIDP has shown to be
reliable and valid in population based studies as well as in studies
of patients with specific disorders [37–39]. An Arabic version of
the OIDP inventory has been validated and used in the Sudan
among 12 years old school children as well as among adult dental
attendees with and without mucocutaneous diseases [40–42]. The
OIDP has also been applied in other low-income countries such
as Tanzania and Uganda [38,39].
In order to control DM in the Sudan, it is important to bridge
the gap between physicians and dentists and to increase the
involvement of the dental profession in the secondary prevention
of this disease. Information about oral manifestations of T2DM
should be made easily available to raise the awareness and
knowledge of the importance of dental care for T2DM patients.
To our knowledge, there is no published data available
documenting the oral diseases and self-reported oral health
situation among adult diabetic patients in the Sudan. The purpose
of this study was to examine the clinical and subjective oral health
indicators among T2DM patients receiving ongoing treatment in
an outpatient specialist clinic and to compare the observations
with age and gender matched non-diabetic controls taken from the
same population. It was hypothesized that T2DM patients were
more likely to have oral disease and oral impacts on daily
performances than non-diabetic controls. A second aim was to -
within the T2DM patients- identify clinical and subjective oral
health indicators that discriminate between well-controlled and
poorly controlled T2DM patients as well as between patients with
long and short duration of the disease. It was hypothesized that
poorly controlled T2DM patients had more oral disease and more
oral impacts on their daily performances than their well-controlled
counterparts. Moreover, it was hypothesized that patients with
long duration of T2DM had poorer oral health than their
counterparts having short duration of the disease.
Materials and Methods
Study design and participants
This study was designed as a gender and age matched case-
control study with a ratio of 2 controls per 1 case. Ethical
clearance was obtained from the Ministry of Health in the Sudan
and from the Norwegian Research Ethical Committee at the
University of Bergen (2012/1470/REK vest). Written informed
consent was obtained from each participant. The objectives, steps
of oral clinical examination and sampling procedures were
explained for the participants. All participants were informed
about their dental diagnosis and referred for appropriate dental
treatment as needed.
Sample size was calculated to be 450 using Openepi version
3.01 with a power of 90%, alpha level of 0.05, ratio of controls to
cases of 2, percentage of exposed controls of 50% and an odds
ratio (OR) of 2 as a minimum difference between groups to be
detected. From July 2012 to December 2012, 157 cases previously
diagnosed with T2DM (63 males and 94 females) who attended for
dental treatment at Jaber Abol’ez Diabetes Center were invited to
participate in the study. A total of 304 non-diabetic controls (119
male and 185 female) were recruited from the outpatient dental
clinic at the Khartoum Dental Teaching Hospital. Illegibility
criteria for enrolment of the cases were (i), being diagnosed with
T2DM for more than one year and attending a specialized
diabetes clinic (ii), having at least 10 remaining natural teeth (iii),
no antibiotic, no steroidal and/or non-steroidal anti-inflammatory
medication used during the last 3 weeks (iv), not treated with
immunosuppressive chemotherapy, no current acute illness, no
professional periodontal treatment received during the last 6
months and no pregnancy or lactation. The non-diabetic controls
were selected according to the same criteria except for being
diagnosed with DM. At the time of enrollment; glycosylated
haemoglobin test (HbA1c) was undertaken for the T2DM cases to
determine the level of glycemic control (well-controlled: HbA1c
#8% and poorly controlled: HbA1c .8%) [19]. The test was
performed at the laboratory of Jaber Abol’ez Diabetes Center
using a commercial kit (LabonaCheckTM A1c analyzer). Individ-
uals in the control group were asked about signs and symptoms of
DM and if suspected, they were referred to Khartoum Teaching
Hospital for confirmation.
Interview
All participants were interviewed by a trained research assistant
using a standardized structured questionnaire. The interview
schedule was constructed in English, but participants were
interviewed in Arabic and some illustrations were used to help
the participants to understand the questions. Socio-demographics were
assessed in terms of age, gender (male, female), educational level
and employment status. Educational level was originally measured
as (0 = illiterate, 1 = literate, 2 = primary school, 3 = middle
school, 4 = high school, 5 = college, 6 = post-graduation studies)
and was recoded into illiterate = 1 (including the original category
0) and literate = 2 (including the categories 1–6). Employment
status was measured as (0 = unemployed, 1 = student, 2 =
housewife, 3 = retired, 4 = employed), then recoded into
unemployed= 1 (including the original categories 0–3) and
employed= 2 (including the original category 4). Lifestyle factors
Oral Health among Patients with Type 2 Diabetes
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were assessed in terms of alcohol consumption (yes/no), smoking
(yes/no), hypertension (yes/no), regular dental attendance (yes/no)
and sugary drinks consumed per day (0 = no, 1= 1 cup or less,
2 = 2 to 3 cups, 3 = 4 cups or more), recoded into no= 1
(including the original category 0) and yes = 2 (including the
categories 1–3). The self-reported main explanatory variables were
assessed in terms of history of dry mouth (yes/no) and OHRQoL
which was assessed using the eight items OIDP frequency
inventory; ‘During the past 6 months, how often have problems
with your mouth and teeth caused you any difficulty with: eating
and chewing food; speaking and pronouncing clearly; cleaning teeth; sleeping
and relaxing; smiling and showing teeth without embarrassment; maintaining
usual emotional state; carrying out major work and social role; and enjoying
contact with people’. Each item was assessed using a 5-point scale: (1)
Never affected; (2) Less than once a month; (3) Once or twice a
month; (4) Once or twice a week; (5) Every, or nearly every day.
An additive sum score (OIDP ADD) was constructed from the 8
items as originally scored (1–5) (range 8–40). Secondly, each OIDP
frequency item was dichotomized, yielding the categories: 0 =
never affected (including the original category 1), 1 = affected
(including the original categories 2–5). Simple count scores (SC)
were created for the OIDP by adding the eight dichotomized
variables. For the purpose of cross-tabulation and logistic
regression analysis, the OIDP SC scores (0–8) was dichotomized
as 0 = no daily performance affected and 1= at least one daily
performance affected. The distribution of the OIDP SC scores
supported this cut-off point.
Oral clinical examination
In preparation for the clinical examination, the main single
investigator (HGM) was trained and calibrated to perform oral
examination and differential diagnosis for dental caries, periodon-
tal disease and other oral disorders at the Department of Clinical
Dentistry-University of Bergen, Norway under the supervision of
the team’s principal investigator (SOI).
For each participant, clinical examination of all teeth (except 3rd
molars) and soft tissues of the oral cavity was performed
immediately after completion of the interview. Tools used for
the examination were (N22) Color Coded Probe 2-4-6-8-10-12
mm markings, (NAB2) Color Coded Nabors Furcation Probe 3-6-
9-12 mm markings, curette, mirror, probe, tweezers and cotton
rolls. For plaque index (PI) [43] and mobility index [44], one value was
recorded for each tooth (range 0-3). The sum of values of all teeth
examined was divided by the number of teeth examined to give
the individual scores. PI and mobility index were recoded into
low= 1 and high= 2 using the median as a cutoff point for the
sub-group analysis. Another dichotomous variable was created for
mobility index (mobility index= 0, mobility index $1). Probing
depth (PD) was measured from the gingival margin to the base of
the periodontal pocket (mm) at four sites of each tooth (mesial,
distal, buccal and lingual). Individual scores were expressed as
percentage of sites with PD of $4mm. Individuals were diagnosed
as having chronic periodontitis if there was at least one site with
was dichotomized into (DMFT= 0, DMFT $1). Another cutoff
(low: DMFT , median, high: DMFT $median) was used for the
sub-group analysis.
Statistical analysis
Statistical Package for Social Sciences (SPSS) version 21 was
used to analyze the data. The Kappa test was performed to assess
the intra-examiner reliability. Chi-square and independent sample
T tests were used to assess the differences in categorical and
continuous variables between the cases and controls and to
identify possible confounding variables. The Cox regression
procedure was used to fit conditional logistic regression models
since each case was paired with 2 controls. Adjusted odds ratios
(ORs) and their 95% confidence intervals (CI) were calculated
with T2DM status (cases/controls) as the outcome variable and
periodontitis, dental caries and OHRQoL as main explanatory
variables whilst adjusted for a number of possible confounding
variables (employment status, educational level, consumption of
sugary drinks, smoking, hypertension, PI and regular dental
attendance). The selection of independents included in the Cox
regression model was based on the theoretical relevance and
statistical significant relationship with T2DM in the bivariate
analysis. Sub-group analysis was performed within the T2DM
group to identify the clinical and self-reported oral health
indicators that discriminated between the well-controlled (HbA1c
#8%) and poorly controlled (HbA1c .8%) patients and between
patients with long (.10 years) and short (#10 years) duration of
the disease. Two binary logistic regression models were construct-
ed to assess the relationship between mobility of teeth and level of
metabolic control and the relationship between DMFT and
duration of T2DM. Age, gender and frequency of regular dental
attendance were adjusted for during the analyses. P values less
than 0.05 were considered statistically significant.
Results
Of the 461 individuals recruited for the study, three participants
from the T2DM group did not continue with the interview due to
time constraints. One participant from the control group was
diagnosed with DM and excluded after the recruitment. The mean
duration of T2DM was (967.4) years. A total of 31.2% of the cases
had experience with the diagnosis for more than 10 years, 70%
were poorly controlled and 50% had a family history of DM. The
oral examination was repeated for 20 participants randomly
selected within 2 weeks. Kappa values (k) were 0.74 for tooth
mobility, 0.80 for root surface caries, 0.88 for periodontal
diagnosis (PD $4mm.) and 1.00 for dental caries.
As shown in Table 1, the mean age for both the cases and
controls was (52610.5) years and 39% of both groups were men.
A total of 34.4% versus 13.9% (P,0.001) of the cases and controls
reported any oral impact (OIDP . 0). The two groups differed
with respect to chewing problems (22.7% versus 10.9%, P,0.001)
and sleeping problems (15.6% versus 5.0%, P,0.001) (data not
the cases than the controls (37.7% versus 10.9%, P,0.001) (data
not shown). Hypertension was also more common in the cases
than the controls (31.8% versus 14.9%, P,0.001). Visible dental
plaque, furcation involvement, tooth mobility, chronic periodon-
titis, root surface caries and less than 21 remaining teeth were all
more frequently observed in the cases group (P,0.05).
The Cox regression analysis, adjusting for possible confounding
variables, revealed statistically significant covariates of T2DM in
terms of tooth mobility (OR=9.63, 95% CI: 4.29–21.58),
furcation involvement (OR=5.23, 95% CI: 2.79–9.80), chronic
periodontitis (OR=3.97, 95% CI: 2.08–7.59), root surface caries,
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shown). Chewing, sleeping, cleaning teeth and smiling were the
impacts most frequently mentioned among the cases, whereas
chewing and sleeping were those most frequently mentioned
among the controls. Reported dry mouth was more common in
percentage of teeth with root caries for each individual. Coronal
caries was measured using DMFT index [46]. Individual scores
were calculated as sum of decayed, missed and filled teeth. DMFT
PD of$4mm. Furcation involvement (FI) [45] was recorded as grade I
(#3mm), grade II (.3mm) and grade III (through and through). A
II). Root surface caries was recorded as (yes/no) and expressed as
dichotomous variable for FI was created (FI# grade I, FI$ grade
(OR=1.80, 95% CI: 1.07–3.02), OIDP (OR=3.85, 95% CI:
2.11–7.01), and having more than 21 remaining teeth (OR=0.34,
95% CI: 0.17–0.68). When all the main explanatory variables
were mutually adjusted for, the statistically significant covariates of
T2DM were tooth mobility, furcation involvement, chronic
periodontitis, OIDP and having more than 21 remaining teeth.
The corresponding ORs were 5.90 (95% CI: 2.26–15.39), 2.96
(95% CI: 1.36–6.45), 4.07 (95% CI: 1.74–9.49), 3.46 (95% CI:
1.61–7.42) and 0.23 (95% CI: 0.08–0.63), respectively (Table 2).
Table 3 depicts the differences in socio-demographic charac-
teristics and clinical indicators between the well- and poorly
controlled T2DM patients and between patients with long and
short duration of the disease. The mean age among short- and
long term T2DM cases was (50.72610.78) and (56.6968.61) years
respectively, (P,0.001). The well- and poorly controlled T2DM
groups consisted of 46.7% and 68.6% women (P,0.05). Regular
dental attendance was reported by 3.8% of the short duration
cases versus 16.7% of the long duration cases, (P,0.05). High
mobility index was less prevalent in the well- than the poorly
controlled T2DM cases (37.8% versus 59.0%, P,0.05), and high
median DMFT index was less frequently found in the short-
compared with the long duration group (57.5% versus 75.0%,
P,0.05). More than 21 remaining teeth were more frequently
observed in patients with short- than long duration of T2DM
(79.2% versus 62.5%, P,0.05).
The multiple logistic regression analyses adjusting for the
confounding effect of age, gender and dental attendance,
revealed that compared to the short duration-T2DM cases,
T2DM cases with long duration were more likely to have DMFT
(i.e. above the median) with OR of 2.94 (95% CI: 1.24–6.94)
(Table 4). Compared to the well-controlled T2DM cases, the
poorly controlled counterparts were more likely to be above the
median mobility index with OR of 2.60 (95% CI: 1.21–5.55)
(Table 5).
Table 1. Distribution of confounders and main explanatory variables according to T2DM status (n = 457).
Confounding factors Categories Cases (n =154) Controls (n=303)
Age, mean (SD) 52.6 (10.5) 52.4 (10.5)
Gender, % (n) Male 39.0 (60) 39.3 (119)
Female 61.0 (94) 60.7 (184)
Education, % (n) Illiterate 26.6 (41) 30.7 (93)
Literate 73.4 (113) 69.3 (210)
Employment status, % (n) Unemployed 64.9 (100) 63.4 (192)
Employed 35.1 (54) 36.6 (111)
Consumption of sugary drinks per day, % (n) No 83.8 (129) 67.7 (205)
Yes 16.2 (25) 32.3 (98)**
Smoking, % (n) No 87.0 (134) 81.5 (247)
Yes 13.0 (20) 18.5 (56)
Hypertension, % (n) No 68.2 (105) 85.1 (258)
Yes 31.8 (49) 14.9 (45)**
Regular dental attendance, % (n) No 92.2 (142) 96.4 (292)
Yes 7.8 (12) 3.6 (11)
Plaque index, % (n) Low (, median) 24.0 (37) 63.0 (191)
High ( $median) 76.0 (117) 37.0 (112)**
Main explanatory variables
Number of present teeth, % (n) #21 teeth 26.0 (40) 9.6 (29)
. 21 teeth 74.0 (114) 90.4 (274)**
Tooth mobility, % (n) No 8.4 (13) 46.9 (142)
Yes 91.6 (141) 53.1 (161)**
Furcation involvement, % (n) No 55.8 (86) 87.8 (266)
Yes 44.2 (68) 12.2 (37)**
Chronic periodontitis, % (n) No 13.6 (21) 45.5 (138)
Yes 86.4 (133) 54.5 (165)**
Dental caries (DMFT), % (n) DMFT= 0 5.2 (8) 4.3 (13)
DMFT. 0 94.8 (146) 95.7 (290)
Root surface caries, % (n) No 47.4 (73) 60.4 (183)
Yes 52.6 (81) 39.6 (120)*
OHRQoL, % (n) OIDP = 0 65.6 (101) 86.1 (261)
OIDP.0 34.4 (53) 13.9 (42)**
*P,0.05.
**P,0.01.
doi:10.1371/journal.pone.0082158.t001
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Discussion
The present study confirmed the hypothesis that clinical
indicators of periodontal disease, furcation involvement, mobility
of teeth and number of teeth present as well as the OIDP
discriminated between T2DM patients and their non-diabetic
controls. The hypothesis that poorly controlled and long duration-
T2DM patients presented with more oral disease and OIDP
compared with their well-controlled and short duration counter-
parts was partly confirmed in this study. Thus, mobility index and
dental caries were the only clinical indicators that discriminated
significantly between the sub-groups of T2DM cases.
Before discussing the findings further, it is appropriate to
consider the limitations and strengths of the study. As both the
cases and controls were attending oral health care services for
dental treatment, they probably presented with more severe oral
diseases and treatment needs compared to their non-dental
attendee counterparts. It would have been an advantage to
identify mild oral problems representing early signs of T2DM so
that the dentist could contribute with referrals of potentially
diseased patients. However, the present findings were restricted to
subjects already diagnosed with T2DM. Subjects in the control
group were asked about signs and symptoms of T2DM. A more
appropriate screening of unidentified individuals with T2DM
among the controls as suggested by Borrell et al., [47] would have
contributed to the internal validity of the results. Although the
control group may represent dental attendees in the general
Khartoum population, it is possible that the recruitment procedure
of the diabetic patients introduced a bias since a convenience
sample attending the Jaber Abol’ez Diabetes Center was utilized
[48]. Nevertheless, the socioeconomic status did not differ between
the cases and controls in this study. The purpose was to identify
covariates of T2DM rather than to estimate disease prevalence in
the Sudanese population in general.
Recall bias is of major concern when a case-control design is
utilized. One advantage of this study includes the verification of
information gathered from the study participants by comparing
with medical records from the registry, thus reducing the risk of
recall- and social desirability bias. The use of the OIDP index with
a long history of validation in various contexts and the availability
of novel clinical measurements are further strengths. Moreover,
many potential confounding factors were considered in the
multivariable analysis [49]. This was considered necessary as
periodontal disease, dental caries and T2DM are multifactorial
diseases.
Consistent with previous studies, the T2DM patients presented
with more visible dental plaque, more missing teeth and were
more likely to suffer from chronic periodontitis compared with the
non-diabetic controls [17,19]. Although the T2DM patients
presented with limited sugary drink consumption and low
frequency of smoking, PI was significantly higher among the cases
than the controls. Presence of more dental plaque and poorer oral
hygiene among diabetic compared to non-diabetic subjects have
been reported in a number of studies and might be attributed to
DM patients having higher levels of glucose in gingival crevicular
fluid (GCF) and saliva [8,19]. The prevalence of poor oral hygiene
Table 2. All main explanatory variables according to T2DM status adjusted for possible confounding variables, (n = 447).
Variables n Adjusted OR (95% CI)a Adjusted OR (95% CI)b
Number of present teeth
#21 teeth 66 1 1
. 21 teeth 381 0.34 (0.17–0.68)** 0.23 (0.08–0.63)**
Tooth mobility
No 153 1 1
Yes 294 9.63 (4.29–21.58)** 5.90 (2.26–15.39)**
Furcation involvement
No 344 1 1
Yes 103 5.23 (2.79–9.80)** 2.96 (1.36–6.45)**
Chronic periodontitis
No 157 1 1
Yes 290 3.97 (2.08–7.59)** 4.07 (1.74–9.49)**
Dental caries (DMFT)
DMFT = 0 21 1 1
DMFT . 0 426 0.82 (0.28–2.37) 0.38 (0.09–1.66)
Root surface caries
No 252 1 1
Yes 195 1.80 (1.07–3.02)* 1.65 (0.84–3.26)
OHRQoL
OIDP= 0 353 1 1
OIDP.0 94 3.85 (2.11–7.01)** 3.46 (1.61–7.42)**
*P,0.05.
**P,0.01.
a) Adjusted for employment status, educational level, consumption of sugary drinks, hypertension, smoking, plaque index and regular dental attendance.
b) Adjusted for employment status, educational level, consumption of sugary drinks, hypertension, smoking, plaque index, regular dental attendance and other main
explanatory variables.
doi:10.1371/journal.pone.0082158.t002
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among dental attendees from the general population in Khartoum
has been reported to be about 39% [50]. This figure is consistent
with that of 37% observed in the control group of the present
study, suggesting that this group mirrors the background
population as well. More missing teeth among the T2DM patients
has been reported to be a characteristic of a population with poor
oral hygiene [18]. Corresponding difference has not been disclosed
in populations with good oral hygiene [51].
Since the relationship between T2DM and periodontal disease
have been investigated in few countries [52], this study emanating
from sub-Saharan Africa provides a valuable contribution to the
literature. Notably, the prevalence of chronic periodontitis as
defined by pocket depths rather than clinical attachment level
might have been underestimated [53]. Moreover, the lack of a
generally accepted case definition throughout studies impedes
comparison of prevalence figures between them [54]. In addition
Table 3. Clinical and self-reported oral health indicators by subgroups of T2DM cases according to glycemic control and duration
of diabetes.
Confounding factors Well-controlled Poorly controlled Short duration: Long duration:
DM: HbA1c #8 DM: HbA1c . 8 DM #10 years DM . 10 years
(n = 45) (n=105) (n= 106) (n= 48)
Age, mean (SD) 53.84 (9.34) 52.13 (10.90) 50.72 (10.78) 56.69 (8.61)**
Gender, % (n)
Male 53.3 (24) 31.4 (33) 37.7 (40) 41.7 (20)
Female 46.7 (21) 68.6 (72)* 62.3 (66) 58.3 (28)
Education, % (n)
Illiterate 22.2 (10) 29.5 (31) 29.2 (31) 20.8 (10)
Literate 77.8 (35) 70.5 (74) 70.8 (75) 79.2 (38)
Employment status, % (n)
Unemployed 51.1 (23) 71.4 (75) 61.3 (65) 72.9 (35)
Employed 48.9 (22) 28.6 (30)* 38.7 (41) 27.1 (13)
Regular dental attendance, % (n)
No 93.3 (42) 91.4 (96) 96.2 (102) 83.3 (40)
Yes 6.7 (3) 8.6 (9) 3.8 (4) 16.7 (8)*
Plaque index, mean (SD) 1.62 (0.41) 1.64 (0.33) 1.62 (0.34) 1.65 (0.37)
Main explanatory variables
Tooth mobility, % (n)
Low (, median) 62.2 (28) 41.0 (43) 50.9 (54) 41.7 (20)
High ($median) 37.8 (17) 59.0 (62)* 49.1 (52) 58.3 (28)
Chronic periodontitis, % (n)
No 15.6 (7) 12.4 (13) 11.3 (12) 18.8 (9)
Yes 84.4 (38) 87.6 (92) 88.7 (94) 81.2 (39)
Furcation involvement, % (n)
No 64.4 (29) 51.4 (54) 57.5 (61) 52.1 (25)
Yes 35.6 (16) 48.6 (51) 42.5 (45) 47.9 (23)
Root surface caries, % (n)
No 51.1 (23) 45.7 (48) 52.8 (56) 35.4 (17)
Yes 48.9 (22) 54.3 (57) 47.2 (50) 64.6 (31)
Dental caries (DMFT), % (n)
Low (, median) 42.2 (19) 34.3 (36) 42.5 (45) 25.0 (12)
High ($median) 57.8 (26) 65.7 (69) 57.5 (61) 75.0 (36)*
Number of present teeth, % (n)
#21 teeth 31.1 (14) 22.9 (24) 20.8 (22) 37.5 (18)
. 21 teeth 68.9 (31) 77.1 (81) 79.2 (84) 62.5 (30)*
OHRQoL, % (n)
OIDP = 0 73.3 (33) 63.8 (67) 69.8 (74) 56.2 (27)
OIDP.0 26.7 (12) 36.2 (38) 30.2 (32) 43.8 (21)
*P,0.05.
**P,0.01.
doi:10.1371/journal.pone.0082158.t003
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to chronic periodontitis per se, clinical signs such as tooth mobility
and furcation involvement were more frequent among the cases
compared to their non-diabetic controls. These results coincide
with findings from previous studies [16,18]. Although the
mechanism by which DM affects periodontal tissues is not fully
understood [55], it has been suggested that the magnitude of
inflammatory response of periodontal tissues to oral micro-flora is
exaggerated in DM patients. Moreover, advanced glycation end
products (AGEs) are formed when excess glucose comes in contact
with specific proteins which triggers series of pro-inflammatory
reactions [56,57].
Although the T2DM patients in this study presented with more
visible dental plaque and more missing teeth than non-diabetic
subjects, there was no difference with respect to DMFT status. In
this aspect, the present findings corroborate with those reported by
other researchers [26,51,58]. A lack of a significant relationship
between DM and dental caries has been attributed to confounding
factors such as xerostomia, periodontal disease and a strict
carbohydrate diet [59]. Nevertheless, a recent study by Jawed et
al., [23] reported higher levels of DMFT among individuals with
than without T2DM. An important finding in this study is that
both the cases and controls presented with high prevalence of
DMFT (95%), reflecting an urgent need for treatment and
preventive oral health care programs. Whereas Hintao et al., [26]
found a significant higher prevalence of root surface caries among
T2DM patients compared to non-diabetic controls, the present
finding suggesting absence of such an association corroborates
those reported by Collin et al., [28] and Lin et al., [30]. The
importance of measuring psychological and social impacts of oral
diseases as a supplement to clinical indicators was pointed out by
Cohen and Jago [33]. In this study, the T2DM patients were
almost 3 times more likely than their non-diabetic controls to have
at least one oral impact on their daily performances. This is at
odds with the results of other studies suggesting that oral problems
might not be a priority in DM subjects who are burdened with
health complications in general [31,32].
The majority (70%) of the T2DM patients investigated in this
study were poorly controlled. This agrees with recent data from
other studies and illustrates the difficulties in maintaining good
glycemic control [60]. In the present study, the poorly controlled
cases were 2.6 times more likely to present with high mobility index
(Table 5). This is consistent with other studies reporting a significant
worse periodontal condition among poorly controlled DM patients
compared to patients with good metabolic control [7–10].
Duration of DM might play an important role when the relation
between DM and oral diseases is investigated [61]. The level of
coronal caries was significantly higher in the long- compared to the
short duration-T2DM group. This finding is in agreement with the
normal pathogenesis of dental caries as ‘‘time’’ is an important
factor for the development of the disease [62]. Moreover, the long
duration-T2DM group had fewer teeth, which corroborates with
the study of Santos et al., [21] in which the number of remaining
teeth was negatively correlated with HbA1c levels.
Conclusion
This study revealed that chronic periodontitis, tooth mobility,
furcation involvement and OIDP were more prevalent among
T2DM patients than their non-diabetic matched controls.
Although pocket depths as a measure of chronic periodontitis
did not associate with the level of glycemic control or the duration
of T2DM, there was an association in the expected direction with
tooth mobility and dental caries. The present findings have
implications for both DM and oral health care provision. For
future prevention and management, it is important to know
whether periodontitis plays a role in the development and control
of DM and its complications [63]. Further large scale prospective
studies are needed to investigate the effect of treatment of
periodontitis on the management and control of T2DM.
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Table 4. DMFT regressed on duration of T2DM; adjusted for
age, gender and regular dental attendance.
Variables n OR (95% CI)
Age 153 0.99 (0.95–1.02)
Gender
Male 59 1
Female 94 3.45 (1.67–7.14)**
Regular dental attendance
No 141 1
Yes 12 0.57 (0.15–2.18)
Duration of DM
DM #10 years 105 1
DM . 10 years 48 2.94 (1.24–6.94)*
*P,0.05.
**P,0.01.
-2 Log likelihood = 183.536, Cox & Snell R2 = 0.114, Nagelkerke R2 = 0.155.
doi:10.1371/journal.pone.0082158.t004
Table 5. Mobility index regressed on the level of glycemic
control; adjusted for age and gender.
Variables n OR (95% CI)
Age 149 1.05 (1.01–1.08)**
Gender
Male 56 1
Female 93 1.32 (0.63–2.78)
Glycemic control
Well-controlled DM 45 1
Poorly controlled DM 104 2.60 (1.21–5.55)*
*P,0.05.
**P,0.01.
-2 Log likelihood = 191.545, Cox & Snell R2 = 0.093, Nagelkerke R2 = 0.124.
doi:10.1371/journal.pone.0082158.t005
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Abstract
The relationship between diabetes and periodontal disease is bidirectional, but information
about the effect of chronic periodontitis on the levels of the glucoregulatory biomarkers lo-
cally in gingival crevicular fluid (GCF) is limited. The aim of this study was to compare the
levels of 10 glucoregulatory biomarkers in GCF, firstly in subjects with type 2 diabetes
(T2DM) presenting with and without chronic periodontitis and secondly, in subjects without
diabetes, with and without chronic periodontitis. The material comprised a total of 152 sub-
jects, stratified as: 54 with T2DM and chronic periodontitis (G1), 24 with T2DM (G2), 30 with
chronic periodontitis (G3) and 44 without T2DM or periodontitis (G4). The levels of the bio-
markers were measured using multiplex biometric immunoassays. Periodontal pocket
depths were recorded in mm. Subsets G1 and G2 and subsets G3 and G4 were compared
independently. Among T2DM subjects, GIP, GLP-1 and glucagon were significantly up-
regulated in G1 compared to G2. Moreover, there were no statistical differences between
the two groups regarding C-peptide, insulin, ghrelin, leptin and PAI-1. Comparisons among
individuals without T2DM revealed significantly lower amounts of C-peptide and ghrelin in
G3 than in G4. The number of sites with pocket depth 4mm correlated negatively with C-
peptide (Spearman’s correlation co-efficient: -0.240, P < 0.01) and positively with GIP and
visfatin (Spearman’s correlation co-efficient: 0.255 and 0.241, respectively, P < 0.01). The
results demonstrate that chronic periodontitis adversely influences the GCF levels of glucor-
egulatory biomarkers, as it is associated with disturbed levels of biomarkers related to the
onset of T2DM and its medical complications.
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Introduction
Diabetes mellitus represents a heterogeneous group of metabolic disorders associated with dis-
turbances of carbohydrate, fat and protein metabolism. There are two major classes of the dis-
ease: Type 1 and Type 2. Type 2 diabetes (T2DM) is characterized by elevated blood glucose
levels caused by increased production of glucose in the liver and increased peripheral insulin
resistance, which might eventually lead to a reduction in insulin secretion [1]. In sub-Saharan
Africa, T2DM is becoming increasingly prevalent, presenting a major public health burden in
countries with scarce resources [2]. In The Sudan, the prevalence is increasing to epidemic pro-
portions, affecting about 18 percent of the population [3]. Of particular concern is the fact that
the onset is insidious and the condition may remain undiagnosed for a long time. In this con-
text, the dental profession has a potentially important role and the condition may first be iden-
tified during a dental examination [4].
Periodontal disease is one of the most common diseases affecting humans [5]. Chronic peri-
odontitis is an inflammatory condition characterized by apical migration of junctional epitheli-
um, leading to formation of deep periodontal pockets around the teeth due to destruction of
periodontal tissue fibers and the supporting bone [6]. Periodontal pockets may host highly vir-
ulent microorganisms and if left untreated; the host inflammatory-immune response pro-
gresses leading to tissue destruction [7]. For many years, chronic periodontitis was regarded as
a local inflammatory condition, but recent research confirms that the condition has a systemic
impact as the total surface area of the ulcerated periodontal pockets may be in the range of 8 to
20 cm2, approximately the size of the palm of an adult hand [8]. Recently, more attention is di-
rected towards the systemic effect of chronic periodontitis including its role in the aetiology of
T2DM as well as its impact on the metabolic control and medical complications associated
with patients baring the disease.
The scientific literature however, shows lack of consensus about the risk of onset of T2DM
in subjects with chronic periodontitis. A review by Sima et al., [9] cited two longitudinal stud-
ies. The first study reported an odds ratio between 1.5 and 2.1 for patients with high periodon-
tal index scores or tooth loss at baseline to develop diabetes [10], while the second one found
no association between periodontal disease and the incidence of diabetes [11].
Gingival crevicular fluid (GCF) is a serum transudate found in the gingival sulcus. It contains
not only connective tissue degradation products but also inflammatory molecules derived from
circulating blood [12]. The levels of biomarkers in the GCF are potentially important as predic-
tors of disease progression [7]. Few studies have investigated the levels of diabetes-related bio-
markers in GCF such as ghrelin [13], leptin [14], and visfatin [15]. In the present study, the
multiplex biometric immunoassay technique was applied in order to determine the amounts of
10 diabetes-related protein biomarkers known to be involved in the regulation of glucose metab-
olism, namely: C-peptide, ghrelin, gastric inhibitory polypeptide (GIP), glucagon-like peptide-1
(GLP-1), glucagon, insulin, leptin, plasminogen activator inhibitor-1 (PAI-1), resistin and visfatin.
The aim of the study was to investigate the influence of chronic periodontitis on the levels
of glucoregulatory biomarkers in the GCF, by comparing the levels of the above biomarkers in
subjects with T2DM, with and without chronic periodontitis, and in subjects without diabetes,
with and without chronic periodontitis. We tested the hypothesis that in patients with T2DM,
chronic periodontitis interferes with the regulation of glucose metabolism and that this effect
is reflected in the relative quantities of the corresponding glucoregulatory biomarkers in the
GCF, compared to the levels in subjects with T2DM who do not have chronic periodontitis.
The second hypothesis tested was that in subjects without T2DM, chronic periodontitis is as-
sociated with increased GCF levels of biomarkers known for their association with the onset
of T2DM.
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Materials and Methods
Subjects and study design
The sample population comprised a total of 152 participants, 78 with T2DM and 74 without
T2DM, representing a randomly selected subset from 461 participants recruited for a previous
study by Mohamed et al. [16]. The T2DM subjects were stratified according to periodontal sta-
tus, into two groups: 54 with chronic periodontitis (G1) and 24 without periodontitis (G2).
Subjects without T2DM were also stratified according to periodontal status, into two groups:
30 with chronic periodontitis (G3) and 44 without periodontitis (G4). The T2DM subjects
were recruited from The Jaber Abol’ez Diabetes Center in Khartoum-Sudan. T2DM was diag-
nosed by specialist physicians at the center according to the criteria of The American Diabetes
Association [17]. Briefly, diagnosis of T2DM was based on one of the following: fasting plasma
glucose of 126 mg/dl ( 7.0 mmol/L), random plasma glucose of 200 mg/dl ( 11.1
mmol/L), or plasma glucose of 200 mg/dl ( 11.1 mmol/L) after 75 g oral glucose tolerance
test. A glycated haemoglobin test (HbA1c) was undertaken at the center’s laboratory, using a
commercially available kit (LabonaCheck A1c analyzer). Subjects without T2DM were re-
cruited from the out-patient dental clinic at the Khartoum Dental Teaching Hospital. Recruit-
ment of the study participants and the eligibility criteria for enrolment have been described in
detail elsewhere [16]. Briefly, the criteria for enrolment were (i), being diagnosed with T2DM
for more than one year and attending a specialized diabetes clinic-for the T2DM patients- (ii),
having at least for 10 remaining teeth (iii), no antibiotic, no steroidal and/or non-steroidal
anti-inflammatory medication used during the last 3 weeks (iv), not treated with immunosup-
pressive chemotherapy, no current acute illness, no professional periodontal treatment received
during the last 6 months and no ongoing pregnancy or lactation.
The study protocol was approved by the Ministry of Health in the Sudan and by the Norwe-
gian Research Ethics Committee at the University of Bergen (2012/1470/REK Vest). Participa-
tion was confirmed by written informed consent and the steps of the clinical examination and
sampling procedures were explained to each participant. All participants were provided with
oral and written oral hygiene instructions, informed of their dental diagnosis and referred for
appropriate dental treatment if needed.
Clinical examination
Periodontal examination included all teeth except 3rd molars. All participants were examined
by a single, calibrated examiner (HGM) using a color-coded periodontal probe (N22, 2-4-6-8-
10-12 mmmarkings), a color-coded Nabors furcation probe (NAB2, 3-6-9-12 mmmarkings),
curette, mirror, probe, tweezers and cotton rolls. Dental plaque was recorded according to the
Silness and Loe Index [18]. Periodontal pocket depths (PD) were measured from the gingival
margin to the base of the periodontal pocket (mm) at four sites on each tooth (mesial, distal,
buccal and lingual). Subjects with at least two sites with PD of 4 mm (not on the same tooth)
with bleeding on probing were diagnosed as having chronic periodontitis [19,20]. It was re-
ported that both periodontal pocket depth and bleeding on probing reflect the current disease
status and are strongly related to the local inflammatory activity [21,22].
GCF sampling
Before the clinical examination, GCF samples were collected on the same day, using paper
strips (PERIOPAPER Gingival Fluid Collection Strips, Oraflow Inc, New York, USA). Four
samples, representing the four quadrants, were collected from each participant. Samples were
collected from the mesiobuccal site of the sulcus/pocket. The 1st molar or, if missing, the 2nd
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molar, 2nd premolar or 1st premolar was sampled respectively. If the target teeth were missing
in one quadrant, then no GCF sample was collected from that quadrant. After removing the
supra-gingival biofilm with sterile cotton pellets, the sites were dried and isolated with cotton
rolls to avoid saliva contamination. To collect the GCF, the paper strips were inserted 2 mm
into the sulcus/pocket and left in place for 30 seconds. Strips that were visually assessed as con-
taminated with blood or saliva were discarded. The four strips were immediately pooled in one
tube, labeled and stored in liquid nitrogen until analysed.
Protein extraction and quantification
For protein extraction, Tween buffer was added to each GCF sample (4 strips). The tubes were
kept in a shaker for 30 minutes and then centrifuged for 10 minutes at 4°C and 1400 rpm. The
extracted protein was quantified using a commercially available kit (Pierce BCA Protein Assay
Kit, Thermoscientific, Rockford, USA) following the manufacturer’s instructions. Absorbance
was measured at 560 nm on a plate reader (FLUOstar OPTIMA- BMG Labtech, Germany) and
the total protein per sample (4 strips) was calculated in micrograms (μg).
Multiplex biomarkers assay
Multiplex biometric immunoassay containing fluorescent dyed magnetic beads conjugated
with monoclonal antibodies specific for the targeted 10 protein biomarkers was used according
to the manufacturer's instructions (Bio-Plex Human Cytokine Assay; Bio-Rad Inc., Hercules,
CA, USA) [23]. Following protein extraction and purification, GCF samples were diluted to a
ratio of 1:4 and incubated with the magnetic beads. After a series of washes with Bio-Plex Pro
wash station, biotinylated detection antibody was added to create a sandwich complex. There-
after, Streptavidin-Phycoerythrin conjugate was added as a fluorescent indicator. A range of
(352290–0.97) pg/ml recombinant cytokines was used to establish the standard curves. Bio-
markers quantities were determined using a multiplex array reader powered by Luminex-200
System. The amounts were calculated using Bio-Plex Manager software and reported as pico-
grams per 30 seconds (pg/30 s) [24].
Statistical analysis
Comparisons were made between the T2DM groups (G1 and G2) and between the groups
without T2DM (G3 and G4) independently. Distributions of the continuous variables among
each group were assessed using Kolmogorov-Smirnov test. Independent sample-T test, Mann-
Whitney U test, chi-square test and Fisher’s Exact test were used to investigate the differences
in the distribution of demographic data between the study groups. Quantities of the detected
biomarkers were compared between the study groups using Mann-Whitney U test. Logistic re-
gression analysis adjusting for age, gender, dental plaque and total protein was applied to test
the relationship between periodontal status and the quantities of biomarkers. Spearman’s cor-
relation coefficients were calculated to assess the correlation between the number of sites with
PD 4 mm and the amount of each biomarker. Stata 13 (Stata Corp. 2013, Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP) was used for statistical analysis. P val-
ues less than 0.05 were considered statistically significant.
Results
As presented in Table 1, the mean ages of the T2DM patients in G1 and G2 were 54.76 ± 1.38
and 50.79 ± 2.09 (P>0.05), respectively. The age ranges were 24–70 and 33–70 years, respec-
tively. There were no significant intergroup differences between G1 and G2 in the demographic
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and clinical indicators. Oral hypoglycemic drugs were the most common drugs for treatment
of diabetes in G1 (66.7%) and insulin in G2 (50.0%). In subjects without T2DM, the mean ages
of G3 and G4 were 55.37 ± 1.77 and 47.15 ± 1.56 (P<0.01), respectively. The age ranges were
38–70 and 24–65 years, respectively. Plaque index was the only clinical indicator that differed
significantly between G3 and G4. Among those with chronic periodontitis, the PD ranged
from 4 to 10 mm in G1, and from 4 to 6 mm in G3, while participants without chronic peri-
odontitis (G2 and G4) had a normal gingival sulcus ranged from 1–3 mm.
Table 1. Demographic characteristics and clinical indicators of the study groups.
Type 2 diabetes No diabetes
Variable Chronic periodontitis
(G1), n = 54
No periodontitis (G2),
n = 24
P
value
Chronic periodontitis
(G3), n = 30
No periodontitis (G4),
n = 44
P
value
Age, mean (SE) 54.76 (1.38) 50.79 (2.09) 0.12a 55.37 (1.77) 47.15 (1.56) <0.01a
Gender, % (n) ) )
Male 42.60 (23) 29.20 (7) 0.38b 60.00 (18) 34.10 (15) 0.05b
Female 57.40 (31) 70.80 (14) 40.00 (12) 65.90 (29)
Education, % (n)
Literate 70.37 (38) 79.17(19) 0.42b 66.67 (20) 77.27 (34) 0.31b
Illiterate 29.63 (16) 20.83 (5) 33.33 (10) 22.73 (10)
Employment, % (n)
) )
Employed 37.04 (20) 29.17 (7) 0.50b 56.67 (17) 36.36 (16) 0.09b
Unemployed 62.96 (34) 70.83 (17) 43.33 (13) 63.64 (28)
Smoking, % (n) )
Yes 13.00 (7) 12.50 (3) 1.00c 26.70 (8) 13.60 (6) 0.27b
No 87.00 (47) 87.50 (21) 73.30 (22) 86.40 (38)
Plaque index, mean
(SE)
1.66 (0.05) 1.49 (0.05) 0.05a 1.49 (0.06) 1.28 (0.06) 0.03a
Pocket depth, % (n)
4–5 mm 59.30 (32) 0.00 (0) ——- 70.00 (21) 0.00 (0) ——-
 6 mm 40.70 (22) 0.00 (0) 30.00 (9) 0.00 (0)
Total protein -μg,
mean (SE)
82.78 (7.53) 77.53 (9.06) 0.92d 84.23 (15.25) 86.50 (9.51) 0.25d
Duration of T2DM,
mean (SE)
8.44 (0.83) 9.67 (1.70) 0.61d ——- ——- ——-
T2DM medication
used, % (n)
) ——- ——- ——-
Dilatory control 0.00 (0) 12.50 (3) <0.01c
Oral-hypoglycemic 66.70 (36) 33.30 (8)
Insulin 29.60 (16) 50.00 (12)
Both 3.70 (2) 4.20 (1)
HbA1c %, mean (SE) 9.17 (0.24) 9.25 (0.49) 0.89a ——- ——- ——-
a Independent sample-T test.
b Chi-square test.
c Fisher’s Exact test.
d Mann-Whitney U test.
n: sample size, SE: standard error of the mean, T2DM: type 2 diabetes, HbA1c: glycated haemoglobin.
doi:10.1371/journal.pone.0127660.t001
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Of the 10 glucoregulatory biomarkers investigated in this study, resistin was excluded from
the analysis, as it was not detected in 60% of the GCF samples. The mean quantities of the de-
tected diabetes-related biomarkers among the study groups are presented in Table 2.
After adjustment for potential confounders, GIP, GLP-1 and glucagon were significantly
higher in G1 than in G2. Moreover, C-peptide, insulin, ghrelin, leptin and PAI-1 were insignif-
icantly higher in G1 than in G2 (Table 3). In contrast, in subjects without T2DM, the levels of
C-peptide and ghrelin were significantly higher in G4 than in G3. All the other biomarkers
under investigation were insignificantly higher in G4 than in G3, except visfatin which was in-
significantly higher in G3 (Table 3).
As the number of diseased sites increased (PD 4 mm), the amount of C-peptide decreased
significantly (Spearman’s correlation co-efficient: -0.240). In contrast, the amounts of both GIP
Table 2. Amounts of the detected glucoregulatory biomarkers (pg/30 s).
Type 2 diabetes No diabetes
Biomarker, mean
(SE)
Chronic periodontitis
(G1),
No periodontitis
(G2),
P
valuea
Chronic periodontitis
(G3),
No periodontitis
(G4),
P
valuea
n = 54 n = 24 n = 30 n = 44
C-peptide 26.22 (0.87) 25.27 (1.55) 0.82 35.15 (1.91) 42.98 (2.52) 0.10
Insulin 24.36 (1.38) 20.02 (1.94) 0.12 25.59 (1.51) 30.92 (2.28) 0.17
GIP 164.21 (3.35) 144.64 (4.54) <0.01 141.45 (3.76) 151.27 (3.14) 0.07
GLP-1 210.99 (5.27) 183.40 (7.65) <0.01 188.63 (7.42) 203.02 (6.52) 0.30
Glucagon 261.77 (8.06) 223.82 (10.72) 0.01 242.91 (9.40) 250.17 (7.29) 0.60
Ghrelin 303.63 (15.82) 239.00 (19.34) 0.04 303.20 (19.00) 374.22 (21.91) 0.03
Leptin 85.85 (5.52) 64.78 (5.49) 0.05 84.46 (6.36) 99.57 (6.66) 0.14
PAI-1 1027.19 (155.80) 901.53 (260.49) 0.32 512.54 (86.75) 619.04 (110.98) 0.18
Visfatin 6411.37 (471.25) 5976.73 (1201.05) 0.13 7013.91 (978.87) 5194.03 (414.78) 0.26
a Mann-Whitney U test.
n: sample size, SE: standard error of the mean, GIP: gastric inhibitory polypeptide, GLP-1: glucagon-like peptide-1, PAI-1: plasminogen activator inhibitor-1.
doi:10.1371/journal.pone.0127660.t002
Table 3. Logistic regression analysis with periodontal status as dependent variable (yes/no).
Type 2 diabetes No diabetes
Biomarker Coefﬁcient (SE) OR (95% CI) P valuea Coefﬁcient (SE) OR (95% CI) P valuea
C-peptide 0.008 (0.041) 1.008 (0.931–1.092) 0.85 -0.053 (0.023) 0.948 (0.907–0.992) 0.02
Insulin 0.060 (0.033) 1.062 (0.996–1.133) 0.07 -0.049 (0.027) 0.952 (0.902–1.005) 0.07
GIP 0.035 (0.014) 1.035 (1.008–1.064) 0.01 -0.028 (0.016) 0.972 (0.942–1.003) 0.08
GLP-1 0.022 (0.010) 1.022 (1.003–1.042) 0.02 -0.009 (0.007) 0.991 (0.977–1.006) 0.12
Glucagon 0.013 (0.006) 1.013 (1.001–1.025) 0.03 -0.003 (0.006) 0.997 (0.986–1.008) 0.60
Ghrelin 0.005 (0.003) 1.005 (0.999–1.010) 0.11 -0.006 (0.003) 0.994 (0.989–0.999) 0.02
Leptin 0.016 (0.010) 1.016 (0.997–1.036) 0.09 -0.015 (0.008) 0.985 (0.970–1.001) 0.06
PAI-1 0.006 (0.024) 1.006 (0.959–1.054) 0.82 -0.079 (0.058) 0.924 (0.825–1.035) 0.17
Visfatin -0.001 (0.006) 0.999 (0.986–1.011) 0.85 0.009 (0.008) 1.009 (0.993–1.025) 0.27
a Adjusted for age, gender, plaque index and total GCF protein.
OR: adjusted odds ratio, CI: conﬁdence interval, SE: standard error, GIP: gastric inhibitory polypeptide, GLP-1: glucagon-like peptide-1, PAI-1:
plasminogen activator inhibitor-1.
doi:10.1371/journal.pone.0127660.t003
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and visfatin increased significantly as the number of diseased sites increased (Spearman’s cor-
relation co-efficient: 0.255 and 0.241, respectively). We also observed a weakly positive correla-
tion between the number of sites with PD 4 mm and the amounts of both GLP-1 and
glucagon (Spearman’s correlation co-efficient: 0.131 and 0.153, respectively) (Table 4).
Discussion
There is ample evidence from the scientific literature that the relationship between diabetes
and chronic periodontitis is bidirectional [25,26]. However, the focus of this report was to in-
vestigate the impact of chronic periodontitis on levels of glucoregulatory biomarkers in the
GCF. In the present study, chronic periodontitis adversely influenced the levels of glucoregula-
tory biomarkers in the GCF, indicating that it might be associated with the onset of T2DM and
the risk of diabetes related medical complications in subjects with the disease. Multiplex tech-
nology has been applied in a few studies, to investigate diabetes-related biomarkers in patients
with systemic conditions such as obesity [27] and gestational diabetes [28]. In the present
study, this high-throughput technology provided a highly accurate analysis of biological sam-
ples, given that it requires less sample volume and is able to detect different proteins within a
broad range of concentrations [29]. When tested on the same analytics, multiplex assays are re-
ported to compare favorably with ELISA with respect to sensitivity, accuracy, and reproducibil-
ity [30].
C-peptide is a polypeptide secreted from the secretory granules of β-cells during the conver-
sion of pro-insulin to insulin [31]. C-peptide and insulin are released into the circulation in
comparable amounts, but C-peptide is a more reliable indicator of β-cell activity, as it has a lon-
ger half-life and is not affected by insulin-specific antibodies [32]. To date, there are no pub-
lished data on the relationship between periodontal disease and C-peptide levels in adults with
T2DM. However, Merchant et al., [33] investigated such an association in a sample comprising
young subjects with both type 1 and 2 diabetes and concluded that periodontal disease was as-
sociated with lower fasting C-peptide. We observed the same trend among subjects without
T2DM, as the level of C-peptide was lower among subjects with periodontitis (G3) than in
those without periodontitis (G4). Moreover, the amount of C-peptide was negatively correlated
with the number of diseased sites with PD 4 mm, suggesting that chronic periodontitis
might be associated with disturbed β-cells activity. In the present study, comparisons of insulin
Table 4. Correlations between number of sites with PD 4mm and the amounts of the detected
biomarkers.
Biomarker Correlation coefﬁcienta P value
C-peptide -0.240 <0.01
Insulin -0.005 0.95
GIP 0.255 <0.01
GLP-1 0.131 0.11
Glucagon 0.153 0.06
Ghrelin -0.017 0.84
Leptin 0.030 0.72
PAI-1 0.081 0.32
Visfatin 0.241 <0.01
a Spearman’s correlation.
GIP: gastric inhibitory polypeptide, GLP-1: glucagon-like peptide-1, PAI-1: plasminogen activator inhibitor-
1.
doi:10.1371/journal.pone.0127660.t004
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among the different study groups showed similar trends, but there was no correlation between
insulin and the severity of periodontal disease.
GLP-1 and GIP are insulin-stimulating hormones secreted from the gastrointestinal system
after food intake [34]. Patients with T2DM do not generally exhibit reduced GLP-1 secretion
[35]. In contrast, results from studies comparing GIP levels in T2DM patients and systemically
healthy controls were inconclusive [34]. In the present study, both GIP and GLP-1 were found
to be significantly higher in G1 than in G2. This observation may be attributable to the fact
that 50% of patients in G2 were under insulin therapy, compared to 29.6% in G1. Thus, exoge-
nous insulin might have down-regulated the insulin-stimulating hormones by negative feed-
back. Moreover, the levels of GIP and GLP-1 were lower in G3 than in G4. Despite the statisti-
cal insignificance, these findings support the hypothesis that chronic periodontitis is associated
with disturbed GCF levels of hormones responsible for regulating the blood glucose levels
among individuals without T2DM.
Glucagon is a hormone secreted by α-cells in response to food intake and hypoglycemia
[36]. It regulates blood glucose levels and counteracts the effect of insulin by increasing blood
glucose levels. In T2DM, the feed-back mechanism which controls glucagon secretion in re-
sponse to blood glucose level seems to malfunction [37]. Thus, glucagon remains inappropri-
ately elevated in hyperglycemia at comparable levels of blood glucose. Our results indicated
no statistical difference in glucagon between G3 and G4. In subjects with T2DM however, the
amount of glucagon was higher in G1 than in G2. This finding suggests that in T2DM sub-
jects, chronic periodontitis may exert a systemic effect by its association with increased
glucagon secretion.
Ghrelin is a peptide hormone secreted from the oral epithelium and fibroblasts. It has a
major role in regulating neutrophil-mediated innate immune response [13]. Low ghrelin con-
centration is associated with T2DM [38]. The amount of ghrelin in G3 was significantly lower
than in G4. Yilmaz et al., [39] reported inconclusive results in a study investigating the level of
plasma ghrelin in systemically healthy subjects with and without periodontitis. In the present
study, the opposite trend was observed in the T2DM groups, as those with chronic periodonti-
tis had higher levels of ghrelin than those without periodontitis. One explanation is that there
might be a synergistic systemic effect of both T2DM and chronic periodontitis, as high ghrelin
levels have been reported in other chronic inflammatory diseases such as Crohn’s disease and
inflammatory bowel disease [40].
Leptin is a hormone secreted by adipose tissues. It exerts an anti-diabetic effect by reducing
insulin resistance [41]. The leptin detected in GCF probably diffuses from the microvasculature
to the gingival tissues, as there are no adipocytes within the gingival tissue [14]. Tatti et al., [42]
have reported higher leptin concentration in systemically healthy individuals than in those with
T2DM. In contrast, earlier investigations comparing Sudanese adults with and without diabetes
have reported elevated plasma leptin levels in subjects with diabetes [43]. The present findings
with respect to subjects without T2DM are consistent with earlier reports of higher levels of lep-
tin in periodontally healthy subjects than in those with periodontal disease [14,44]. This has
been attributed to the fact that during inflammation, the amount of leptin decreases because the
increased vascular permeability allows leptin to escape from the gingival tissue [44]. In this con-
text, it is noteworthy that detection of high local leptin levels in T2DM patients with periodontal
disease is regarded as one of the indicators of cardiovascular complications [45]. PAI-1 is a ser-
ine protease inhibitor secreted by endothelial cells, fibroblasts, liver and adipose tissue [46]. In-
creased PAI-1 concentration is reported to be associated with venous thrombosis, pulmonary
embolism and the aetiology of T2DM [47,48]. In the present study, the results of PAI-1 were in-
significant. Visfatin is an adipokine secreted mainly by visceral adipose tissue [49]. It is also se-
creted by neutrophils in response to pathogens and acts as a pro-inflammatory cytokine which
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stimulates monocytes to produce inflammatory mediators [50]. In the present study, there was
a significant positive correlation between PD and visfatin, a finding which is in concordance
with a previous report by Pradeep et al [15].
It was not possible to measure the GCF volume. Instead, we used total GCF protein as a sur-
rogate measure of the GCF volume in the multivariate analysis as an attempt to control for the
potential effect of variability of GCF volume on our results [51]. Data on the study participant’s
height and weight were unavailable. Thus, we were not able to calculate the body mass index
(BMI) which is a proxy variable reflecting the amount of adipose tissue for each participant.
This might affect our findings, as some of the biomarkers studied are secreted by adipocytes
such as leptin, PAI-1 and visfatin.
Within the limitations of the study, our data imply that chronic periodontitis is associated
with disturbance of the local expressions of biomarkers related to the onset of T2DM and its
medical complications in GCF. Large-scale longitudinal studies are required to confirm the as-
sociation between chronic periodontitis and the onset of T2DM and its medical complications.
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Abstract
Background: Pathological changes in periodontal tissues are mediated by the interaction between microorganisms
and the host immune-inflammatory response. Hyperglycemia may interfere with this process. The aim of this study
was to compare the levels of 27 inflammatory molecules in the gingival crevicular fluid (GCF) of patients with type
2 diabetes, with and without chronic periodontitis, and of chronic periodontitis subjects without diabetes. A
putative correlation between glycated haemoglobin (HbA1c) and levels of the inflammatory molecules was also
investigated.
Methods: The study population comprised a total of 108 individuals, stratified into: 54 with type 2 diabetes and
chronic periodontitis (DM + CP), 30 with chronic periodontitis (CP) and 24 with type 2 diabetes (DM). Participants
were interviewed with the aid of structured questionnaire. Periodontal parameters (dental plaque, bleeding on
probing and periodontal pocket depth) were recorded. The GCF levels of the 27 inflammatory molecules were
measured using multiplex micro-bead immunoassay. A glycated haemoglobin (HbA1c) test was performed for
patients with diabetes by boronate affinity chromatography.
Results: After adjustment for potential confounders, the DM + CP group had higher levels of IL-8 and MIP-1β, and
lower levels of TNF-α, IL-4, INF-γ, RANTES and IL-7 compared to the CP group. Moreover, the DM + CP group had
lower levels of IL-6, IL-7 and G-CSF compared to the DM group. The DM group had higher levels of IL-10, VEGF,
and G-CSF compared to the CP group. The levels of MIP-1α and FGF were lower in diabetes patients (regardless of
their periodontal status) than in chronic periodontitis subjects without diabetes. Diabetes patients (DM + CP and
DM) had higher Th-2/Th-1 ratio compared to the CP group. HbA1c correlated positively with the pro-inflammatory
cytokines (Pearson correlation coefficient = 0.27, P value: 0.02).
Conclusion: Type 2 diabetes and chronic periodontitis may influence the GCF levels of inflammatory molecules
synergistically as well as independently. Type 2 diabetes was associated with high Th-2/Th-1 ratio, and modulated
the local expression of molecules involved in the anti-inflammatory and healing processes.
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Background
Diabetes mellitus represents a heterogeneous group of
metabolic disorders in which elevated blood glucose
levels result in disturbance of carbohydrate, fat and pro-
tein metabolism [1]. The most common form is type 2
diabetes [2]. Diabetes is a major public health concern
with 380 million people suffering from the disease
worldwide, and about 80 % of the patients are from low-
and middle-income countries [3]. It is expected that
Africa will take the lead in terms of the largest pro-
portional increase in adults with diabetes by 2030 [4].
Prevalence of diabetes in The Sudan, as in many
other low-income countries, is increasing to epidemic
proportions [5]. In 2014, the prevalence of the disease
in The Sudan was about 18 % [3], which ranks The
Sudan among countries with high prevalence of dia-
betes in Africa and the world. It also reflects the change in
life style and the urbanization movement of the population.
Chronic hyperglycemia is associated with irreversible
complications such as nephropathy, retinopathy, neur-
opathy, cardiovascular diseases, peripheral vascular dis-
eases, delayed healing and periodontal diseases [6].
Periodontal diseases, including the reversible form (gin-
givitis), are highly prevalent and affect up to 90 % of
adults worldwide [7]. Chronic periodontitis is character-
ized by apical migration of the epithelial attachment ac-
companied by loss of connective tissue and alveolar
bone [8]. These changes are mediated by the interaction
between pathogens and the host immune-inflammatory
response [9]. Although periodontal pathogens are con-
sidered as the initiative factor of the disease, [10] tissue
destruction in chronic periodontitis is the consequence
of the host response to those pathogens [11].
The exact mechanism by which diabetes affects peri-
odontal tissues is not fully elucidated [12]. An altered
immune-inflammatory response to bacterial pathogens
has been suggested [11]. Hyperglycemia can affect peri-
odontal tissues by increasing oxidative stress as a result
of the imbalance between reactive oxygen species and
antioxidants, which may eventually lead to accumulation
of Advanced Glycation End products (AGE) [13]. The
binding of AGE to their receptors (RAGE) triggers intra-
cellular events that enhance the production of pro-
inflammatory cytokines, chemokines and cell adhesion
molecules [14]. Hyperglycemia can be assessed by measur-
ing the concentration of glycated haemoglobin (HbA1c),
which reflects mean glucose levels over the previous 8–12
weeks [15].
One means of investigating the local inflammatory sta-
tus of the oral cavity is by analysis of gingival crevicular
fluid (GCF), a non-invasive approach for assessing the
presence or absence of various inflammatory molecules
[16]. GCF is a transudate or an inflammatory exudate that
can be collected from the gingival crevice surrounding the
teeth. It contains components of circulating blood, local
tissues and most importantly, host-derived inflammatory
molecules [16, 17].
Most of the studies of GCF inflammatory molecules in
individuals with diabetes have generally been based on
small subject samples and investigation of a limited
number of inflammatory molecules, with inconclusive
results [12]. Multiplex analysis of inflammatory mole-
cules, whereby a large number of inflammatory mole-
cules can be investigated at the same time, would
facilitate understanding of the inflammatory process in-
volved in both diabetes and periodontal diseases.
The aim of this study was to investigate the effect of
type 2 diabetes on the local expression of inflammatory
molecules involved in periodontal inflammation and
healing by comparing GCF levels of 27 inflammatory
molecules in patients with type 2 diabetes, with and
without chronic periodontitis, and in chronic periodon-
titis subjects without diabetes. A putative correlation be-
tween HbA1c and the molecules under investigation was
also explored. We tested the hypothesis that type 2 dia-
betes adversely influences the local expression of the in-
flammatory molecules under investigation.
Methods
Study design and participants
In all, 108 individuals were enrolled in the study, repre-
senting a randomly selected subset from 461 participants
recruited for a previous study by Mohamed et al. [18].
The subjects were stratified into three groups: 54 with
type 2 diabetes and chronic periodontitis (DM + CP), 30
with chronic periodontitis (CP) and 24 with type 2 dia-
betes (DM). The study participants were aged 24-70
years. Diabetes patients were recruited from The Jaber
Abol’ez Diabetes Center in Khartoum-Sudan. Diabetes
was diagnosed by specialist physicians at the center ac-
cording to the criteria of The American Diabetes Associ-
ation [19]. Whole blood samples obtained from patients
with diabetes were analysed for HbA1c by boronate af-
finity chromatography using a commercially available kit
(LabonaCheck™ A1c analyzer) [20]. The CP group was
recruited from the out-patient dental clinic at the
Khartoum Dental Teaching Hospital. Recruitment of
study participants and eligibility criteria for enrolment
have been described earlier [18]. Briefly, criteria for en-
rolment were (i), being diagnosed with type 2 diabetes
for more than one year and attending a specialized dia-
betes clinic -for patients with diabetes- (ii), having at
least 10 remaining teeth (iii), no antibiotic, no steroidal
and/or non-steroidal anti-inflammatory medication used
during the last 3 weeks (iv), not treated with immuno-
suppressive chemotherapy, no current acute illness, no
professional periodontal treatment received during the
last 6 months and no ongoing pregnancy or lactation.
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Demographic data were obtained from the study partici-
pants by means of a structured questionnaire.
The study protocol was approved by The Ministry of
Health in The Sudan and The Norwegian Research Ethics
Committee at The University of Bergen (2012/1470/REK
Vest). The study participants were enrolled between July
and December 2012. Written informed consent was
obtained from each participant after the project ob-
jectives, the steps in the oral clinical examination
and the sampling procedures had been explained.
The participants were informed of their dental diag-
nosis and referred for appropriate dental treatment if
indicated.
Clinical periodontal examination
All clinical assessments, group allocations and sampling-
site selection were undertaken by a single, calibrated
examiner (HGM). The periodontal examination included
all teeth except the 3rd molars using a color-coded peri-
odontal probe (N22, 2-4-6-8-10-12 mm markings), a
color-coded Nabors furcation probe (NAB2, 3-6-9-12
mm markings), curette, mirror, probe, tweezers and cot-
ton rolls. The clinical examination comprised dental
plaque assessment using the Silness and Loe Index [21],
bleeding on probing (BoP), scored as present or absent,
and probing depth (measured from the gingival margin
to the base of the periodontal pocket in millimeters) at
four sites on each tooth (mesial, distal, buccal and lin-
gual). Participants were diagnosed as having chronic
periodontitis if they had at least two sites with bleeding
pockets of ≥ 4 mm (not on the same tooth) [22, 23]. The
oral examination was repeated for 20 participants ran-
domly selected within 2 weeks. Intra-examiner reliability
was assessed by Cohen's kappa coefficient [24]. Kappa
value (κ) was 0.88 for chronic periodontitis (yes/no).
GCF sampling
GCF samples were collected using perio-paper strips,
(PERIOPAPER® Gingival Fluid Collection Strips, Oraflow
Inc., New York, USA). Four samples, each representing
a quadrant, were collected from each participant. The
strip was inserted into the mesiobuccal site of the sul-
cus/pocket of the 1st molar. If missing, the 2nd molar,
2nd premolar or 1st premolar was sampled, respectively.
Quadrants with no posterior teeth were excluded from
the sampling. After the supra-gingival biofilm had been
removed with sterile cotton pellets, the sites were dried
and isolated with cotton rolls. The paper strips were
inserted 2 mm into the sulcus/pocket and left in place
for 30 s. Strips that were visually assessed as contami-
nated with blood or saliva were discarded. The 4 strips
were immediately pooled in one tube, labeled and stored
in liquid nitrogen for further analysis.
Protein extraction and quantification
For protein extraction, Tween buffer (230 μl) was added
to each of the tubes containing the 4 strips. The tubes
were shaken for 30 min and then centrifuged for 10 min
at 4 °C and 1400 rpm. The extracted protein was quanti-
fied using a commercially available kit and following the
manufacturer's instructions (Pierce™ BCA Protein Assay
Kit, Thermo scientific, Rockford, USA). Absorbance was
measured at 560 nm on a plate reader (FLUOstar
OPTIMA- BMG Labtech, Germany). Total protein
per sample (4 strips) was calculated in micrograms (μg).
Analysis and grouping of inflammatory molecules
Following protein extraction, GCF samples (20 μl each)
were processed by multiplex immunoassay containing
fluorescent dyed microspheres conjugated with mono-
clonal antibody specific for 27 inflammatory molecules
(Bio-Plex Human Cytokine Assay; Bio-Rad Inc., Hercules,
CA, USA) [25]. The following molecules were investi-
gated: IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, Basic
Fibroblast Growth Factor (FGF), Granulocyte Colony
Stimulating Factor (G-CSF), Granulocyte-Monocyte Col-
ony Stimulating Factor (GM-CSF), Interferon-γ (INF-γ),
Interferon Inducible Protein-10 (IP-10), Monocyte
Chemo-attractive Protein-1 (MCP-1), Macrophage In-
flammatory Protein-1α (MIP-1α), Macrophage Inflam-
matory Protein-1β (MIP-1β), Platelet-Derived Growth
Factor (PDGF), Regulated Upon Activation, Normally
T-Expressed, and Presumably Secreted (RANTES),
Tumor Necrosis Factor-α (TNF-α) and Vascular Endo-
thelial Growth Factor (VEGF). Samples were diluted
1:4 (50 μl in total) and incubated with coupled beads.
Complexes were washed, incubated with detection anti-
body and thereafter, with Streptavidin-Phycoerythrin. A
range of 105876 – 0.29 pg/ml recombinant cytokines was
used to establish the standard curves. The levels of the
inflammatory molecules were measured on a multi-
plex array reader (Bio-Plex Workstation from Bio-Rad
Laboratories). The final quantities were calculated
using software provided by the manufacturer and
were reported as picograms per 30 s (pg/30 s) [26].
Based on the biological effect of each molecule, the
molecules under investigation were grouped as: pro-
inflammatory cytokines (IL-1β, IL-6, IL-9, IL-12 and
TNF-α), anti-inflammatory cytokines (IL-4 and IL-10),
chemokines (IL-8, IP-10, MCP-1, MIP-1α, MIP-1β and
RANTES) and T-helper 2/T-helper 1 ratio (Th-2/Th-1)
(IL-4, IL-6, IL-9, IL-10/INF-γ, IL-2).
Statistical analysis
Inter-group differences in demographic and clinical
data were assessed using chi-square and Fisher’s
exact test for categorical variables, one way analysis
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of variance (ANOVA) with post-hoc (Sidak) adjust-
ment for multiple comparisons for normally distrib-
uted continuous variables, and Kruskal-Wallis and
Mann-Whitney test for skewed data. Since the distri-
bution of the levels of the studied molecules is
skewed, the natural logarithm links were calculated
and used to detect the differences between the study
groups, and one way analysis of variance (ANOVA)
with post-hoc (Sidak) was conducted. Generalized
linear models (GLM) with Gaussian family and log
function were used to adjust for the potentially con-
founding effect of age, gender, smoking status, dental
plaque, BoP and total protein on the outcome (mol-
ecule quantities). A possible correlation between
HbA1c and the inflammatory status was investigated
using Pearson correlation. Stata 13 (StataCorp. 2013.
Stata Statistical Software: Release 13. College Station,
TX: StataCorp LP.) was used for data analysis. P
values less than 0.05 were considered statistically
significant.
Results
The demographic characteristics and clinical parame-
ters of the study groups are presented in Table 1.
BoP was the only clinical parameter that differed sig-
nificantly between the groups. It was higher in the
DM + CP group than in the CP and DM groups. The
following inflammatory molecules, which were not
detected in more than 30 % of the GCF samples,
were excluded from the analysis: (IL-1ra, IL-5, IL-13,
IL-15 and eotaxin). The unadjusted means of the
quantities of the detected molecules across the study
groups are presented in Table 2. After adjustment
for potential confounders (age, gender, smoking sta-
tus, BoP, dental plaque index and total protein), the
DM + CP group had higher levels of IL-8 and MIP-
1β, and lower levels of TNF-α, IL-4, INF-γ, RANTES
and IL-7 compared to the CP group. Moreover, the
DM + CP group had lower levels of IL-6, IL-7 and
G-CSF than the DM group. The DM group had
higher levels of IL-10, VEGF, and G-CSF than the
CP group. Both diabetes groups (DM+CP and DM) had
lower levels of MIP-1α and FGF compared to chronic
periodontitis subjects without diabetes (CP) (Table 3).
The Th-2/Th-1 ratio was significantly higher in the
diabetes groups (DM +CP and DM) than in the CP
group (Fig. 1d). A weak positive correlation was ob-
served between HbA1c and the levels of the pro-
inflammatory cytokines (Pearson correlation coefficient:
0.27, P value: 0.02) (Fig. 2), while the correlation be-
tween HbA1c and the anti-inflammatory cytokines was
not statistically significant (Pearson correlation coeffi-
cient: -0.11, P value: 0.33) (Fig. 3).
Discussion
Pro-inflammatory cytokines induce inflammatory re-
sponse to various stimuli such as bacterial lipopolysac-
charides [27]. In patients with diabetes, IL-1β is
regarded as one of the key cytokines in inflammatory
periodontal tissue destruction [28]. In the present study,
the level of IL-1β was highest in the DM+CP group,
Table 1 Distribution of socio-demographic and clinical indicators
by study groups
Variable DM + CP (n = 54) CP (n = 30) DM (n = 24)
Age, mean (SE)1 54.76 (1.37) 55.37 (1.83) 50.79 (2.05)
Gender, % (n)2
Male 42.59 (23) 60.00 (18) 29.17 (7)
Female 57.41 (31) 40.00 (12) 70.83 (17)
Education, % (n)2
Illiterate 29.63 (16) 33.33 (10) 20.83 (5)
Literate 70.37 (38) 66.67 (20) 79.17 (19)
Employment, % (n)2
Unemployed 62.96 (34) 43.33 (13) 70.83 (17)
Employed 37.04 (20) 56.67 (17) 29.17 (7)
Smoking, % (n)3
Yes 12.96 (7) 26.67 (8) 12.50 (3)
No 87.04 (47) 73.33 (22) 87.50 (21)
Hypertension, % (n)2
Yes 31.48 (17) 20.00 (6) 29.17 (7)
No 68.52 (37) 80.00 (24) 70.83 (17)
Regular dental
attendance, % (n)3
Yes 3.70 (2) 10.00 (3) 8.33 (2)
No 96.30 (52) 90.00 (27) 91.67 (22)
Duration of diabetes,
mean (SE)4
8.44 (0.83) ——— 9.67 (1.70)
HbA1c %, mean (SE)5 9.17 (0.24) ——— 9.25 (0.49)
Plaque index, mean
(SE)1
1.66 (0.05) 1.40 (0.06) 1.47 (0.07)
Percentage of teeth
with BoP, mean (SE)1
58.88 (2.85)a 28.97 (3.82)b** 32.51 (4.28)b**
Pocket depth, % (n)2
4-5 mm 59.30 (32) 70.00 (21) 0.00 (0)
≥6 mm 40.70 (22) 30.00 (9) 0.00 (0)
Pocket depth, mean
(SE)4
4.16 (0.09) 4.25 (0.12) ———
Total protein -μg,
mean (SE)6
82.78 (7.53) 84.23 (15.25) 77.84 (9.06)
Different letters indicate statistically significant differences
1one-way ANOVA
2chi-square test
3Fisher’s exact test
4Mann-Whitney U test
5Independent sample T test
6Kruskal-Wallis test
**P < 0.01
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albeit not statistically significant. A recent meta-analysis
reported that type 2 diabetes patients with chronic peri-
odontitis were found to have significantly higher GCF
levels of IL-1β than their systemically healthy counter-
parts [29]. In contrast, others have failed to confirm an
association between levels of IL-1β and diabetes in indi-
viduals with periodontal disease [30, 31]. These incon-
sistencies might be attributed to the difference in HbA1c
levels and the duration of diabetes. Contradictory results
were reported from studies of TNF-α levels in oral fluids
among patients with diabetes and chronic periodontitis
[12]. In the present study, the levels of both TNF-α and
IL-7 were lower in the DM+ CP group than in the CP
group. In contrast, other studies have reported higher
GCF levels of TNF-α and IL-7 in patients with type 2
diabetes than in systemically healthy individuals [29, 32].
In this context, it is of interest to note that the levels of
pro-inflammatory cytokines and chemokines in the DM
group were comparable with those in the CP group,
reflecting a local active inflammatory process in the DM
group (Fig. 1a–1c). A weak positive correlation was ob-
served between HbA1c and the levels of pro-
inflammatory cytokines. Another study reported a sig-
nificant positive correlation between IL-1β levels in GCF
and HbA1c [33].
Studying the effect of IL-6 and IL-10, particularly in
cross-sectional studies, is complicated by the fact that
both are multifunctional cytokines (i.e. pro- and anti-
inflammatory) [34, 35]. IL-6 is involved in activation of
osteoclasts and Th-17 cells [36]. In contrast, it also in-
duces the production of IL-1ra, thus contributes to the
anti-inflammatory process [37]. There is no evidence to
support an association between increased levels of IL-6
and destructive periodontal disease among individuals
with hyperglycemia [38]. However, Javed et al., [39] re-
ported that up-regulation of IL-6 together with IL-1α
could be associated with diabetes related periodontal tis-
sue destruction. In the present study, the levels of the
anti-inflammatory cytokine IL-4 were lower in the
DM + CP group than in the CP group. It has been re-
ported that IL-4 is down-regulated in patients with type 2
diabetes [40]. In addition, in an in-vivo animal model for
ligament healing, IL-4 was found to contribute to the
proliferative phase of healing [41].
Chemokines are small peptides that recruit immune
cells from the circulation to the tissues as needed [42].
Most investigations of the role of chemokines have fo-
cused on IL-8 [12]. In the present study, IL-8 was up-
regulated in the DM+CP group compared to the CP
Table 2 Levels of the detected inflammatory molecules among
the study groups (pg/30s)
Inflammatory
molecule, mean (SE)
DM + CP (n = 54) CP (n = 30) DM (n = 24)
IL-1β 350.50 (31.18) 260.31 (41.45) 261.74 (46.34)
IL-6 9.01 (0.83)a 11.12 (1.11)ab 12.67 (1.27)b*
IL-9 6.91 (0.57) 9.64 (0.76) 8.57 (0.87)
IL-12 13.93 (1.07) 16.44 (1.43) 17.13 (1.63)
TNF-α 17.70 (1.84)a 31.57 (2.47)b** 22.05 (2.82)ab
IL-4 0.83 (0.06)a 1.26 (0.09)b** 0.92 (0.10)ab
IL-10 27.74 (1.43)ab 23.68 (1.90)a 33.02 (2.17)b**
IL-2 8.01 (0.98)a* 8.93 (1.30)a* 12.68 (1.48)b
INF-γ 29.55 (2.61)a** 47.50 (3.50)b 33.89 (3.92)a*
IL-8 633.87 (48.22) 501.96 (62.25) 507.65 (69.60)
IP-10 19.32 (2.30)a 24.60 (3.01)ab 29.13 (3.43)b*
MCP-1 6.10 (0.87)a 10.73 (1.11)b** 7.88 (1.24)ab
MIP-1α 3.14 (0.27)a* 4.52 (0.36)b 2.98 (0.40)a*
MIP-1β 23.53 (2.64) 21.37 (3.54) 26.03 (3.95)
RANTES 32.93 (2.77) 45.64 (3.72) 40.12 (4.16)
FGF 76.91 (4.62)a** 105.16 (6.20)b 76.34 (6.93)a*
PDGF 13.05 (0.93)a 17.22 (1.24)b* 15.45 (1.39)ab
VEGF 212.01 (11.75) 188.50 (15.77) 222.83 (17.63)
IL-7 2.63 (0.31)a 4.85 (0.42)b** 4.24 (0.47)b**
G-CSF 122.73 (12.48)a 131.02 (16.75)ab 196.73 (19.13)b**
GM-CSF 621.28 (21.82) 558.27 (29.28) 555.30 (33.44)
IL-17 72.04 (3.71)a 246.03 (62.90)b** 79.98 (6.68)ab
Different letters indicate statistically significant differences using one-way
ANOVA for natural log. links of the amounts of inflammatory molecules
*P < 0.05
**P < 0.01
Table 3 Adjusted means of the levels of inflammatory molecules
(pg/30s)
Inflammatory
molecule,
mean (SE)
DM + CP (n = 54) CP (n = 30) DM (n = 24)
IL-6 9.01 (0.94)a 11.11 (1.30)ab 14.01 (1.50)b*
TNF-α 17.68 (2.06)a 31.64 (3.16)b** 23.13 (3.20)ab
IL-4 0.84 (0.07)a 1.25 (0.11)b* 0.96 (0.11)ab
IL-10 28.82 (1.66)ab 22.46 (1.99)a 33.72 (2.42)b**
INF-γ 30.62 (2.99)a 45.77 (4.29)b* 36.88 (4.62)ab
IL-8 699.48 (53.44)a 464.17 (57.03)b* 503.04 (71.04)ab
MIP-1α 3.05 (0.32)a* 4.79 (0.47)b 2.99 (0.45)a*
MIP-1β 28.71 (3.05)a 16.84 (2.86)b* 22.37 (3.40)ab
RANTES 31.94 (3.14)a 48.01 (4.70)b* 41.16 (4.79)ab
FGF 71.66 (5.17)a** 113.28 (7.90)b 80.86 (7.93)a**
VEGF 215.04 (12.69)ab 177.52 (16.40)a 255.82 (19.39)b**
IL-7 2.81 (0.35)a 4.47 (0.51)b* 4.78 (0.56)b*
G-CSF 131.71 (14.41)a* 116.98 (17.79)a** 206.60 (21.25)b
Different letters indicate statistically significant differences using GLM with
Gaussian family and log. function adjusting for age, gender, smoking status,
BoP, dental plaque index and total protein
*P < 0.05
**P < 0.01
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Fig. 1 Levels of inflammatory molecules in GCF of the study groups. a: pro-inflammatory cytokines (IL-1β, IL-6, IL-9, IL-12, TNF-α), b: anti-inflammatory
cytokines (IL-4, IL-10), c: chemokines (IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES), d: Th-2/Th-1 ratio: (IL-4, IL-6, IL-9, IL-10) / (INF-γ, IL-2), **: P < 0.01
Fig. 2 Correlation between HbA1c and the pro-inflammatory cytokines. Pearson correlation coefficient: 0.27, P value: 0.02
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group. The same trend has been observed in an investi-
gation of serum levels of IL-8 [43]. MIP-1α is a potent
chemokine that attracts macrophages, T-cytotoxic and
natural killer cells [44]. It was down-regulated in both
diabetes groups (DM+ CP and DM) compared to the
CP group. In contrast, Duarte et al., [32] reported higher
levels of MIP-1α in patients with poorly controlled type
2 diabetes compared to systemically healthy controls.
The present study demonstrated lower levels of
RANTES in the DM +CP group compared to the CP
group. It was reported that levels of RANTES negatively
correlate with increased inflammation [45].
Type 2 diabetes might adversely affect periodontal
health by down-regulating molecules involved in peri-
odontal tissue regeneration and healing process such as
FGF and PDGF [46, 47]. FGF was detected in lower
amounts in the diabetes groups (DM+ CP and DM)
than in the CP group. Moreover, the levels of VEGF
were higher in the DM group compared to the CP
group. This observation might be explained by the fact
that oxidative stress induces the VEGF signaling in pa-
tients with type 2 diabetes [48]. Moreover, our VEGF re-
sults corroborate with a previous study which reported a
non-significant trend towards increased VEGF in GCF
of patients with type 2 diabetes and chronic periodontitis
compared to systemically healthy individuals with
chronic periodontitis [49]. In contrast, Guneri et al., [50]
concluded that GCF levels of VEGF were elevated in
subjects with chronic periodontitis regardless of their
diabetic status.
According to the cytokines they produce, Th-cells are
divided into Th-1, Th-2, Th-17 and T-regulatory cells.
Th-1 secretes IL-2 and INF-γ, while Th-2 secretes IL-4,
IL-6, IL-9, IL-10 and IL-13 [51, 52]. Only limited infor-
mation is available about the role of Th-cells in type 2
diabetes patients with periodontitis [12]. Th-2/Th-1 ratio
was higher in both diabetes groups (DM +CP and DM)
than in the CP group, indicating enhanced humoral
response and progression of periodontal disease among
patients with type 2 diabetes via Th-2/B-cell axis [53, 54].
In the present study, the low levels of some of the pro-
inflammatory molecules detected in type 2 diabetes pa-
tients compared to those without diabetes can be ex-
plained by the fact that some of the patients with diabetes
were receiving insulin therapy, which might affect the
local expression of inflammatory molecules [43, 55].
Moreover, the more pronounced clinical signs of peri-
odontal disease in individuals with type 2 diabetes can be
attributed to the disturbance in the balance between the
molecules involved in active inflammatory process on
the one hand, and the molecules involved in control-
ling inflammation, healing and regeneration of periodontal
tissues on the other hand [56, 57]. Up to date, there is no
ideal biomarker that can be nominated for disease detection
or progression. Therefore, the interest has been shifted to-
wards considering combinations of various host responses
[11, 58]. In the present study, the GCF volume was not
measured. Therefore, total GCF protein was used as a sur-
rogate measure of the GCF volume in the multivariate ana-
lysis to control for the potential effect of variability of GCF
volume on our results [59]. In addition, pocket depth and
bleeding on probing were both used to define cases with
periodontitis, as clinical attachment loss data were not
available. Consequently, the effect of type 2 diabetes on the
study outcome might be underestimated [60]. Nevertheless,
it was reported that both periodontal pocket depth and
Fig. 3 Correlation between HbA1c and the anti-inflammatory cytokines. Pearson correlation coefficient: -0.11, P value: 0.33
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BoP reflect the current disease status and are strongly re-
lated to the local inflammatory activity compared to clinical
attachment loss, which reflects past disease experience
[61–63].
Conclusions
Type 2 diabetes and chronic periodontitis may adversely in-
fluence the GCF levels of inflammatory molecules synergis-
tically as well as independently. Moreover, type 2 diabetes
was associated with high Th-2/Th-1 ratio, and adversely in-
fluenced the local expression of molecules involved in the
anti-inflammatory and healing processes. Further prospect-
ive studies are warranted to produce sufficient evidence to
support the application of specific GCF biomarkers for pre-
diction and prognosis of periodontal disease among pa-
tients with diabetes.
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Abstract 
Objectives: This study compared the occurrence of periodontal pathogens in plaque samples 
obtained from patients with type 2 diabetes, with and without chronic periodontitis, and from 
chronic periodontitis subjects without diabetes. Additionally, levels of salivary MMP-8, MMP-9, 
RANKL and OPG were compared across the study groups.  
Methods: The study enrolled 31 patients with type 2 diabetes and chronic periodontitis 
(DM+CP), 29 with chronic periodontitis only (CP) and 20 with type 2 diabetes only (DM). 
Questionnaire-guided interviews were conducted and dental plaque index, bleeding on probing 
and periodontal pocket depth were recorded. Polymerase chain reaction (PCR) was utilized to 
determine the prevalence of the periodontal pathogens. The levels of salivary MMP-8, MMP-9, 
RANKL and OPG were determined by enzyme linked immunosorbent assay (ELISA).  
Results: The CP group had the highest prevalence of P.gingivalis (81.5%), followed by the 
DM+CP (59.3%) and DM (55.0%) groups (P > 0.05). Similar trends were observed for 
P.intermedia and T.denticola. The prevalence of T.forsthysia was 100% in both periodontitis 
groups (DM+CP and CP) compared to 90% in the DM group. All plaque samples in the DM 
group were negative for A.actinomycetemcomitans, while the prevalence in the DM+CP and CP 
groups was 7.4% and 11.1%, respectively. There were no significant differences between the 
groups regarding the concentrations of MMP-8, MMP-9 or OPG, while the concentrations of 
RANKL were below the detection limit.  
Conclusions: Our data show that type 2 diabetes has no significant influence on either the 
prevalence of the investigated periodontal pathogens, or the levels of salivary MMP-8, MMP-9 
and OPG. 
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Introduction 
Chronic periodontitis is an inflammatory condition that affects oral tissues surrounding the teeth. 
It is characterized by destruction of periodontal connective tissues and tooth-supporting bone 
accompanied by apical migration of the epithelial attachment, potentially leading to tooth loss 
(1). This process is guided by the host immune-inflammatory reaction in response to putative 
pathogenic bacteria that are embedded in dental plaque (2). Dental plaque is a biofilm attached to 
the tooth surface and harbors a complex microbiological community (3), among which, some 
have been found to be highly associated with chronic periodontitis such as Porphyromonas 
gingivalis, Actinobacillus actinomycetemcomitans, Tannerella forsythia, Treponema denticola, 
Campylobacter rectus and Prevotella intermedia (4, 5). 
It is now widely accepted that chronic periodontitis is one of the classical complications 
of diabetes (6). There is, however, contradictory evidence about the effect of type 2 diabetes on 
dental plaque microbiota. Some studies have reported significant differences in the bacterial 
composition of dental plaque between individuals with and without type 2 diabetes (7, 8), while 
others failed to detect any difference (9, 10).  
One of the suggested mechanisms by which hyperglycemia might influence chronic 
periodontitis is by interfering with the host immune-inflammatory response (11). As part of the 
host response to bacterial challenge, resident and chemo-attracted immune cells secrete a group 
of zinc-dependent endopeptidase enzymes, collectively known as matrix metalloproteinases 
(MMPs). These enzymes are responsible for most of the extracellular matrix degradation in both 
healthy and diseased tissues (12). MMP-8 (collagenase-2) and MMP-9 (gelatinase-B) are the 
most common MMPs involved in periodontal tissue destruction (13). Most of the MMPs detected 
in saliva are secreted by polymorphonuclear leukocytes (14). The action of MMPs is opposed by 
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tissue inhibitors of metalloproteinases (TIMPs), thus the imbalance between both enzymes can 
shape periodontal disease progression (12, 15). 
A balance between osteoblasts and osteoclasts maintains the integrity of bone tissues (16). 
Accordingly, bone resorption occurs if the balance is shifted towards increased osteoclast 
activity. Osteoclasts are activated by the osteoclast differentiation factor called receptor activator 
of nuclear factor-κB ligand (RANKL) (17). It is mainly secreted by activated T- and B-cells (18). 
The action of RANKL can be blocked by osteoprotegerin (OPG), a soluble decoy receptor that 
competes with RANKL by binding to its receptor (RANK) on the surface of pre-osteoclasts and 
osteoclasts (19). RANKL/OPG ratio has been reported to be a good surrogate marker for 
periodontitis-induced bone destruction (20). Further, it has been reported that type 2 diabetes is 
associated with higher gingival crevicular fluid (GCF) levels of RANKL (21). Moreover, a 
positive correlation between RANKL/OPG ratios in GCF and glycated hemoglobin (HbA1c) has 
been also observed (22).  
Saliva is a promising point-of-care diagnostic tool because it can be utilized in chair-side 
detection of disease markers, as it contains a vast number of locally as well as systemically 
expressed proteins (23). In addition, it can be easily collected with minimum invasiveness and 
cost. The combined analysis of periodontitis related salivary markers and bacterial pathogens is a 
powerful approach for disease detection and follow-up (24).  
The aim of this study was to investigate the influence of type 2 diabetes on the prevalence 
of six putative periodontal pathogens in subgingival plaque samples obtained from patients with 
and without chronic periodontitis. The impact of type 2 diabetes on levels of salivary MMP-8, 
MMP-9, RANKL and OPG was also investigated. We tested the hypothesis that type 2 diabetes 
adversely influences the prevalence of the periodontal pathogens investigated and the levels of 
salivary MMP-8, MMP-9, RANKL and OPG. 
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Materials and methods 
Study design and participants 
In total, 80 individuals were included in this descriptive cross-sectional study representing a 
randomly selected subset from 461 participants recruited for a previous study by Mohamed et al. 
(25). The subjects were stratified into three groups: 31 with type 2 diabetes and chronic 
periodontitis (DM+CP), 29 with chronic periodontitis (CP) and 20 with type 2 diabetes (DM). 
The study participants were enrolled between July and December 2012. Patients with type 2 
diabetes were enrolled from Jaber Abol’ez Diabetes Center in Khartoum-Sudan. Diabetes was 
diagnosed by specialist physicians at the center according to the criteria of the American Diabetes 
Association (26). An HbA1c test was performed for patients with type 2 diabetes to determine the 
level of glycemic control (well-controlled: HbA1c ≤ 8% and poorly controlled: HbA1c > 8%) 
using a commercially available kit (LabonaCheckTM A1c analyzer). Participants in the CP group 
were recruited from the outpatient dental clinic at the Khartoum Dental Teaching Hospital. 
Eligibility criteria for participation were (i), being diagnosed with type 2 diabetes for more than 
one year -for patients with diabetes - (ii), having at least 10 remaining teeth (iii), no antibiotic, no 
steroid and/or non-steroidal anti-inflammatory medication used during the last 3 weeks (iv), no 
immunosuppressive chemotherapy, no current acute illness, no professional periodontal treatment 
received during the last 6 months and no ongoing pregnancy or lactation. Questionnaire-guided 
interviews were conducted for all participants after enrolment (25). Ethnicity was categorized 
into Afro-Arab and African tribes (27). 
The study protocol was approved by The Ministry of Health in The Sudan and The 
Norwegian Research Ethics Committee at The University of Bergen (2012/1470/REK Vest). 
Written informed consents were obtained from all participants and the steps of the oral clinical 
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examination and the sampling procedures were explained. The participants were informed of 
their dental diagnosis and referred for appropriate dental treatment if indicated. 
Clinical examination 
The clinical examination was performed by a single examiner (HGM). The examination included 
all teeth except the 3rd molars using a color-coded periodontal probe (N22, 2-4-6-8-10-12 mm 
markings), a color-coded Nabors furcation probe (NAB2, 3-6-9-12 mm markings), curette, 
mirror, probe, tweezers and cotton rolls. Dental plaque was assessed using the Silness and Loe 
Index (28). Bleeding on probing (BoP) was recorded as present or absent, and probing depths 
were scored as mm (from the gingival margin to the base of the periodontal pocket) at four sites 
per tooth (mesial, distal, buccal and lingual). Participants were diagnosed as having chronic 
periodontitis if they had at least two sites with bleeding pockets of ≥ 4mm (not on the same tooth) 
(29).  
Subgingival plaque samples 
Four microbial samples were obtained from each participant, representing the four quadrants. The 
samples were collected form the 1st molar. If missing, the 2nd molar, 2nd premolar or 1st premolar 
was sampled, respectively. Quadrants with no posterior teeth were excluded from the sampling. 
After removing the supra-gingival biofilm with sterile cotton pellets, the selected sites were dried 
and isolated with cotton rolls. A sterile paper point ISO (International Organization for 
Standardization) size 40 was inserted in the sulcus/pocket. Thereafter, the four paper points were 
pooled into one tube, labeled and stored in liquid nitrogen for further analysis. 
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Saliva samples 
Unstimulated whole saliva samples were collected from all the study participants before the 
clinical examination. Participants were asked to refrain from eating or drinking for at least one 
hour prior to saliva collection. Donors, sitting comfortably in an upright position with their heads 
tilted slightly downwards, were instructed to allow saliva to collect in their mouths before gently 
expectorating into a sterile 10 ml tube for 5 minutes. The samples were then aliquoted and 
immediately stored in liquid nitrogen for further analysis.   
DNA purification 
Bacterial DNA was extracted and purified using the MasterPure DNA purification kit according 
to the manufacturer's instructions (Epicentre Biotechnologies, Madison, Wisconsin). Briefly, the 
pooled samples were suspended in 300 μl TE buffer and incubated overnight with 1 μl lysozyme 
solution at 37 °C. Next day, tissue and cell lysis solution, protease and RNase were added.  
Thereafter, protein precipitation reagent was added and the mixture was centrifuged. The 
supernatant was collected, mixed with isopropanol and then centrifuged. Finally the DNA pellet 
was washed with ethanol and re-suspended in 25 μl TE buffer. The amount of DNA was 
measured for each sample by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). 
Polymerase chain reaction 
After DNA purification, conventional polymerase chain reaction (PCR) was performed under 
standard conditions to investigate the prevalence of P.gingivalis, T.forsythia, P.intermedia, 
T.denticola, C.rectus, and A.actinomycetemcomitans. A set of specific primers were used for the 
PCR (30): P.gingivalis, sense, 5́′-AGGCAGCTTGCCATACTGCGG-3′ and antisense, 5′-
ACTGTTAGCAACTACCGATGT-3′; T.forsythia, sense, 5′-GCGTATGTAACCTGCCCGCA-3′ 
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and antisense, 5′-TGCTTCAGTGTCAGTTATACCT-3′; C.rectus, sense, 5′-TTTCG-GAGCG 
TAAACTCCTTTTC-3′ and antisense, 5′-TTTCTGCAAGCAGACACTCTT-3′; P.intermedia, 
sense, 5′-TTTGTTGGGGAGTAAAGCGGG-3′ and antisense, 5′-TCAACAT-CTCTGTATCCT 
GCGT-3′; T.denticola, sense, 5′-TAATACCGAATGTGCTCATTTACAT-3′ and antisense, 5′- 
TCAAAGAAGCATTCCCTCTTCTTCTTA-3′; and A.actinomycetemcomitans, sense, 5′-AAA 
CCCATCTCTGAGTTCTTCTTC-3′ and antisense, 5′-ATGCCAACTTGACGTTAAAT-3′.  
The final reaction volume (50 μl) consisted of 100 μM dNTP, 0.4 μM of each primer, 
1.75 mM MgCl2, 1 U of AmpliTaq Gold® DNA Polymerase (Applied Biosystems, Foster City, 
CA, USA) and 50 ng of extracted DNA. The target genes were amplified in a thermocycler 
(GeneAmp PCR system 9700, Applied Biosystems, Foster City, CA, USA) as follows: one cycle 
at 95 °C for 10 minutes, 40 cycles at 95 °C for 30 seconds for denaturation, 62 °C for 30 seconds 
for annealing, 72 °C for 1 minute for extension, and a final extension of 72 °C for 10 minutes. 
The annealing temperature was adjusted for the A.actinomycetemcomitans to 60 °C. Negative 
control (master mix without DNA template) was included in each PCR run. The PCR products 
were loaded and separated by agarose gel electrophoresis (2.2% FlashGel DNA system; Lonza, 
Walkersville, MD). The stained DNA bands were visualized by ultraviolet light and the data were 
reported as present or absent (Figure 1). 
Enzyme linked immunosorbent assay 
Frozen saliva samples were thawed, centrifuged at 14000 rpm for 15 minutes and the 
supernatants were collected. The levels of MMP-8, MMP-9, OPG (Sigma-Aldrich, St. Louis, 
MO, USA) and RANKL (MyBiosource, CA, USA. and PeproTech EC, London, UK) were 
determined using enzyme linked immunosorbent assays (ELISA) according to the manufacturers’ 
9 
 
instructions. Optical densities were determined using a microplate reader (FLUOstar OPTIMA- 
BMG Labtech, Germany). The final concentrations are presented in pg/ml. 
Statistical analysis  
Potential differences in demographic and clinical indicators between the study groups were tested 
using chi-square and Fisher’s exact test for categorical variables, independent sample T test and 
one-way ANOVA for normally distributed variables, and Mann-Whitney U test and Kruskal-
Wallis test for skewed data. Frequencies of detection of the microbes under investigation are 
expressed in (%), and chi-square test or Fisher’s exact test was used to examine the statistical 
differences between the study groups. The concentrations of the detected salivary molecules were 
compared by Kruskal-Wallis test. Adjustment for the potentially confounding effect of age, 
gender, smoking status and ethnicity was done by logistic regression analysis for the prevalence 
of bacteria, and by generalized linear models (GLM) with Gaussian family and log function for 
concentrations of salivary markers. Stata 13 (Stata Corp. 2013, Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP) was used for statistical analysis. P values less than 0.05 
were considered statistically significant, and were adjusted for multiple comparisons when 
indicated.  
Results 
The distributions of the demographic and clinical indicators across the study groups are presented 
in Table 1. The age of the study participants ranged from 24 to 70 years. In general, the clinical 
periodontal parameters (dental plaque index, BoP and periodontal pocket depth ≥ 6 mm) differed 
significantly between the study groups; with the DM+CP group having the highest scores. 
The CP group had the highest prevalence of P.gingivalis (81.5%), followed by DM+CP 
(59.3%) and DM (55.0%) (P > 0.05). The same trend was observed for P.intermedia and 
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T.denticola. The prevalence of T.forsthysia was 100% in both periodontitis groups (DM+CP and 
CP) compared to 90% in the DM group. C.rectus was detected in plaque samples of all the study 
participants. All plaque samples in the DM group were negative for A.actinomycetemcomitans 
while the prevalence in the DM+CP and CP groups was 7.4% and 11.1%, respectively (Table 2). 
Comparisons of salivary MMP-8, MMP-9 and OPG across that study groups were not 
statistically significant (Table 3). Nonetheless, there was a trend towards increased concentration 
of MMP-8 in the chronic periodontitis groups (DM+CP and CP) compared to the DM group. In 
addition, the levels of the molecules under investigation did not differ significantly between well-
controlled- and poorly controlled type 2 diabetes patients (Figure 2). The concentrations of 
RANKL were below the detection limit in all saliva samples. 
Regardless of the diabetic status, MMP-8 levels remained higher in subjects with positive 
P.gingivalis and P.intermedia scores than in those with negative scores, albeit not statistically 
significance (Figure 3). The levels of MMP-9 followed the same pattern as MMP-8 for 
P.gingivalis results. On the other hand, subjects without diabetes had similar MMP-9 level 
comparing those with positive, and negative P.intermedia scores (Figure 4). In patients with type 
2 diabetes, the concentration of OPG did not discriminate between those with and without 
P.gingivalis or P.intermedia in their plaque samples, while for those without diabetes, individuals 
with positive P.gingivalis and P.intermedia scores tend to have higher concentrations of OPG 
(Figure 5). 
Discussion 
Periodontal pathogens are considered as the triggering factor of the disease (31). Recently, it was 
suggested that periodontal tissue destruction is mediated by the host inflammatory response when 
the balance in the relative quantities of the existing bacteria in dental plaque is disturbed (32, 33). 
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The pathogens that are responsible for this imbalance are called “keystone pathogens” (34). In the 
present study, most of the investigated microbes were more prevalent in individuals with chronic 
periodontitis (DM+CP and CP) compared to the DM group. In addition, the effect of type 2 
diabetes on the prevalence of the investigated bacteria was not significant. Similar findings were 
reported by others using different methodological approaches (10, 35). Field et al., (10) reported 
that P.gingivalis is significantly higher in chronic periodontitis patients with and without type 2 
diabetes than in type 2 diabetes patients without periodontitis, which is in line with our findings, 
although the difference in our patients was not statistically significant. Moreover, our results 
demonstrated that 30% of the plaque samples obtained from participants with chronic 
periodontitis scored negative for P.gingivalis (data not shown). Although P.gingivalis is one of 
the keystone pathogens in chronic periodontitis, it is not always detectable in periodontally 
diseased sites (36).  
In the present study, the prevalence of A.actinomycetemcomitans was relatively low in all 
the study groups. Elabdeen et al., (37) investigated subgingival microorganisms in Sudanese 
patients (with an age range of 13-30 years) with aggressive periodontitis using DNA-DNA 
hybridization (checkerboard) technique. They reported relatively low levels of P.gingivalis and 
A.actinomycetemcomitans in aggressive periodontitis patients as well as in healthy controls. 
Additionally, studies among patients with chronic periodontitis from Italy (38), Thailand (39) and 
Japan (40) reported low prevalence of A.actinomycetemcomitans. In that regard, a study from 
China demonstrated a low prevalence of P.intermedia in patients with type 2 diabetes and chronic 
periodontitis when compared to systemically healthy individuals with chronic periodontitis (41). 
The same trend was observed in the present study. It is noteworthy that periodontal microbiota 
may vary according to the geographical areas, which makes comparisons in that regard between 
studies from different geographical backgrounds rather difficult (4). 
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The role of MMP-8 and MMP-9 in periodontal tissue destruction is well established (12).  
In the present study, as in a study from another group, (42)  there were no significant differences 
in the levels of salivary MMP-8 and MMP-9 between the study groups. Another study reported 
no significant difference comparing MMP-8 in GCF between individuals with and without type 2 
diabetes (43), while others reported higher MMP-8 in saliva of patients with type 2 diabetes than 
in subject without the disease (44, 45). Moreover, Javed et al., (46) investigated the level of 
salivary MMP-8 among pre-diabetic patients. They concluded that MMP-8 levels did not differ 
significantly between chronic periodontitis subjects with and without pre-diabetes. 
In the present study, there was a trend towards increased OPG levels in both the DM+CP 
and CP groups compared to the DM group. This can be attributed to the fact that OPG levels 
increases in response to increased osteoclastogenesis (47).  Moreover, our data demonstrate that 
the level of glycemic control did not affect the concentrations of molecules under investigation. A 
follow-up study investigating the GCF levels of RANKL and OPG over 6 months found no 
difference in OPG concentrations between well- and poorly controlled type 2 diabetes patients at 
any time point, while RANKL remained significantly higher in the poorly-controlled group at all 
the study time points (22). 
The association between the systemic levels of OPG and the non-oral medical 
complications of type 2 diabetes is well documented (48, 49). In contrast, information about its 
levels in oral fluids of type 2 diabetes patients and its association with periodontal disease is 
scarce. Costa et al., (44) reported elevated levels of salivary OPG in patients with type 2 diabetes 
compared to systemically healthy subjects with chronic periodontitis. Another study among 
patients with type 1 diabetes concluded that those with diabetes had higher plasma concentration 
of OPG and lower RANKL/OPG ratio compared to individuals without diabetes (50). In contrast, 
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an experimental study among rats demonstrated that type 1 diabetes influences periodontal bone 
tissues by decreasing OPG and increasing the RANKL/OPG ratio (51).  
In the present study, a qualitative PCR method was used, as the aim was to investigate the 
prevalence (presence or absence) of the bacteria under investigation. It is simple, rapid and with 
comparable sensitivity to other PCR methods (52). Moreover, the four plaque samples obtained 
from each participant were pooled. It has been reported that pooling design counteracts the inter-
subject variations and does not adversely affect gene analysis when compared to non-pooled 
design (53). In the present study, periodontal pocket depth and bleeding on probing were used to 
define cases with chronic periodontitis. Both periodontal parameters reflect current disease status, 
and have been reported to be associated with local inflammatory activity as well as ecological 
changes at sample sites (54, 55).  
Within the limitations of the present study, our data suggest that type 2 diabetes has no 
significant influence on the prevalence of the investigated periodontal pathogens. Moreover, we 
were unable to detect a significant difference in levels of salivary MMP-8, MMP-9 and OPG 
between individuals with and without type 2 diabetes. These findings suggest that the impaired 
periodontal parameters in seen patients with type 2 diabetes might be due to disturbed host 
immune-inflammatory response to the periodontal pathogens rather than disturbed bacterial 
composition of dental plaque as suggested in an earlier study among the same study population 
(56). Large follow-up studies are needed to trace the potential effect of type 2 diabetes on 
bacterial composition of dental plaque and on bone remodeling markers in oral fluids.    
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Table 1. Distribution of socio-demographic and clinical indicators 
Different letters indicate statistically significant differences 
1 one-way ANOVA 
2 chi-square test 
3 Fisher’s exact test 
4 Mann-Whitney U test 
5 independent sample T test 
6 Kruskal-Wallis test  
* P < 0.05 
** P < 0.01 
 
Variable DM+CP  
(n= 31) 
CP 
 (n= 29) 
DM 
 (n= 20) 
Age, mean (SE)1 53.55 ( 1.82) 52.03 (1.34) 51.15 (2.39) 
Gender, % (n)2 
Male 
Female 
 
48.40 (15) 
51.60 (16) 
 
48.30 (14) 
51.70 (15) 
 
30.00 (6) 
70.00 (14) 
Ethnicity, % (n)3 
Afro-Arab 
African 
 
93.55 (29) 
6.45 (2) 
 
82.76 (24) 
17.24 (5) 
 
63.16 (12) 
36.84 (7) 
Education, % (n)2 
Illiterate 
Literate 
 
25.80 (8) 
74.20 (23) 
 
34.50 (10) 
65.50 (19) 
 
25.00 (5) 
75.00 (15) 
Employment, % (n)2 
Unemployed 
Employed 
 
51.60 (16) 
48.40 (15) 
 
51.70 (15) 
48.30 (14) 
 
75.00 (15) 
25.00 (5) 
Smoking, % (n)3 
Yes 
No 
 
16.10 (5) 
83.90 (26)  
 
31.00 (9) 
69.00 (20) 
 
10.00 (2) 
90.00 (18) 
Hypertension, % (n)2 
Yes 
No 
 
29.00 (9) 
71.00 (22) 
 
17.20 (5) 
82.80 (24) 
 
30.00 (6) 
70.00 (14) 
Regular dental attendance, % (n)3 
Yes 
No 
 
0.00 (0) 
100.00 (31) 
 
6.90 (2) 
93.10 (27) 
 
10.00 (2) 
90.00 (18) 
Duration of diabetes- years, mean 
(SE)4 
8.40 (1.09) ----- 10.50 (1.99) 
HbA1c %, mean (SE)5 9.17 (0.34) ----- 9.37 (0.52) 
Plaque Index, mean (SE)1 1.68 (0.07)a 1.42 (0.06)b* 1.47 (0.06)ab 
Percentage of teeth with BoP, mean 
(SE)6 
56.95 (3.71)a 22.21 (2.50)b** 29.50 (3.99)b** 
 
Pocket depth, mean (SE)4 4.18 (0.05) 4.25 (0.09) ----- 
Pocket depth, % (n)3 
4-5 mm 
≥ 6 mm 
 
58.10 (18) 
41.90 (13) 
 
86.20 (25)* 
13.80 (4) 
 
----- 
----- 
21 
 
Table 2. Prevalence of periodontal pathogens detected by PCR (n = 74) 
 
Bacteria, % (n) DM+CP  
(n= 27) 
CP 
 (n= 27) 
DM 
(n= 20) 
P.gingialis1 + 59.3 (16) 81.5 (22) 55.0 (11) 
- 40.7 (11) 18.5 (5) 45.0 (9) 
P.intermedia1 + 44.4 (12)b* 77.8 (21)a 30.0 (6)b** 
 - 55.6 (15) 22.2 (6) 70.0 (14) 
T.forsthysia2 + 100.0 (27) 100.0 (26) 90.0 (18) 
 - 0.0 (0) 0.0 (0) 10.0 (2) 
T.denticola2 + 88.9 (24) 100.0 (27) 70.0 (14) 
 - 11.1 (3) 0.0 (0) 30.0 (6) 
C.rectus2 + 100.0 (27) 100.0 (27) 100.0 (20) 
 - 0.0 (0) 0.0 (0) 0.0 (0) 
A.actinomycetemcomitans 2 + 7.4 (2) 11.1 (3) 0.0 (0) 
 - 92.6 (25) 88.9 (24) 100.0 (20) 
Different letters indicate statistically significant differences, adjusting for age, gender, smoking status and 
ethnicity 
1 chi-square test 
2 Fisher’s Exact test 
* P < 0.05 
** P < 0.01 
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Table 3. Concentrations of the detected inflammatory molecules by ELISA (n = 80) 
No significant differences between the study groups (Kruskal-Wallis test), adjusting for age, gender, 
smoking status and ethnicity 
 
 
  
Inflammatory molecule, 
mean (SE) 
DM+CP 
(n= 31) 
CP 
(n= 29) 
DM  
(n= 20) 
MMP-8 1256.27 (166.65) 1305.30 (193.85) 923.35 (194.74) 
MMP-9 16188.39 (1303.30) 14147.76 (1274.33) 11378.75 (1401.43) 
OPG 33.51 (7.11) 39.91 (10.02) 23.53 (4.26) 
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Figure 1. Representative results of electrophoresis of PCR products from dental plaque samples 
obtained from patients (112 to 154) using P.intermrdia and T.forsythia specific primers  
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Figure 2. Distribution of salivary MMP-8, MMP-9 and OPG concentrations (pg/ml) in well- and 
poorly-controlled type 2 diabetes patients. 
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Figure 3. Distribution of salivary MMP-8 concentrations (pg/ml) according to the prevalence of 
P.gingivalis (P.g) and P.intermrdia (P.i) in subjects with and without type 2 diabetes. 
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Figure 4. Distribution of salivary MMP-9 concentrations (pg/ml) according to the prevalence of 
P.gingivalis (P.g) and P.intermrdia (P.i) in subjects with and without type 2 diabetes. 
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Figure 5. Distribution of salivary OPG concentrations (pg/ml) according to the prevalence of 
P.gingivalis (P.g) and P.intermrdia (P.i) in subjects with and without type 2 diabetes. 
 
